documents incorporated reference document part proxy statement annual meeting part iii stockholders held april filed securities exchange commission within days close fiscal year covered reporttable contents pag e part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases item equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data f inancial statements n otes consolidated financial statements r eport independent registered public accounting firm b upplementary data item changes disagreements accountants accounting financial disclosure item controls procedures anagements report item b information part iii item directors executive officers corporate governance item executive compensation security ownership certain beneficial owners management related stockholder item matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures consent independent registered public accounting firm part tem business merck co inc merck company global researchdriven pharmaceutical company discovers develops manufactures markets broad range innovative products improve human animal health companys operations principally managed products basis comprised two reportable segments pharmaceutical segment vaccines segment pharmaceutical segment includes human health pharmaceutical products marketed either directly joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations institutions vaccines segment includes human health vaccine products marketed either directly joint venture products consist preventative pediatric adolescent adult vaccines primarily administered physician offices merck sells human health vaccines primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value pharmaceutical vaccine products health care professionals private practice group practices managed care organizations financial information information pharmaceutical segment vaccines segment see item managements discussion analysis financial condition results operations item financial statements supplementary data overview merck continued execute strategy reclaim leadership position pharmaceutical industry made evident successful launches five novel medicines vaccines areas cancer prevention diabetes advancement drug candidates every phase companys pipeline continued success newer inline products additionally company developing new commercial model designed broaden engagement customers scientific leaders leverage alternative channels complement effectiveness sales force drive growth key markets five products received us food drug administration fda approval gardasil quadrivalent human papillomavirus types recombinant vaccine first vaccine prevention cervical cancer genital warts caused certain types human papillomavirus hpv januvia sitagliptin phosphate first medicine class enhances natural body system improve blood sugar control patients type diabetes zostavax zoster vaccine live okamerck first vaccine adults years age older reduce incidence shingles disease every year afflicts estimated one million people united states alone rotateq rotavirus vaccine live oral pentavalent pediatric vaccine help prevent rotavirus gastroenteritis infants children effects take lives nearly children age five worldwide every year zolinza vorinostat novel medicine treat patients suffering advanced cutaneous tcell lymphoma ctcl addition company three drug candidates currently fda review janumet previously referred mka investigational oral medicine combining sitagliptin phosphate metformin type diabetes designed provide additional treatment option patients need one oral agent help control blood sugar emend injection mk intravenous therapy chemotherapyinduced nausea vomiting cinv arcoxia mercks selective cox inhibitor osteoarthritis additionally company anticipates filing three new drug applications nda fda mk firstinclass hiv integrase inhibitor gaboxadol novel compound mercks alliance h lundbeck treatment insomnia mka extendedrelease er niacin combined laropiprant novel flushing pathway inhibitor cholesterol management addition midyear merck expects four products phase iii development additionally targeted acquisitions made year sirna therapeutics inc sirna glycofi inc glycofi abmaxis inc abmaxis well alliances collaborations complement mercks strong internal research capabilities continue help company build pipeline support longterm growth merck working deliver innovative differentiated products market faster efficiently company successfully reduced late development product cycle times anticipates reductions coming year additionally mercks new commercial model expected lower spending per primary care brand united states interim targeted reduction expected achieved end still appropriately supporting product launches illustrated successful launch five new products redeployment launches achieved increase sales force initial phase global restructuring program designed reduce companys cost structure increase efficiency enhance competitiveness underway initial steps include implementation new supply strategy merck manufacturing division intended create leaner costeffective customer focused manufacturing model threeyear period part program merck announced plans sell close five manufacturing sites two preclinical sites end three manufacturing sites closed sold ceased operations two preclinical sites closed end eliminate approximately positions companywide approximately positions eliminated end comprised actual headcount reductions elimination contractors vacant positions however company continues hire new employees companys business requires company also sold certain facilities related assets connection restructuring program pretax costs restructuring program million comprised million primarily representing accelerated depreciation asset impairment costs million separation restructuring related costs expected million million end initial phase restructuring program relating manufacturing strategy expected substantially complete cumulative pretax costs program expected range billion billion merck continues expect initial phase cost reduction program yield cumulative pretax savings billion respect vioxx litigation date vioxx product liability lawsuits plaintiffs whose claims scheduled trial claims seven dismissed claims seven withdrawn trial calendar plaintiffs juries decided mercks favor nine times plaintiffs favor four times addition recent california trial involving two plaintiffs jury could reach verdict either plaintiff mistrial declared new jersey state judge set aside one nine merck verdicts respect four plaintiffs verdicts merck already filed appeal sought judicial review cases one four federal judge overturned damage award shortly trial addition consolidated trial two plaintiffs currently ongoing coordinated proceeding new jersey superior court judge carol e higbee another trial commenced state court illinois company spent million aggregate including million fourth quarter vioxx legal defense costs worldwide company recorded charges million increase reserve solely future legal defense costs related vioxx litigation december balance reserve million reserve based certain assumptions best estimate amount company believes time spent vioxx litigation fully discussed item legal proceedings earnings per common share assuming dilution including impact global restructuring program per share acquired research charge related acquisition sirna per share acquired research charge related acquisition glycofi per share discussed acquisitions additional reserves established solely future legal defense costs vioxx litigation discussed item legal proceedings impact adopting new accounting standard requiring expensing stock options discussed item managements discussion analysis financial condition results operations product sales sales companys products follows millions singulair cozaarhyzaar fosamax zocor primaxin cosopttrusopt proscar vasotecvaseretic cancidas maxalt propecia vioxx vaccinesbiologicals total presented net discounts returns amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders among singulair montelukast sodium leukotriene receptor antagonist respiratory product chronic treatment asthma relief symptoms allergic rhinitis cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate companys significant hypertension andor heart failure products fosamax alendronate sodium fosamax plus alendronate sodiumcholecalciferol mercks osteoporosis products treatment case fosamax prevention osteoporosis zocor simvastatin mercks atherosclerosis product primaxin imipenem cilastatin sodium cancidas caspofungin acetate antibacterialantifungal product cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution largestselling ophthalmological products proscar finasteride urology product treatment symptomatic benign prostate enlargement maxalt rizatriptan benzoate acute migraine product propecia finasteride product treatment male pattern hair loss among products included within vaccinesbiologicals varivax varicella virus vaccine live okamerck vaccine help prevent chickenpox mmr ii measles mumps rubella virus vaccine live vaccine measles mumps rubella proquad measles mumps rubella varicella okamerck virus vaccine live pediatric combination vaccine measles mumps rubella varicella gardasil vaccine prevention cervical cancer genital warts caused certain types hpv pneumovax pneumococcal vaccine polyvalent vaccine prevention pneumococcal disease rotateq vaccine help protect rotavirus gastroenteritis infants children zostavax vaccine help prevent shingles herpes zoster primarily includes sales human pharmaceuticals pharmaceutical animal health supply sales companys joint ventures revenue companys relationship astrazeneca lp primarily relating sales nexium esomeprazole magnesium prilosec omeprazole us product approvals february fda approved rotateq pediatric vaccine prevent rotavirus gastroenteritis infants children rotateq oral pentavalent threedose liquid vaccine contains five reassortant rotaviruses merck also submitted applications licensure rotateq countries including australia canada countries asia latin america sanofi pasteur msd spmsd mercks vaccine joint venture sanofi pasteur european union eu rotateq also received regulatory approval mexico november may fda approved zostavax prevention herpes zoster shingles individuals years age older also approved regulatory authorities eu australia may zostavax first medical option approved prevention shingles june fda approved gardasil first vaccine prevent cervical cancer vulvar vaginal precancers caused hpv types prevent lowgrade precancerous lesions genital warts caused hpv types united states estimated approximately women diagnosed cervical cancer year approximately women die october fda approved oral zolinza treatment cutaneous manifestations patients ctcl form nonhodgkins lymphoma progressive persistent recurrent disease following two systemic therapies ctcl cancer tcells type white blood cell affects skin october fda approved januvia first dipeptidyl peptidase dpp inhibitor available united states treatment type diabetes januvia approved monotherapy addon therapy either two types oral diabetes medications metformin thiazolidinediones improve blood sugar glucose control patients type diabetes diet exercise enough june us centers disease control preventions cdc advisory committee immunization practices acip unanimously voted recommend children years age routinely receive second dose varicellacontaining vaccine help protect chickenpox committee also recommended children adolescents adults received one dose varicellacontaining vaccine receive second catchup dose accomplished routine healthcare visits school collegeentry requirements mercks varivax combination vaccine proquad vaccines help protect chickenpox available united states voluntary withdrawal vioxx september merck announced voluntary worldwide withdrawal vioxx arthritis acute pain medication companys decision effective immediately based new threeyear data prospective randomized placebocontrolled clinical trial approve adenomatous polyp prevention vioxx trial stopped designed evaluate efficacy vioxx mg preventing recurrence colorectal polyps patients history colorectal adenomas combination two trials assess cardiovascular safety vioxx study increased relative risk confirmed cardiovascular events heart attack stroke became apparent beginning months treatment patients taking vioxx compared taking placebo approximately first months approve study vioxx placebo curves appeared similar respect approve results similar results two placebocontrolled studies described us labeling vioxx time withdrawal company estimates million us prescriptions written vioxx may august based estimate company estimates number patients taken vioxx united states since launch approximately million number patients outside united states taken vioxx undetermined time october company received letter senator charles grassley chairman senate committee finance requesting certain documents information related vioxx company also received requests information congressional committees company cooperated inquiries continued describe reasons companys voluntary withdrawal vioxx answer questions related companys development extensive testing medicine disclosures results studies february fda held joint meeting arthritis advisory committee drug safety risk management advisory committee committees discussed overall benefittorisk considerations including cardiovascular gastrointestinal safety concerns cox selective nonsteroidal antiinflammatory drugs related agents february members committees asked vote whether overall risk versus benefit profile vioxx supports marketing united states members committees voted support marketing vioxx united states company looks forward discussions fda regulatory authorities vioxx previously announced board directors company appointed special committee review companys actions prior voluntary withdrawal vioxx act board responding shareholder litigation matters related withdrawal vioxx advise board respect action taken result review december special committee retained honorable john martin jr debevoise plimpton llp conduct independent investigation senior managements conduct respect cardiovascular safety profile vioxx period vioxx developed marketed review completed third quarter full report including appendices made public september company provided copy full report appendices website wwwmerckcomnewsroomvioxxmartinreporthtml company included website address inactive textual reference intend active link website incorporate reference information contained therein acquisitions may merck acquired abmaxis privatelyheld biopharmaceutical company dedicated discovery optimization monoclonal antibody mab products human therapeutics diagnostics approximately million june merck acquired glycofi privatelyheld biotechnology company leader field yeast glycoengineering addition specific carbohydrate modifications proteins yeast optimization biologic drug molecules approximately million december merck acquired sirna publiclyheld biotechnology company leader developing new class medicines based rna interference rnai technology total value approximately billion acquisition sirna expected increase mercks ability use rnai technology turn targeted gene human cell potentially rendering inoperative gene responsible triggering specific disease joint ventures company number joint ventures relating pharmaceutical vaccines segments p harmaceutical company scheringplough corporation scheringplough entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas december cholesterolmanagement partnership agreements expanded include countries world excluding japan october zetia ezetimibe marketed ezetrol outside united states first new class cholesterollowering agents launched united states july vytorin marketed inegy outside united states combination product containing active ingredients zetia zocor approved united states company entered agreement astra ab astra develop market astra products united states company astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining company astra restructured joint venture whereby company acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership company maintains limited partner interest partnership renamed astrazeneca lp became exclusive distributor products kbi retained rights company earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing companys share undistributed partnership gaap earnings conjunction restructuring payment million astra purchased option buy companys interest kbi products excluding companys interest gastrointestinal medicines nexium prilosec company also granted astra option shares option buy companys common stock interest kbi exercise price based present value estimated future net sales nexium prilosec april astra merged zeneca group plc forming astrazeneca ab astrazeneca result merger exchange companys relinquishment rights future astra products existing pending us patents time merger astra paid million subject trueup calculation may require repayment portion amount merger also triggers partial redemption companys limited partner interest furthermore result merger astrazenecas option buy companys interest kbi products exercisable company right require astrazeneca purchase interest addition shares option exercisable two years astras purchase companys interest kbi products exercise option astra also provided year combined annual sales two products fall minimum amount provided case long either merck option astrazenecas option exercised exercise price based present value estimated future net sales nexium prilosec determined time exercise company formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture expanded europe canada significant joint venture products pepcid ac famotidine overthecounter form companys ulcer medication pepcid famotidine well pepcid complete overthecounter product combines companys ulcer medication antacids calcium carbonate magnesium hydroxide march company sold johnson johnson interest european joint venture v accines company connaught laboratories inc sanofi pasteur sa agreed collaborate development marketing combination pediatric vaccines promote selected vaccines united states combination vaccine development efforts continue agreement vaccines currently promoted company pasteur mrieux connaught sanofi pasteur sa formed joint venture market human vaccines europe collaborate development combination vaccines distribution existing eu european free trade association company sanofi pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributors rest territory ther company rhnepoulenc sa sanofiaventis sa combined respective animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species competition markets company conducts business highly competitive often highly regulated global efforts toward health care cost containment continue exert pressure product pricing access competition involves intensive search technological innovations ability market innovations effectively longstanding emphasis research development company well prepared compete search technological innovations additional resources meet competition include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products joint ventures licenses refining sales marketing efforts address changing industry conditions enhance product portfolio company continues pursue external alliances earlystage latestage product opportunities including joint ventures targeted acquisitions however introduction new products processes competitors may result price reductions product replacements even products protected patents example number compounds available treat diseases typically increases time resulted slowing growth sales certain companys products legislation enacted states united states particularly area human pharmaceutical products allows encourages instances absence specific instructions prescribing physician mandates use generic products containing active chemical innovators product rather brandname products governmental pressures toward dispensing generic products significantly reduced sales certain companys products longer protected patents zocor lost market exclusivity us company experienced significant decline zocor sales thereafter distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices managed care organizations fourth quarter company implemented new distribution program us wholesalers moderate fluctuations sales caused wholesaler investment buying improve efficiencies distribution company pharmaceutical products new program lowered previous limits average monthly purchases company pharmaceutical products us customers following implementation program fluctuations sales caused wholesaler investment buying significantly moderated raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys pharmaceutical vaccines segments government regulation investigation pharmaceutical industry subject global regulation regional country state local agencies particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states food drug administration modernization act fda modernization act passed culmination comprehensive legislative reform effort designed streamline regulatory procedures within fda improve regulation drugs medical devices food legislation principally designed ensure timely availability safe effective drugs biologics expediting premarket review process new products key provision legislation reauthorization prescription drug user fee act permits continued collection user fees prescription drug manufacturers augment fda resources earmarked review human drug applications helps provide resources necessary ensure prompt approval safe effective new drugs united states government expanded health care access enacting medicare prescription drug improvement modernization act signed law december prescription drug coverage began january legislation supports companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time legislation ensure prescription drug costs controlled competitive pressures encouraging appropriate use medicines addressing costcontainment pressure company made continuing effort demonstrate medicines help save costs overall patient health care many years pharmaceutical industry federal state oversight approval process new drugs drug safety advertising promotion drug purchasing reimbursement programs formularies variously review company believes continue able conduct operations including introduction new drugs market regulatory environment one type federal initiative contain federal health care spending prospective capitated payment system first implemented reduce rate growth medicare reimbursement hospitals system establishes advance flat rate reimbursement health care patients payor fiscally responsible type payment system cost containment systems widely used public private payors caused hospitals health maintenance organizations customers company costconscious treatment decisions including decisions regarding medicines made available patients company continues work private federal employers slow increases health care costs companys efforts demonstrate medicines help save costs areas encouraged use companys medicines helped offset effects increasing cost pressures also federal state governments pursued methods directly reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria provide minimum discounts defined nonfederal average manufacturer price purchases certain components federal government department veterans affairs department defense initiatives states seek rebates beyond minimum required medicaid legislation cases patients beyond eligible medicaid federal vaccines children entitlement program cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children company awarded cdc contract april effect march supply pediatric vaccines vaccines children program aggregate estimated value million signing january patients previously eligible medicaid also medicare beneficiaries years older disabled left state administered medicaid system covered new medicare prescription drug benefit outside united states company encounters similar regulatory legislative issues countries business primary thrust governmental inquiry action toward determining drug safety effectiveness often mechanisms controlling prices reimbursement prescription drugs profits prescription drug companies eu adopted directives concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use companys policies procedures already consistent substance directives consequently believed material effect companys business company subject jurisdiction various regulatory agencies therefore subject potential administrative actions actions may include seizures products civil criminal sanctions certain circumstances company may deem advisable initiate product recalls company believes able compete effectively within environment addition certain countries within eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives european commission ec proposals complete single market pharmaceuticals improve competitive climate variety means including market deregulation company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business patents trademarks licenses patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage patent portfolios developed products introduced company normally provide market exclusivity basic patents effect following major products united states cancidas comvax haemophilus b conjugate hepatitis b recombinant vaccine cosopt cozaar crixivan emend fosamax gardasil hyzaar invanz ertapenem sodium maxalt primaxin propecia recombivax hb hepatitis b vaccine recombinant rotateq singulair januvia trusopt zolinza zostavax basic patents also effect united states zetia vytorin developed merckscheringplough partnership basic patent also effect sustivastocrin efavirenz bristolmyers squibb bms exclusive license company sells sustiva united states canada certain european countries company markets stocrin countries throughout world basic patent aggrastat tirofiban hydrochloride united states divested product company retains basic patents aggrastat outside united states fda modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant exclusivity provisions reauthorized october best pharmaceuticals children act passed january fda granted additional six months market exclusivity united states invanz august fda granted additional six months market exclusivity united states trusopt october fda granted additional six months market exclusivity united states cozaarhyzaar february fda granted additional six months market exclusivity united states singulair august information respect companys patents see patent litigation expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states market exclusivity may available federal law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset general increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties june zocor lost market exclusivity united states company experienced significant decline us zocor sales time june basic patent united states covering proscar expired result company experienced significant decline us proscar sales time basic patent proscar also covers propecia however propecia protected additional patents expire october fda granted additional six months market exclusivity united states fosamax february fosamax weekly january however january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid company exhausted options appeal decision based court appeals decision fosamax lose market exclusivity united states february fosamax plus lose us market exclusivity april company expects significant declines products sales products respective loss market exclusivity worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalties received patent knowhow licenses rights amounted million company also paid royalties amounting million patent knowhow licenses holds r esearch development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities expenditures companys research development programs billion billion billion company maintains ongoing commitment research broad range therapeutic areas clinical development support new products company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development mercks new research development model designed increase productivity improve probability success prioritizing companys research development resources nine priority disease areas alzheimers disease atherosclerosis cardiovascular disease diabetes novel vaccines obesity oncology targeted therapies pain sleep disorders therapeutic areas carefully chosen based set criteria including unmet medical needs scientific opportunity commercial opportunity within therapeutic areas merck commit resources achieve research breadth depth develop bestinclass targeted differentiated products valued highly patients payers physicians company also make focused investments pursue specific mechanisms following selected disease areas antibiotics antifungals antivirals hepatitis c virus human immunodeficiency virus asthma chronic obstructive pulmonary disease neurodegeneration ophthalmology osteoporosis schizophrenia stroke addition company capitalize selected opportunities outside areas continuing commercialize attractive clinical development candidates pipeline pursuing appropriate external licensing opportunities development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug may marketed united states recorded data preclinical clinical experience included nda biologics license application fda required approval development certain products also subject government regulations covering safety efficacy united states many foreign countries companys scientists discover new compound believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase ii studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness data phase ii trials satisfactory company commences largescale phase iii trials confirm compounds efficacy safety upon completion trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed united states fda approval process begins complete nda submitted received fda pursuant prescription drug user fee act fda review period targets ndas supplemental ndas either six months priority review ten months standard review within days receipt nda fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review review timelines defined fda act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information days extensions review period communicated company fda act application issuing approval letter nonapprovable letter approvable letter based fda statistics drug development time initiation preclinical testing nda approval range years average years company three drug candidates currently fda review june fda accepted standard review nda mk intravenous prodrug emend treatment cinv company anticipates decision nda second quarter july fda accepted standard review nda janumet companys investigational oral medicine combining januvia metformin designed provide additional treatment patients needing one oral agent help control blood sugar treatment type diabetes company expects fda action nda end march company also moving forward planned regulatory filings countries outside united states arcoxia companys investigational selective cox inhibitor remains standard review fda united states response fdas approvable letter merck included results medal multinational etoricoxib diclofenac arthritis longterm program showed rate confirmed thrombotic cardiovascular events similar arcoxia diclofenac widely used nonsteroidal anti inflammatory drug world company anticipates fda action april company expects fda advisory committee meeting held prior fda action arcoxia currently available countries europe latin america asiapacific region middle eastnorthern africa company anticipates filing three ndas fda company plans file nda mk fda second quarter received fast track designation indication treatmentexperienced patients interim week data doseranging phase ii trial mk companys investigational hiv integrase inhibitor patients advanced hiv infection presented th annual conference retroviruses opportunistic infections february results showed oral investigational medication three doses studied combination optimized background therapy obt greater antiretroviral activity obt alone study results also showed mk combination obt generally well tolerated patients failing antiretroviral therapy art resistant least one drug three available classes oral arts limited active arts options treatment american society microbiologys th annual international conference antimicrobial agents chemotherapy september company presented interim week data ongoing study treatmentexperienced patients demonstrated mk maintaining viral load regression august th international aids conference company presented interim week data phase ii doseranging trial mk conducted treatmentnave hivinfected patients data showed mk twice daily used combination tenofovir lamivudine achieved comparable viral load reduction efavirenz combined agents previously untreated patients september american society microbiologys th annual international conference antimicrobial agents chemotherapy company presented additional interim week data phase ii doseranging study treatmentnave patients demonstrated increase lipid levels patients taking mk tenofovir lamivudine company entered phase iii clinical trials mka support mkb investigational therapies lipid management mka represents novel approach lowering ldlc raising hdlc lowering triglycerides mkb combines mka proven benefits simvastatin potentially reduce risk coronary heart disease beyond statins provide alone company plans file mka fda file mkb november company presented data phase ii study american heart associations scientific sessions chicago showed coadministration mk er niacin significantly reduced flushing patients dyslipidemia compared patients took er niacin alone flushing characterized redness skin warming burning face neck caused dilation blood vessels near skin common niacininduced side effect cause discomfort patients significant factor leading discontinuation niacin therapy october company h lundbeck denmark announced submission nda gaboxadol novel investigational drug phase iii development treatment insomnia occur mid phase ii clinical studies gaboxadol showed improved sleep quality well increased slowwave sleep without suppressing rem sleep december merck announced gaboxadol likely scheduled compound also midyear merck expects four products phase iii development including mk b discussed company initiated targeted phase iii program investigational compound treatment obesity mk investigational cannabinoid receptor inverse agonist results early clinical studies indicate mk demonstrated significant weightloss efficacy versus placebo generally safe welltolerated however reported another cannabinoid receptor inverse agonist psychiatric adverse experiences observed announced december company plans start phase iii testing mk calcitonin gene related peptide receptor antagonist treatment migraine headaches phase iii program expected commence first quarter also announced december company anticipates mk cathepsin k inhibitor treatment osteoporosis enter phase iii testing mid companys clinical pipeline includes candidates following areas arthritis atherosclerosis cancer cardiovascular disease diabetes endocrine disorders glaucoma infectious diseases insomnia neurodegenerative disease obesity osteoporosis psychiatric disease pain respiratory disease urogenital disorders company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies company completed transactions including targeted acquisitions research collaborations preclinical clinical compounds technology transactions across broad range therapeutic categories march neuromed pharmaceuticals ltd neuromed merck signed research collaboration license agreement research develop commercialize novel compounds treatment pain neurological disorders including neuromeds lead compound nmed mk currently phase ii development treatment pain also march merck signed agreement nicox sa nicox collaborate development new antihypertensive drugs using nicoxs proprietary nitric oxidedonating technology september company announced expanded scope existing strategic collaboration foxhollow technologies inc foxhollow atherosclerotic plaque analysis addition merck acquired stake foxhollow purchase million common stock october ambrilia biopharma inc ambrilia biopharmaceutical company developing innovative therapeutics fields cancer infectious diseases merck announced ambrilia entered exclusive licensing agreement granting merck worldwide rights ambrilias hivaids protease inhibitor program november j david gladstone institutes merck announced major collaboration license agreement research development drugs treat neurodegenerative diseases including alzheimers disease linked apoeregulated mechanisms body also november advinus therapeutics p ltd advinus merck announced formed drug discovery clinical development collaboration area metabolic disorders advinus merck work together develop clinically validated drug candidates metabolic disorders merck retaining right advance promising candidates latestage clinical trials december merck idera pharmaceuticals idera announced formed broad collaboration research develop commercialize ideras tolllike receptor agonists incorporating therapeutic prophylactic vaccines developed merck oncology infectious diseases alzheimers disease chart reflects companys current research pipeline february candidates shown phase iii include specific products candidates shown phase ii include advanced compound specific mechanism given therapeutic area backup compounds regardless phase development additional indications therapeutic area additional line extensions formulations inline products shown phase alzheimers disease mk atherosclerosis mk cancer mk mk mk mk mk v cardiovascular mk mk diabetes mk mk mk mk phase endocrine mk mk glaucoma mk infectious disease mk mk mk v aureus v flu insomnia mk mk osteoporosis mk parkinsons disease mk psychiatric disease mk mk mk phase ii alzheimers disease mk arthritis mkatherosclerosis mk mk cancer mk mk diabetes mk endocrine mk hiv v hpv v infectious disease pediatric v migraine mk osteoporosis mk overactive bladder mk mk pain mk mk mk respiratory disease mk stroke mk phase iii atherosclerosis mkb mka er niacin laropiprant hiv mk raltegravir insomnia gaboxadol obesity mk taranabant fda review cinv emend injection mk diabetes janumet osteoarthritis arcoxia us approvals rotavirus gastroenteritis rotateq shingles zostavax cervical cancer genital warts gardasil diabetes januvia cancer ctcl zolinza licensed alliance acquisition pipeline multiple licenses including csl ltd proofofconcept moleculeall product service marks appearing type form different surrounding text trademarks service marks owned licensed merck subsidiaries affiliates including zetia vytorin trademarks owned entities merckscheringplough partnership except noted cozaar hyzaar registered trademarks ei du pont de nemours company wilmington de prilosec nexium trademarks astrazeneca group us trademarks vasotec vaseretic owned biovail laboratories incorporated us trademark aggrastat owned guilford pharmaceuticals inc e mployees end company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups part costreduction initiative announced october completed end company eliminated positions company completed similar program positions eliminated december november company announced first phase global restructuring program designed reduce companys cost structure increase efficiency enhance competitiveness initial steps include implementation new supply strategy merck manufacturing division intended create leaner costeffective customerfocused manufacturing model threeyear period result merck incur certain costs associated exit disposal activities part global restructuring program company expects eliminate approximately positions manufacturing divisions worldwide representing global work force end half position reductions expected occur united states remainder countries december approximately positions eliminated throughout company since inception program approximately eliminated comprised actual headcount reductions elimination contractors vacant positions however company continues hire new employees companys business requires merck intends sell close five manufacturing facilities worldwide two preclinical sites reduce operations number sites end three manufacturing facilities closed sold ceased operations two preclinical sites closed company also sold certain facilities related assets connection restructuring program remaining sites identified saleclosure expected closed end subject compliance legal obligations pretax costs restructuring million million expected million million end initial phase restructuring program substantially complete cumulative pretax costs restructuring activities announced november expected range billion billion approximately cumulative pretax costs non cash relating primarily accelerated depreciation facilities scheduled closure e nvironmental matters company believes compliance material respects applicable environmental laws regulations company incurred capital expenditures approximately million environmental protection facilities company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million years amounts consider potential recoveries insurers parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million december although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year g eographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states sales sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions recent years company expanding operations countries located latin america middle east africa eastern europe asia pacific changes government policies economic conditions making possible company earn fair returns business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas companys business discussed item financial statements supplementary data vailable information companys internet website address wwwmerckcom company make available free charge investor information portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished securities exchange commission sec companys corporate governance guidelines charters board directors seven standing committees available companys website wwwmerckcomaboutcorporategovernance information available print stockholder requests company tem risk factors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forward looking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results company faces significant litigation related vioxx september company voluntarily withdrew vioxx arthritis acute pain medication market worldwide december approximately product liability lawsuits involving approximately plaintiff groups alleging personal injuries resulting use vioxx filed company state federal courts united states company also defendant approximately purported class actions related use vioxx suits referred vioxx product liability lawsuits addition vioxx product liability lawsuits various purported class actions individual lawsuits brought company several current former officers directors company alleging company made false misleading statements regarding vioxx violation federal state securities laws suits referred vioxx securities lawsuits addition various putative class actions brought company several current former employees officers directors company alleging violations employee retirement income security act erisa suits referred vioxx erisa lawsuits addition shareholder derivative suits previously filed dismissed appeal several shareholders filed demands company asserting claims board members company officers suits demands referred vioxx derivative lawsuits together vioxx securities lawsuits vioxx erisa lawsuits vioxx shareholder lawsuits company also named defendant actions various countries outside united states suits referred vioxx foreign lawsuits company also sued four states respect marketing vioxx company anticipates additional lawsuits relating vioxx filed andor certain current former officers directors future sec conducting formal investigation company concerning vioxx us department justice issued subpoena requesting information relating companys research marketing selling activities respect vioxx federal health care investigation criminal statutes also ongoing investigations certain congressional committees local authorities europe group attorneys general thirtyone states district columbia conducting investigation companys sales marketing vioxx company cooperating authorities investigations investigations referred vioxx investigations company predict outcome investigations however could result potential civil andor criminal liability date vioxx product liability litigation plaintiffs whose claims scheduled trial claims seven dismissed claims seven withdrawn trial calendar plaintiffs juries decided mercks favor nine times plaintiffs favor four times addition recent california trial involving two plaintiffs jury could reach verdict either plaintiff mistrial declared new jersey state judge set aside one nine merck verdicts respect four plaintiffs verdicts merck already filed appeal sought judicial review cases one four federal judge overturned damage award shortly trial addition consolidated trial two plaintiffs currently ongoing coordinated proceeding new jersey superior court judge higbee another trial commenced state court illinois vioxx product liability litigation discussed fully item legal proceedings outcomes vioxx product liability trials interpreted indicate trend outcome may likely future vioxx trials company currently anticipates number vioxx product liability lawsuits tried trial oregon securities case scheduled company predict whether trial proceed schedule timing vioxx shareholder lawsuit trials company believes meritorious defenses vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend companys insurance coverage respect vioxx lawsuits adequate cover defense costs losses company spent million including million fourth quarter aggregate legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation third quarter company recorded charge million fourth quarter recorded another charge million increase reserve solely future legal defense costs related vioxx litigation million december million december reserve based certain assumptions described legal proceedings best estimate amount company believes time spent company currently able estimate amount damages may required pay connection vioxx lawsuits vioxx investigations proceedings expected continue years currently early stage company little information course proceedings take view inherent difficulty predicting outcome litigation particularly many claimants claimants seek unspecified damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits company established reserves potential liability relating vioxx lawsuits vioxx investigations series unfavorable outcomes vioxx lawsuits vioxx investigations resulting payment substantial damages fines resulting criminal penalties could material adverse effect companys business cash flow results operations financial position prospects certain companys major products going lose patent protection near future occurs company expects significant decline sales products company depends upon patents provide exclusive marketing rights products period time product patents several companys products recently expired expire united states countries company faces strong competition lower price generic drugs loss patent protection one companys products typically leads rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss patent protection material adverse effect companys results operations june zocor companys statin modifying cholesterol lost market exclusivity united states zocor already lost basic patent protection many markets throughout world company experienced significant decline zocor sales worldwide sales zocor billion compared billion worldwide sales zocor expected billion billion september company appealed decision opposition division opposition division european patent office epo revoked companys patent europe covers onceweekly administration alendronate decision upheld therefore presently company entitled market exclusivity fosamax major european markets addition mercks basic patent covering use alendronate challenged several european countries company received adverse decisions germany holland united kingdom decision united kingdom upheld appeal company appealed decisions germany holland company expects significant decline european sales fosamax loss exclusivity sales fosamax outside united states already adversely affected availability generic alendronate sodium products markets including united kingdom canada germany january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid company exhausted options appeal decision based court appeals decision fosamax fosamax plus lose market exclusivity united states february april respectively company expects significant decline fosamax fosamax plus sales united states products respective loss market exclusivity companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products year declines sales products zocor fosamax mean companys future success dependent pipeline new products including new products develops joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties support research development efforts company must make ongoing substantial expenditures without assurance efforts funding result commercially successful product company must also commit substantial efforts funds resources recruiting retaining high quality scientists personnel pharmaceutical research development expertise based fda statistics drug development time initiation preclinical testing nda approval range years average years description research development process see research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals accordingly company may abandon product invested substantial amounts time money risks encountered research development process include following preclinical testing new compound may yield disappointing results clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved fda intended use may possible obtain patent new drug sales new product may disappointing company state certainty whether products development launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products zocor fosamax lose patent protection displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including european commission united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval mandate product withdrawals even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents infringement similar claims company company aggressively defends important patents within outside united states including filing claims infringement parties see item legal proceedings patent litigation particular manufacturers generic pharmaceutical products time time file abbreviated new drug applications anda fda seeking market generic forms companys products prior expiration relevant patents owned company company normally responds vigorously defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases third party patents may prevent company marketing selling product particular geographic area one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products company faces intense competition lowercost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states political pressure reduce spending prescription drugs led legislation encourages use generic products although companys policy actively protect patent rights generic challenges companys products arise time may able prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially results operations cash flow company faces intense competition new products companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective effectively marketed sold companys products alternatively case generic competition may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business results operations company faces pricing pressure respect products companys products subject increasing price pressures restrictions worldwide including united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act act act included prescription drug benefit individuals first went effect january increased purchasing power entities negotiate behalf medicare beneficiaries could result pricing pressures company expects pricing pressures increase future changes laws regulations could adversely affect companys business aspects companys business including research development manufacturing marketing pricing sales litigation intellectual property rights subject extensive legislation regulation changes applicable federal state laws agency regulations could material adverse effect companys business c autionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forward looking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following significant litigation related vioxx competition generic products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors tem b unresolved staff comments none tem properties companys corporate headquarters located whitehouse station new jersey companys us pharmaceutical business conducted divisional headquarters located upper gwynedd west point pennsylvania companys vaccines business conducted divisional headquarters located west point principal research facilities human health products located rahway new jersey west point company also production facilities human health products nine locations united states puerto rico branch warehouses provide services throughout country outside united states subsidiaries company owns interest manufacturing plants properties australia canada japan singapore south africa countries western europe central south america asia capital expenditures million compared billion united states amounted million million abroad expenditures amounted million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products tem legal proceedings company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions v ioxx litigation p roduct liability lawsuits previously disclosed individual putative class actions filed company state federal courts alleging personal injury andor economic loss respect purchase use vioxx actions filed federal court coordinated multidistrict litigation us district court eastern district louisiana mdl district judge eldon e fallon number actions filed state court coordinated separate coordinated proceedings state courts new jersey california texas counties philadelphia pennsylvania clark county nevada december company served aware named defendant approximately lawsuits include approximately plaintiff groups alleging personal injuries resulting use vioxx approximately putative class actions alleging personal injuries andor economic loss actions discussed paragraph collectively referred vioxx product liability lawsuits lawsuits approximately lawsuits representing approximately plaintiff groups slated federal mdl approximately lawsuits representing approximately plaintiff groups included coordinated proceeding new jersey superior court judge carol e higbee addition vioxx product liability lawsuits discussed claims plaintiffs dismissed december plaintiffs whose claims dismissed prejudice ie brought either plaintiffs courts additional plaintiffs claims dismissed without prejudice ie brought mdl judge fallon july indicated would schedule trial series cases period november following categories heart attack short term use ii heart attack long term use iii stroke iv cardiovascular injury involving prescription written april labeling vioxx revised include results vigor trial trials began november concluded december next scheduled trial mdl retrial barnett v merck issue damages discussed several vioxx product liability lawsuits currently scheduled trial company provided list trials website wwwmerckcom periodically update appropriate company included website address inactive textual reference intend active link website incorporate reference information contained therein merck entered tolling agreement tolling agreement mdl plaintiffs steering committee establishes procedure halt running statute limitations tolling certain categories claims allegedly arising use vioxx nonnew jersey citizens tolling agreement applies individuals filed lawsuits may may eventually file lawsuits claimants seek toll claims alleging injuries resulting thrombotic cardiovascular event results myocardial infarction ischemic stroke tolling agreement provides counsel additional time evaluate potential claims tolling agreement requires tolled claims filed federal court december approximately claimants entered tolling agreements merck voluntarily withdrew vioxx market september many states twoyear statute limitations product liability claims requiring claims must filed within two years plaintiffs learned could learned potential cause action result may view september deadline filing vioxx cases important note however law regarding statutes limitations complex varies state state factspecific cases might affected existence pending class actions example states three year statutes limitations instances statute limitations even longer merck expects legal arguments concerning proper application statutes decisions judges presiding individual cases state federal proceedings company previously disclosed outcomes several vioxx product liability lawsuits tried prior september see chart august barnett v merck case judge fallon mdl jury new orleans louisiana returned plaintiff verdict second federal vioxx case go trial jury awarded million compensatory damages million punitive damages august judge fallon overturned excessive damages portion verdict ordered new trial damages judge fallon set retrial october issue damages merck filed motions new trial issues judgment matter law currently pending court plaintiff opposed mercks motion asked judge reduce amount award rather retry case juries found favor merck counts fourth fifth cases go trial mdl jury returned verdict merck mason v merck november dedrick v merck december november judge fallon denied motion filed mdl certify nationwide class persons allegedly suffered personal injury result taking vioxx december jury albright v merck case tried state court birmingham alabama returned verdict merck counts company previously disclosed april garza v merck jury rio grande city texas returned verdict favor plaintiff september texas state court granted companys request investigate possible jury bias juror admitted prior trial several occasions borrowed money plaintiff december court entered judgment plaintiff amount million plus interest reduced original award million texas state cap punitive damages company seeking new trial appeal verdict court grant new trial october california superior court los angeles consolidated trial began cases appell v merck arrigale v merck january judge victoria chaney declared mistrial plaintiffs jury reported deadlocked october coordinated proceeding new jersey superior court judge higbee dismissed claims united kingdom plaintiffs plaintiffs appealed first case scheduled trial texas coordinated proceeding rigby v merck scheduled begin trial november rigby case voluntarily dismissed october plaintiff filed notice nonsuit court consolidated trial hermans v merck humeston v merck began january coordinated proceeding new jersey superior court judge higbee humeston v merck first tried judge higbee set aside november jury verdict favor merck ordered new trial grounds newly discovered evidence hermanshumeston trial separated two phases general phase regarding mercks conduct plaintiffspecific phase jury questions deliberation phase regarding mercks conduct jury answers questions affirmative case move phase ii phase ii plaintiff present specific case end phase ii jury deliberate answer questions respect two plaintiffs jury answer separate verdict sheets course one deliberation case moves punitive phase single presentation side one jury deliberation plaintiffs first case scheduled trial philadelphia coordinated proceeding mccool v merck scheduled begin trial february plaintiff voluntarily dismissed prejudice case january september new jersey superior court appellate division heard argument plaintiffs appeal judge higbees dismissal sinclair v merck case putative class action originally filed december sought creation medical monitoring fund judge higbee granted companys motion dismiss may january appellate division reversed decision remanded case back judge higbee factual inquiry company petitioned new jersey supreme court review appellate divisions decision date vioxx product liability lawsuits plaintiffs whose claims scheduled trial claims seven dismissed claims seven withdrawn trial calendar plaintiffs juries decided mercks favor nine times plaintiffs favor four times addition recent california trial involving two plaintiffs jury could reach verdict either plaintiff mistrial declared new jersey state judge set aside one nine merck verdicts respect four plaintiffs verdicts merck already filed appeal sought judicial review cases one four federal judge overturned damage award shortly trial addition consolidated trial two plaintiffs currently ongoing coordinated proceeding new jersey superior court judge higbee another trial schwaller v merck commenced state court madison county illinois following chart sets forth results us vioxx product liability trials date state federal verdict date plaintiff court result comments aug ernst texas verdict plaintiff jury awarded plaintiff million court reduced amount approximately million plus interest judgment appeal nov humeston nj verdict merck judge ordered new trial judge overturned currently ongoing verdict feb plunkett federal mistrial jury merck prevailed february retrial deadlocked first trial plaintiff moved new trial verdict merck retrial april mcdarby nj verdict plaintiff plaintiff awarded million damages mercks motion new trial pending plaintiffs motion attorneys fees april cona nj verdict merck however jury awarded plaintiff failure warn claim nominal sum consumer fraud act claim mercks motion new trial consumer fraud act claim pending plaintiffs motion attorneys fees april garza texas verdict plaintiff judge reduced million jury award million plus interest merck moved new trial july doherty nj verdict merck plaintiff moved new trial aug grossberg california verdict merck plaintiff moved new trial aug barnett federal verdict plaintiff plaintiff awarded million damages judge ruled award grossly excessive scheduled new trial damages october mercks motion new trial remaining issues pending sept smith federal verdict merck nov mason federal verdict merck dec dedrick federal verdict merck plaintiff moved new trial dec albright alabama verdict merck plaintiff moved new trial jan arrigaleappell california mistrial declared jury deadlocked ther lawsuits previously disclosed july new jersey state trial court certified nationwide class third party payors unions health insurance plans paid whole part vioxx used plan members insureds named plaintiff case seeks recovery certain vioxx purchase costs plus penalties based allegations purported class members paid vioxx would known products alleged risks merck believes class improperly certified trial courts ruling procedural address merits plaintiffs allegations company intends defend vigorously march new jersey superior court appellate division affirmed class certification order july new jersey supreme court decided exercise discretion hear companys appeal appellate divisions decision august appellate division ordered stay proceedings superior court pending ruling supreme court oral argument new jersey supreme court scheduled take place march previously reported company also named defendant separate lawsuits brought attorneys general alaska louisiana mississippi montana texas utah actions allege company misrepresented safety vioxx seek recovery cost vioxx purchased reimbursed state agencies ii reimbursement sums paid state agencies medical services treatment persons injured vioxx iii damages various common law theories andor iv remedies various state statutory theories including state consumer fraud andor fair business practices medicaid fraud statutes including civil penalties hareholder lawsuits previously disclosed addition vioxx product liability lawsuits company various current former officers directors defendants various putative class actions individual lawsuits federal securities laws state securities laws vioxx securities lawsuits vioxx securities lawsuits pending federal court transferred judicial panel multidistrict litigation jpml united states district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx securities lawsuits purposes plaintiffs request certification class purchasers company stock may october complaint alleges defendants made false misleading statements regarding vioxx violation sections b securities exchange act seeks unspecified compensatory damages costs suit including attorneys fees complaint also asserts claim section securities exchange act certain defendants relating sales merck stock addition complaint includes allegations sections securities act certain defendants made incomplete misleading statements registration statement certain prospectuses filed connection merck stock investment plan dividend reinvestment plan defendants filed motion dismiss complaint oral argument motion dismiss scheduled take place march previously disclosed august complaint filed oregon state court state oregon oregon state treasurer behalf oregon public employee retirement fund company certain current former officers directors complaint brought oregon securities law alleges plaintiff suffered damages connection purchases merck common stock artificially inflated prices due companys alleged violations law related disclosures vioxx current former officers directors entered tolling agreement june dismissed without prejudice case july court denied companys motion dismiss complaint required plaintiff amend complaint plaintiff filed amended complaint september merck filed motion require plaintiffs make complaint definite certain denied court merck filed answer complaint january previously disclosed various shareholder derivative actions filed federal court transferred shareholder mdl consolidated purposes judge chesler vioxx derivative lawsuits consolidated complaint arose substantially factual allegations made vioxx securities lawsuits vioxx derivative lawsuits purportedly brought assert rights company assert claims certain members board past present certain executive officers breach fiduciary duty waste corporate assets unjust enrichment abuse control gross mismanagement may judge chesler granted defendants motion dismiss denied plaintiffs request leave amend complaint plaintiffs appeal district courts decision refusing leave amend complaint currently pending united states court appeals third circuit previously disclosed october two individual shareholders made demand board directors company take legal action mr raymond gilmartin former chairman president chief executive officer individuals allegedly causing damage company respect allegedly improper marketing vioxx july board received another shareholder letter demanding board take legal action board management merck allegedly causing damage company relating companys allegedly improper marketing vioxx december demands rejected board directors previously announced board directors appointed special committee review companys actions prior voluntary withdrawal vioxx act board responding shareholder litigation matters related withdrawal vioxx advise board respect action taken result review december special committee retained honorable john martin jr debevoise plimpton llp conduct independent investigation senior managements conduct respect cardiovascular safety profile vioxx period vioxx developed marketed review completed third quarter full report including appendices made public september company provided copy full report appendices website wwwmerckcomnewsroomvioxxmartinreporthtml company included website address inactive textual reference intend active link website incorporate reference information contained therein addition previously disclosed various putative class actions filed federal court employee retirement income security act erisa company certain current former officers directors vioxx erisa lawsuits together vioxx securities lawsuits vioxx derivative lawsuits vioxx shareholder lawsuits transferred shareholder mdl consolidated purposes consolidated complaint asserts claims behalf certain companys current former employees participants certain companys retirement plans breach fiduciary duty lawsuits make similar allegations allegations contained vioxx securities lawsuits october defendants moved dismiss erisa complaint july judge chesler granted part denied part defendants motion dismiss nternational lawsuits previously disclosed addition lawsuits discussed company named defendant litigation relating vioxx various countries collectively vioxx foreign lawsuits europe well canada brazil argentina australia turkey israel dditional lawsuits based media reports sources company anticipates additional vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits filed andor certain current former officers directors future nsurance previously disclosed company product liability insurance claims brought vioxx product liability lawsuits stated upper limits approximately million deductibles coinsurance insurance provides coverage legal defense costs potential damage amounts incurred connection vioxx product liability lawsuits company believes insurance coverage extends additional vioxx product liability lawsuits may filed future company directors officers insurance coverage applicable vioxx securities lawsuits vioxx derivative lawsuits stated upper limits approximately million company fiduciary insurance vioxx erisa lawsuits stated upper limits approximately million additional insurance coverage claims may also available upperlevel excess policies provide coverage variety risks disputes certain insurers availability insurance coverage likely additional disputes companys insurance coverage respect vioxx lawsuits adequate cover defense costs losses previously disclosed companys upper level excess insurers provide excess insurance potentially applicable vioxx lawsuits commenced arbitration seeking among things cancel policies void obligations policies raise coverage issues respect vioxx lawsuits merck intends contest vigorously insurers claims attempt enforce rights applicable insurance policies amounts actually recovered policies discussed section may less amounts specified preceding paragraph nvestigations previously disclosed november company advised staff sec commencing informal inquiry concerning vioxx january company announced received notice sec issued formal notice investigation also company received subpoenas us department justice doj requesting information related companys research marketing selling activities respect vioxx federal health care investigation criminal statutes addition previously disclosed investigations conducted local authorities certain cities europe order determine whether criminal charges brought concerning vioxx company cooperating governmental entities respective investigations vioxx investigations company predict outcome inquiries however could result potential civil andor criminal dispositions previously disclosed company received number civil investigative demands cid group attorneys general states district columbia investigating whether company violated state consumer protection laws marketing vioxx company cooperating attorneys general responding cids addition company received subpoena september state california attorney general seeking documents information related placement vioxx californias medical formulary company cooperating attorney general responding subpoena r eserves company currently anticipates number vioxx product liability lawsuits tried throughout trial oregon securities case scheduled company predict whether trial proceed schedule timing vioxx shareholder lawsuit trials company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits company established reserves potential liability relating vioxx lawsuits vioxx investigations including cases verdicts judgments entered company postverdict proceedings appeal cases company believes strong points raise appeal therefore unfavorable outcomes cases probable unfavorable outcomes vioxx litigation defined could material adverse effect companys financial position liquidity results operations legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december company reserve million solely future legal defense costs related vioxx litigation company spent million aggregate including million fourth quarter legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation third quarter fourth quarter company recorded charges million million respectively increase reserve solely future legal defense costs related vioxx litigation million december increasing reserve company considered factors considered previously established reserves vioxx litigation management believes better estimate companys expenses reasonably estimate costs significant factors considered establishment ongoing review reserve vioxx legal defense costs follows actual costs incurred company development companys legal defense strategy structure light scope vioxx litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx product liability lawsuits events scheduled trials expected occur throughout inherent inability predict ultimate outcomes trials limit companys ability reasonably estimate legal costs beyond end company anticipate need increase reserve every quarter continue monitor legal defense costs review adequacy associated reserves may determine increase reserves legal defense costs time future based upon factors set forth believes would appropriate ther product liability litigation previously disclosed company defendant product liability lawsuits united states involving fosamax fosamax litigation december cases filed merck either federal state court including cases seek class action certification well damages medical monitoring actions plaintiffs allege among things suffered osteonecrosis jaw generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax august jpml ordered fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax mdl coordinated pretrial proceedings fosamax mdl transferred judge john keenan united states district court southern district new york result jpml order cases judge keenan judge keenan issued case management order setting forth schedule governing proceedings focuses primarily upon resolving class action certification motions company intends defend lawsuits december company established reserve approximately million solely future legal defense costs fosamax litigation significant factors considered establishment reserve fosamax litigation legal defense costs follows actual costs incurred company thus far development companys legal defense strategy structure light creation fosamax mdl number cases brought company anticipated timing progression related costs pretrial activities fosamax litigation company continue monitor legal defense costs review adequacy associated reserves due uncertain nature litigation company unable estimate costs beyond end unfavorable outcomes fosamax litigation could material adverse effect companys financial position liquidity results operations c ommercial litigation beginning company named number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states company settled federal class action represented single largest group claims settled substantially remaining cases satisfactory terms remaining cases inactive several years company engaged conspiracy admission wrongdoing made included settlement agreements previously disclosed company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels jpml ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case may court granted companys motion dismiss consolidated class action dismissed company class action case subsequent companys dismissal plaintiffs filed amended consolidated class action complaint name company defendant company many pharmaceutical manufacturers defendants similar complaints pending federal state court brought individually number counties state new york company defendants awaiting final ruling motion dismiss suffolk county case first new york county cases filed addition december company defendant state cases brought attorneys general kentucky illinois alabama wisconsin mississippi arizona hawaii alaska defended previously disclosed company named defendant antitrust cases federal court minnesota state court california alleging unlawful conspiracy among different sets pharmaceutical manufacturers protect high prices united states impeding importation united states lowerpriced pharmaceuticals canada court dismissed federal claims minnesota case prejudice plaintiffs filed notice appeal federal court appeals eighth circuit affirmed dismissal federal claims state claims action dismissed without prejudice refiled jurisdiction california antitrust action parties engaged discovery defendant manufacturers filed summary judgment december court granted summary judgment favor merck defendants dismissed case plaintiffs filed notice appeal california state appeals court previously disclosed suit federal court alabama two providers health services needy patients alleges pharmaceutical companies overcharged plaintiffs class similarly situated pharmaceuticals purchased plaintiffs program established section b public health service act company defendants filed motion dismiss complaint numerous grounds recently denied court denial motion dismiss case dismissed voluntarily parties previously disclosed january doj notified federal court new orleans louisiana going intervene time pending federal false claims act case filed seal december company court issued order unsealing complaint filed physician louisiana ordered complaint served complaint alleged companys discounting pepcid certain louisiana hospitals led increases costs medicaid dismissed amended complaint filed seal case administratively closed court seal lifted state louisiana filed amended complaint incorporating allegations contained sealed amended complaint allegations contained sealed amended complaint unknown april company named qui tam lawsuit nevada false claims act suit nevada attorney general intervened alleges company inappropriately offered nominal pricing marketing pricing inducements certain customers also failed comply obligations medicaid best price scheme related arrangements may companys motion dismiss action denied district court company defending lawsuit g overnmental proceedings previously disclosed company received subpoena doj connection investigation companys marketing selling activities including nominal pricing programs samples company also reported received cid attorney general texas regarding companys marketing selling activities relating texas previously disclosed company received another cid attorney general texas asking additional information regarding companys marketing selling activities related texas including respect certain nominal pricing programs samples april company received subpoena office inspector general district columbia connection investigation companys interactions physicians district columbia maryland virginia november company received letter request doj connection investigation companys pricing pepcid september company received subpoena illinois attorney general subpoena seeks information related repackaging prescription drugs activity relating merck illinois matter previously disclosed company received letter doj advising existence qui tam complaint alleging company violated certain rules related calculations best price federal pricing benchmark calculations certain may affect companys medicaid rebate obligation doj informed company intend intervene action closed investigation lawsuit continues however company cooperating investigations company predict outcome investigations however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations addition time time federal state foreign regulators authorities may seek information practices pharmaceutical industry companys business practices inquiries investigations discussed section feasible predict outcome inquiries previously disclosed february italian antitrust authority ica adopted measure commencing formal investigation merck sharp dohme italia spa msd italy company article italian competition law article ec ascertain whether company msd italy committed abuse dominant position refusing grant acs dobfar spa dobfar italian company voluntary license companys italian supplementary protection certificate spc pursuant domestic legislation passed permit dobfar manufacture imipenem cilastatin ic active ingredients tienam italy sale outside italy countries patent protection expired never existed hearing ica held may june ica found preliminary basis companys refusal grant license abuse dominant position imposed interim measures requiring company grant license manufacture ic italy stockpiling purposes expiration spc november italian administrative court denied companys appeal icas order companys spc expired january proceedings ica continued merits article investigation effort resolve matter company offered commitment ica pursuant company would grant nonexclusive licenses italian spc finasteride respect finasteride mg treatment benign prostate hyperplasia deadline ica adopt final decision whether companys commitment warrants closure case march v accine litigation previously disclosed company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella andor trivalent vaccines measles mumps rubella including companys mmr ii conditions include autism without inflammatory bowel disease epilepsy encephalitis encephalopathy guillainbarre syndrome transverse myelitis claimants proceeding companys knowledge intending proceed company company defend lawsuits previously disclosed company also party individual class action product liability lawsuits claims united states involving pediatric vaccines eg hepatitis b vaccine contained thimerosal preservative used vaccines merck distributed thimerosalcontaining pediatric vaccines united states since fall december approximately active thimerosal related lawsuits approximately plaintiffs defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines two cases scheduled trial dismissed one state court case ohio voluntarily dismissed plaintiffs second federal district court case texas court entered summary judgment favor defendants plaintiffs ultimately voluntarily dismissed appeal company defend lawsuits however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations company successful cases type either dismissed stayed ground action prohibited national childhood vaccine injury act vaccine act vaccine act prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court vaccine act filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods company party vaccine court proceedings petitions brought united states department health human services cases trial dates referred preceding paragraph dismissed brought plaintiffs claimed made timely withdrawal vaccine court petitions company aware approximately cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders thimerosalcontaining vaccines involved vaccine court proceeding company vaccines company sole source mmr ii vaccine domestically june special masters presiding vaccine court proceedings scheduled begin hearing petitioners government present evidence issue whether vaccines cause autism spectrum disorders hearing expected last number weeks since party company participate proceedings p atent litigation time time generic manufacturers pharmaceutical products file andas fda seeking market generic forms companys products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic form fosamax prilosec nexium propecia trusopt cosopt prior expiration companys astrazenecas case prilosec nexium patents concerning products generic companies andas generally include allegations noninfringement invalidity unenforceability patents generic manufacturers received fda approval market generic form prilosec company filed patent infringement suits federal court companies filing andas generic alendronate fosamax finasteride propecia dorzolamide trusopt dorzolamidetimolol cosopt astrazeneca company filed patent infringement suits federal court companies filing andas generic omeprazole prilosec esomeprazole nexium similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products february schering plough received notice generic company indicating filed anda zetia challenging us patents listed zetia merck schering plough market zetia joint venture considering appropriate response february company received notice generic company indicating filed anda montelukast challenging us patent listed singulair company considering appropriate response previously disclosed january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid company exhausted options appeal decision based court appeals decision fosamax fosamax plus lose market exclusivity united states february april respectively company expects significant decline us fosamax fosamax plus sales products respective loss market exclusivity may federal court canada trial division issued decision refusing bar approval generic alendronate ground mercks patent weekly alendronate likely invalid decision appealed generic alendronate launched canada june july merck sued federal court canada apotex seeking damages lost sales generic weekly alendronate due patent proceeding previously disclosed september company appealed decision opposition division epo revoked companys patent europe covers onceweekly administration alendronate march board appeal epo upheld decision opposition division thus presently company entitled market exclusivity fosamax major european markets addition mercks basic patent covering use alendronate challenged several european countries company received adverse decisions germany holland united kingdom decision united kingdom upheld appeal company appealed decisions germany holland june company filed lawsuits federal court barr laboratories inc teva pharmaceutical industries ltd teva asserting respective manufacturing processes making alendronate products would infringe one process patents company october action australia challenging validity companys australian patent onceweekly administration alendronate patent found invalid decision upheld appeal addition previously disclosed japan proceeding filed challenging validity companys japanese patent onceweekly administration alendronate january company sued hitech pharmacal co inc hitech amityville new york patent infringement response hitechs application fda seeking approval generic version mercks ophthalmic drugs trusopt cosopt used treating elevated intraocular pressure people ocular hypertension glaucoma lawsuit merck sued enforce patent covering active ingredient dorzolamide present trusopt cosopt case district court entered judgment mercks favor hitech appealed hearing appeal conducted december decision pending merck elected enforce two us patents listed fda cover combination dorzolamide timolol two active ingredients cosopt lawsuit automatically stays fda approval hi techs andas months january adverse court decision whichever may occur earlier patent covering dorzolamide provides exclusivity trusopt cosopt october including six months pediatric exclusivity time company expects sales products decline case omeprazole trial court united states rendered opinion october upholding validity companys astrazenecas patents covering stabilized formulation omeprazole ruling one defendants omeprazole product infringe patents three defendants products found infringe formulation patents december us court appeals federal circuit affirmed decision trial court respect companys patent infringement claims certain generic manufacturers omeprazole products trial concluded june decision pending company astrazeneca received notice october ranbaxy laboratories limited ranbaxy filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium november company astrazeneca sued ranbaxy united states district court new jersey accordingly fda approval ranbaxys anda stayed months april adverse court decision whichever may occur earlier company astrazeneca received notice january ivax pharmaceuticals inc subsequently acquired teva filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium march company astrazeneca sued teva united states district court new jersey accordingly fda approval tevas anda stayed months september adverse court decision whichever may occur earlier case finasteride anda filed seeking approval generic version propecia alleging invalidity companys patents company filed patent infringement lawsuit district court delaware september company reached settlement generic company dr reddys laboratories drl drl may sell generic mg finasteride product beginning january europe company aware various companies seeking registration generic losartan active ingredient cozaar company patent rights losartan via license ei du pont de nemours company du pont company du pont filed patent infringement proceedings various companies portugal spain norway ther litigation july merck served shareholder derivative suit filed new jersey superior court hunterdon county company certain current former officers directors lawsuit seeks recover cancel compensation awarded companys executive officers asserts claims breach fiduciary duty waste unjust enrichment july court granted defendants motion dismiss based plaintiffs failure make presuit demand mercks board directors denied plaintiffs request leave amend thus case terminated november individual shareholder delivered letter board alleging company sustained damages companys adoption change control separation benefits plan cic plan november shareholder made demand board take legal action boards current former members allegedly causing damage company respect adoption cic plan response demand letter independent members board determined november board meeting board would take shareholders request consideration remains consideration previously disclosed august united states district court district new jersey granted motion company medco health solutions inc medco health certain officers directors dismiss shareholder derivative action involving claims related companys revenue recognition practice retail copayments paid individuals medco health provides pharmaceutical benefits well allegations complaint dismissed prejudice plaintiffs appealed decision december us court appeals third circuit upheld district courts decision dismissing suit sent issue whether companys board directors properly refused shareholder demand relating companys treatment retail copayments back district court reconsideration different legal standard plaintiffs moved remand action state court august district court granted motion february shareholder derivative suit currently pending superior court new jersey chancery division hunterdon county previously disclosed prior spinoff medco health company medco health agreed settle class action basis series lawsuits asserting violations erisa gruer cases company medco health certain plaintiffs counsel filed settlement agreement federal district court new york cases commenced number plaintiffs including participants number pharmaceutical benefit plans medco health pharmacy benefit manager well trustees plans consolidated medco health company agreed proposed settlement order avoid significant cost distraction prolonged litigation proposed class settlement agreed plaintiffs five cases filed medco health company proposed settlement company medco health agreed pay total million medco health agreed modify certain business practices continue certain specified business practices period five years financial compensation intended benefit members settlement class includes erisa plans medco health administered pharmacy benefit time since december district court held hearings hear objections fairness proposed settlement approved settlement yet determined number class member plans properly elected participate settlement settlement becomes final appeals resolved certain class member plans indicated participate settlement cases initiated three plans two individuals remain pending southern district new york plaintiffs cases asserted claims based erisa well federal state laws similar claims asserted settling class members gruer cases company medco health named defendants cases three notices appeal filed appellate court heard oral argument may december appellate court issued decision vacating district courts judgment remanding cases district court allow district court resolve certain jurisdictional issues hearing held address issues february district court issued ruling august resolving jurisdictional issues favor settling plaintiffs class members party previously appealed district courts judgment renewed appeals renewed appeals presently briefed spinoff medco health medco health assumed substantially liability exposure matters discussed foregoing two paragraphs cases defended medco health various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed item opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided item e nvironmental matters company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs insurers former site owners operators recalcitrant potentially responsible parties june potassium thiocyanate accidentally discharged companys plant west point pennsylvania upper gwynedd township authoritys wastewater treatment plant wissahickon creek causing fishkill federal state agencies investigating discharge company currently cooperating investigations tem submission matters vote security holders applicable executive officers registrant ages february r ichard clark age april chairman chief executive officer president may chief executive officer president june president merck manufacturing division responsible companys manufacturing information services operational excellence organizations worldwide january chairman president chief executive officer medco health solutions inc medco health formerly whollyowned subsidiary company january president medco health avid w anstice age september executive vice president strategy initiatives responsible endtoend global support function initiatives providing strategic direction key pharmaceutical emerging markets china india august president human healthasia pacific responsible companys prescription drug business asia pacific region japan australia new zealand companys joint venture relationship scheringplough january president human health responsible companys prescription drug business japan latin america canada australia new zealand companys joint venture relationship scheringplough march president americas us human health responsible one two prescription drug divisions comprising us human health well companys prescription drug business canada latin america companys joint venture relationship schering plough j ohn canan age september vice president controller responsible corporate controllers group june vice president corporate audit assurance services september vice president controller asia joint ventures responsible financial operational oversight asia human health several companys joint ventures august controller asia pacific human health c elia colbert age january vice president secretary since september assistant general counsel since november w illie deese age may president merck manufacturing division responsible companys global manufacturing procurement operational excellence functions january senior vice president global procurement prior january mr deese senior vice president global procurement logistics glaxosmithkline plc k enneth c frazier age november executive vice president general counsel responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company december senior vice president general counsel responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company irian graddickweir age september senior vice president human resources prior september dr graddickweir executive vice president human resources employee communications att held several senior human resources leadership positions att years communications services provider teven b kelmar age august vice president public affairs prior august mr kelmar led global public affairs communications function novartis ag since p eter kim age january president merck research laboratories mrl february executive vice president research development mrl j udy c lewent age august executive vice president chief financial officer responsible companys strategic planning financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc subsidiary company january executive vice president chief financial officer president human health asia responsible financial corporate development functions internal auditing corporate licensing companys prescription drug business asia north asia south companys joint venture relationships merck capital ventures llc february executive vice president chief financial officer since april responsible financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc february company announced ms lewent intends retire july p eter loescher age may president global human health responsible companys four marketing sales divisions us human health human health asia pacific human health intercontinental europe middle east africa canada latin america merck vaccines prior may mr loescher served president chief executive officer ge healthcare bio sciences medical diagnostics life sciences business since acquired amersham health mr loescher president amersham health becoming chief operating officer ark e mcdonough age february vice president treasurer responsible companys treasury function providing financial support human resources january assistant treasurer global capital markets responsible managing companys investment financing portfolios treasury share repurchase program september senior director human health finance responsible providing global franchisebased financial reporting analytics key customers argaret g mcglynn age august president merck vaccines global responsibilities vaccines business including companys sanofipasteur joint venture january president us human health responsible one two prescription drug divisions hospital specialty product franchises comprising us human health ushh managed care group ushh august executive vice president customer marketing sales ushh tefan oschmann age september president europe middle east africa canada april senior vice president worldwide human health marketing october executive vice president worldwide marketing january managing director msd germany subsidiary company j chris scalet age january senior vice president global services chief information officer cio responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative march senior vice president information services cio responsible areas information technology services including application development technical support voice data communications computer operations worldwide prior march mr scalet senior vice president information technology cio international paper company global forest products paper packaging company dam h schechter age july president us human health commercial responsibility united states companys portfolio prescription medicines october general manager us human health division responsible neuropsychiatry osteoporosis migraine respiratory new products franchises february vice presidentgeneral manager merckscheringplough pharmaceuticals us joint venture august vice president merck human health division arthritis analgesia franchise business group w endy l yarno age september chief marketing officer responsible global marketing services global alliance management global pricing global human health business practices compliance three franchises oncology specialty neuroscience respiratory bone arthritis analgesia infectious diseases hospital products november general manager business unit us human health january executive vice president worldwide human health marketing december senior vice president human resources officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board part ii tem market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk common stock market price information set forth table based historical nyse market prices following table also sets forth calendar periods indicated dividend per share information c ash dividends paid per common share ear h q r q nd q st q c ommon stock market prices th q rd q nd q st q high low h igh low january approximately stockholders record equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity plans close business december table include information tax qualified plans merck co inc employee savings security plan number securities remaining available number future issuance securities equity issued upon weightedaverage compensation plans exercise exercise price excluding outstanding outstanding securities options warrants options warrants reflected column plan category rights rights b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following stockholderapproved plans incentive stock plan incentive stock plan incentive stock plan incentive stock plan nonemployee directors stock option plan non employee directors stock option plan nonemployee directors stock option plan excludes approximately shares restricted stock units performance share units assuming maximum payouts incentive stock plan also excludes shares phantom stock deferred merck co inc deferral program december additional shares reserved deferral program beginning january onetenth percent outstanding shares merck common stock last business day preceding calendar year plus shares authorized deferral program issued reserved future issuance december actual amount shares issued prospectively equals amount participants elect defer payouts companys various incentive programs executive incentive plan phantom stock increased amount dividends would paid equivalent number shares merck common stock divided market price merck common stock table include information equity compensation plans options warrants rights assumed company connection mergers acquisitions pursuant remain outstanding options warrants rights collectively assumed plans include following medco containment services inc class c nonqualified stock option plan sibia neurosciences inc equity incentive plan provantage health services inc stock incentive plan rosetta inpharmatics inc employee stock plans total shares merck common stock may purchased assumed plans weighted average exercise price grants may made assumed plans performance graph following graph compares cumulative total stockholder return stock price appreciation plus reinvested dividends companys common stock cumulative total return including reinvested dividends dow jones us pharmaceutical index djuspr formerly referred dow jones pharmaceutical index united states owned companies standard poors index sp index five years ended december amounts rounded nearest dollar percent comparison fiveyear cumulative total return merck co inc dow jones us pharmaceutical index sp index end period value cagr merck djuspr sp merck djuspr sp assumes value investment company common stock index december dividends reinvested compound annual growth rate issuer purchases equity securities three month period ended december follows issuer purchases equity securities tota l numbe r millio ns total shares purchased approx dollar value number average part shares may yet shares price paid publicly announced purchased period purchased per share plans programs plans programs october october november november december december total share repurchases made part plan announced july purchase billion merck shares tem selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report erck co inc subsidiaries millions except per share amounts r esults year sales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income continuing operations taxes taxes income income continuing operations income discontinued operations net taxes net income basic earnings per common share continuing operations discontinued operations net income earnings per common share assuming dilution continuing operations discontinued operations net income cash dividends declared cash dividends paid per common share capital expenditures depreciation yearend position working capital property plant equipment net total assets longterm debt stockholders equity financial ratios income continuing operations sales net income average total assets yearend statistics average common shares outstanding millions average common shares outstanding assuming dilution millions number stockholders record number employees prior year amounts reflect impact retrospectively adopting securities exchange commission interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile see note consolidated financial statements amounts include impact restructuring actions acquired research expenses resulting acquisitions made year additional vioxx legal defense costs incremental impact expensing stock options amounts include impact net tax charge primarily associated american jobs creation act repatriation restructuring actions additional vioxx legal defense costs amounts include impact withdrawal vioxx vioxx legal defense costs restructuring actions amounts include impact implementation new distribution program us wholesalers restructuring actions amount add result rounding decrease primarily reflects impact spinoff medco healthi tem managements discussion analysis financial condition results operations escription mercks business merck global researchdriven pharmaceutical company discovers develops manufactures markets broad range innovative products improve human animal health companys operations principally managed products basis comprised two reportable segments pharmaceutical segment vaccines segment pharmaceutical segment includes human health pharmaceutical products marketed either directly joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations institutions vaccines segment includes human health vaccine products marketed either directly joint venture products consist preventative pediatric adolescent adult vaccines primarily administered physician offices merck sells human health vaccines primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value pharmaceutical vaccine products health care professionals private practice group practices managed care organizations verview merck continued execute strategy reclaim leadership position pharmaceutical industry made evident successful launches five novel medicines vaccines areas cancer prevention diabetes advancement drug candidates every phase companys pipeline continued success newer inline products additionally company developing new commercial model designed broaden engagement customers scientific leaders leverage alternative channels complement effectiveness sales force drive growth key markets five products received us food drug administration fda approval gardasil first vaccine prevention cervical cancer genital warts caused certain types human papillomavirus hpv januvia first medicine class enhances natural body system improve blood sugar control patients type diabetes zostavax first vaccine adults years age older reduce incidence shingles disease every year afflicts estimated one million people united states alone rotateq pediatric vaccine help prevent rotavirus gastroenteritis infants children effects take lives nearly children age five worldwide every year zolinza novel medicine treat patients suffering advanced cutaneous tcell lymphoma ctcl addition company three drug candidates currently fda review janumet previously referred mka investigational oral medicine combining sitagliptin phosphate metformin type diabetes designed provide additional treatment option patients need one oral agent help control blood sugar emend injection mk intravenous therapy chemotherapyinduced nausea vomiting cinv arcoxia mercks selective cox inhibitor osteoarthritis additionally company anticipates filing three new drug applications nda fda mk firstinclass hiv integrase inhibitor gaboxadol novel compound mercks alliance h lundbeck treatment insomnia mka extendedrelease er niacin combined laropiprant novel flushing pathway inhibitor cholesterol management addition midyear merck expects four products phase iii development additionally targeted acquisitions made year sirna therapeutics inc sirna glycofi inc glycofi abmaxis inc abmaxis well alliances collaborations complement mercks strong internal research capabilities continue help company build pipeline support longterm growth merck working deliver innovative differentiated products market faster efficiently company successfully reduced late development product cycle times anticipates reductions coming year additionally mercks new commercial model expected lower spending per primary care brand united states interim targeted reduction expected achieved end still appropriately supporting product launches illustrated successful launch five new products redeployment launches achieved increase sales force initial phase global restructuring program designed reduce companys cost structure increase efficiency enhance competitiveness underway initial steps include implementation new supply strategy merck manufacturing division intended create leaner costeffective customer focused manufacturing model threeyear period part program merck announced plans sell close five manufacturing sites two preclinical sites end three manufacturing sites closed sold ceased operations two preclinical sites closed end eliminate approximately positions companywide approximately positions eliminated end comprised actual headcount reductions elimination contractors vacant positions however company continues hire new employees companys business requires company also sold certain facilities related assets connection restructuring program pretax costs restructuring program million comprised million primarily representing accelerated depreciation asset impairment costs million separation restructuring related costs expected million million end initial phase restructuring program relating manufacturing strategy expected substantially complete cumulative pretax costs program expected range billion billion merck continues expect initial phase cost reduction program yield cumulative pretax savings billion respect vioxx litigation date vioxx product liability lawsuits plaintiffs whose claims scheduled trial claims seven dismissed claims seven withdrawn trial calendar plaintiffs juries decided mercks favor nine times plaintiffs favor four times addition recent california trial involving two plaintiffs jury could reach verdict either plaintiff mistrial declared new jersey state judge set aside one nine merck verdicts respect four plaintiffs verdicts merck already filed appeal sought judicial review cases one four federal judge overturned damage award shortly trial addition consolidated trial two plaintiffs currently ongoing coordinated proceeding new jersey superior court judge carol e higbee another trial commenced state court illinois company spent million aggregate including million fourth quarter vioxx legal defense costs worldwide company recorded charges million increase reserve solely future legal defense costs related vioxx litigation december balance reserve million reserve based certain assumptions best estimate amount company believes time spent vioxx litigation fully discussed note consolidated financial statements earnings per common share assuming dilution including impact global restructuring program per share acquired research charge related acquisition sirna per share acquired research charge related acquisition glycofi per share discussed acquisitions additional reserves established solely future legal defense costs vioxx litigation discussed impact adopting new accounting standard requiring expensing stock options discussed sharebased compensation c ompetition health care environment markets company conducts business highly competitive often highly regulated global efforts toward health care cost containment continue exert pressure product pricing access united states government expanded health care access enacting medicare prescription drug improvement modernization act signed law december prescription drug coverage began january legislation supports companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time legislation ensure prescription drug costs controlled competitive pressures encouraging appropriate use medicines addressing costcontainment pressure company made continuing effort demonstrate medicines help save costs overall patient health care addition pricing flexibility across companys product portfolio encouraged growing use medicines mitigated effects increasing cost pressures outside united states difficult environments encumbered government costcontainment actions company worked partnership payers allocating scarce resources optimize health care outcomes limiting potentially detrimental effects government policies sales growth access innovative medicines vaccines support discovery development innovative products benefit patients company also working governments many emerging markets eastern europe latin america asia encourage increase investments health thereby improve citizens access medicines within europe european institutions european commission ec recognized economic importance researchbased pharmaceutical industry value innovative medicines society result working industry representatives complete single market pharmaceuticals improve competitive climate variety means including market deregulation order advance related policy debate ec launched high level pharmaceutical forum hlpf end initiative aims improving prospects researchbased pharmaceutical industry europe thus health prospects patients benefit innovative therapies active dialogue among stakeholders health care system payers patients initiative attempt tackle key policy issues europe promoting greater pricing flexibility medicines ii ensuring health authorities apply best practices evaluation relative effectiveness medicines iii improving greater access information medicines patients europe company actively engaged ec stakeholders order achieve successful outcome hlpf would help european patients gain greater quicker access medicines company committed improving access medicines enhancing quality life people around world african comprehensive hivaids partnerships achap botswana partnership government botswana bill melinda gates foundation merck company foundationmerck co inc supporting botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support may company initiated similar partnership peoples republic china focused initially sichuan province help strengthen chinas response hiv epidemic catalyze access hiv medicines developing countries price reduction guidelines company announced merck makes profit sale current hivaids medicines worlds poorest countries hardest hit pandemic offers hivaids medicines significantly reduced prices mediumincome countries february merck announced reduced price stocrin least developed countries world hardest hit pandemic end patients developing countries treated antiretroviral regimens containing either crixivan stocrin actions merck working independently partners public private sectors alike focus critical barriers access medicines developing world need sustainable financing increased international assistance additional investments education training health infrastructure capacity developing countries company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business although one predict outcome legislative regulatory advocacy initiatives company well positioned respond evolving health care environment market forces patents certain companys products expire merck entered may continue enter authorized generic agreements allow company benefit medicines become available generic form company anticipates worldwide trend toward costcontainment continue resulting ongoing pressures health care budgets company continues successfully launch new products contribute health care debates monitor reforms new products policies strategies enable maintain strong position changing economic environment cquisitions december merck completed acquisition sirna approximately billion sirna biotechnology company leader developing new class medicines based rna interference rnai technology could significantly alter treatment disease transaction accounted business combination excess purchase price fair value acquired net assets recorded goodwill million goodwill deductible tax purposes company recorded charge million acquired research associated sirnas compounds currently development related development treatments hepatitis b hepatitis c viruses preclinical development well licensing agreements held sirna charge deductible tax purposes ongoing activity respect compounds development expected material companys research development expenses allocation purchase price also resulted recognition intangible asset million related deferred tax liability million related sirnas developed technology acquisition sirna expected increase mercks ability use rnai technology turn targeted gene human cell potentially rendering inoperative gene responsible triggering specific disease see note consolidated financial statements june merck acquired glycofi privatelyheld biotechnology company leader field yeast glycoengineering addition specific carbohydrate modifications proteins yeast optimization biologic drug molecules million cash million purchase price net million shares already owned net transaction costs company recorded million charge acquired research connection acquisition deductible tax purposes company also recorded million intangible asset million net deferred taxes related glycofis developed technology may merck acquired abmaxis privatelyheld biopharmaceutical company dedicated discovery optimization monoclonal antibody products human therapeutics diagnostics million cash substantially purchase price allocated intangible asset relating abmaxis technology platform acquisitions independent scientific merits combination glycofi abmaxis platforms potentially synergistic giving merck ability operate across entire spectrum therapeutic antibody discovery development commercialization see note consolidated financial statements perating results ales worldwide sales increased total primarily driven higher volumes foreign exchange price changes virtually impact sales growth sales performance reflects strong growth singulair onceaday oral medicine indicated chronic treatment asthma relief symptoms allergic rhinitis companys vaccines include gardasil help protect cervical cancer genital warts caused certain types hpv proquad combination vaccine simultaneous vaccination measles mumps rubella varicella rotateq help protect rotavirus gastroenteritis infants children also contributing sales growth higher revenues companys relationship astrazeneca lp azlp primarily driven nexium increased sales cozaarhyzaar high blood pressure addition sales reflect certain supply sales associated activities expected continue beyond including companys arrangement dr reddys laboratories drl sale generic simvastatin sales growth partially offset lower sales zocor companys statin modifying cholesterol proscar urology product treatment symptomatic benign prostate enlargement mercks us marketing exclusivity zocor expired june proscar lost us marketing exclusivity june domestic sales increased foreign sales declined foreign sales represented total sales domestic sales benefited launch three new vaccines foreign sales negatively affected loss marketing exclusivity continued generic erosion related zocor fosamax products worldwide sales decreased total reflecting decrease related voluntary worldwide withdrawal vioxx offset revenue growth products growth reflects favorable effect foreign exchange favorable effect price changes volume increase foreign sales represented total sales sales companys products follows millions singulair cozaarhyzaar fosamax zocor primaxin cosopttrusopt proscar vasotecvaseretic cancidas maxalt propecia vioxx vaccinesbiologicals presented net discounts returns amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders among singulair leukotriene receptor antagonist respiratory product chronic treatment asthma relief symptoms allergic rhinitis cozaarhyzaar vasotec companys significant hypertension andor heart failure products fosamax fosamax plus marketed fosavance throughout european union eu treatment case fosamax prevention osteoporosis zocor mercks atherosclerosis product primaxin cancidas anti bacterialantifungal products cosopt trusopt largestselling ophthalmological products proscar urology product treatment symptomatic benign prostate enlargement maxalt acute migraine product propecia product treatment male pattern hair loss among products included within vaccinesbiologicals varivax vaccine help prevent chickenpox mmr ii vaccine measles mumps rubella proquad pediatric combination vaccine measles mumps rubella varicella gardasil vaccine prevention cervical cancer genital warts caused certain types hpv pneumovax vaccine prevention pneumococcal disease rotateq vaccine help protect rotavirus gastroenteritis infants children zostavax vaccine help prevent shingles herpes zoster individuals years age older primarily includes sales human pharmaceuticals pharmaceutical animal health supply sales companys joint ventures revenue companys relationship azlp primarily relating sales nexium prilosec revenue azlp billion billion billion respectively also includes certain supply sales associated activities expected continue beyond including companys arrangement drl sale generic simvastatin egment revenues millions pharmaceutical segment revenues vaccines segment revenues segment revenues revenues otal revenues accordance segment reporting requirements vaccines segment revenues exclude million million million respectively vaccines sales certain nonus subsidiaries managed included pharmaceutical segment includes nonreportable human animal health segments revenues primarily comprised miscellaneous corporate revenues sales related divested products businesses supply sales included segment results p harmaceutical segment revenues sales pharmaceutical segment decreased primarily due declines zocor proscar postpatent expiration partially offset increases singulair cozaarhyzaar singulair mercks onceaday oral respiratory medicine indicated treatment chronic asthma relief symptoms allergic rhinitis continued strong performance reflecting continued demand asthma seasonal perennial allergic rhinitis medications singulair continues number one prescribed product us respiratory market total sales singulair billion increase global sales cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension billion increase cozaar hyzaar compete fastestgrowing class antihypertensive market angiotensin ii antagonists aiia cozaarhyzaar remained number two branded aiia united states europe december companys japanese subsidiary launched preminent known hyzaar worldwide markets firsteverfixeddose combination japan angiotensin receptor blocker hydrochlorothiazide treatment hypertension japan second largest pharmaceutical market world global sales fosamax fosamax plus treatment postmenopausal male andor glucocorticoidinduced osteoporosis billion decrease sales outside united states affected availability generic alendronate sodium products key markets including united kingdom canada germany company ongoing litigation certain european countries based companys alendronate patents fosamax fosamax plus together remain prescribed medicine worldwide treatment osteoporosis fosamax fosamax plus lose market exclusivity united states february april respectively company expects significant declines us fosamax fosamax plus sales products respective loss market exclusivity august fosamax marketed fosamac became first onceweekly oral medicine osteoporosis launched japan worldwide sales zocor mercks statin modifying cholesterol billion decrease sales zocor negatively affected loss us marketing exclusivity june global sales zocor expected billion billion february company entered agreement drl authorized sale generic simvastatin terms agreement company reimbursed costplus basis drl supplying finished goods receives share net profits recorded drl merck continues offer branded zocor manufacture simvastatin branded zocor vytorin companys investigational compound mkb merck recorded million associated drl arrangement simvastatin revenue expected continue beyond october januvia approved fda first dipeptidyl peptidase dpp inhibitor available united states treatment type diabetes dpp inhibitors represent new class prescription medications improve blood sugar control patients type diabetes enhancing natural body system called incretin system januvia approved monotherapy addon therapy either two oral diabetes medications metformin thiazolidinediones tzds improve blood sugar glucose control patients type diabetes diet exercise enough january company received positive opinion januvia committee medicinal products human use chmp european medicines agency emea europe chmp opinion recommended januvia approved eu treatment type diabetes following conclusion chmp review opinion januvia transmitted ec ec adopts opinion januvia first prescription medication new class drugs known dpp inhibitors enhance bodys ability lower blood sugar glucose elevated decision applicable countries members eu marketing authorization ec expected early april adoption opinion including eu merck anticipates approval januvia least another countries clinical studies show januvia provides significant ac measure average blood glucose level two threemonth period reductions monotherapy added two commonly used types diabetes drugs metformin tzds treatment januvia associated weight gain increased risk hypoglycemia januvia available countries including united states mexico brazil regulatory filings around world moving forward global sales januvia million october fda approved zolinza treatment cutaneous manifestations patients ctcl progressive persistent recurrent disease following two systemic therapies approval zolinza represents first anticancer treatment approved ctcl since products experiencing growth include cosopt treat glaucoma propecia male pattern hair loss maxalt treat migraine pain arcoxia treatment arthritis pain invanz treatment selected moderate severe infection adults emend prevention acute delayed nausea vomiting associated moderately highly emetogenic cancer chemotherapy well treatment postoperative nausea vomiting also contributing mercks total sales revenue resulting companys relationship azlp primarily relating sales nexium proscar mercks urology product treatment symptomatic benign prostate enlargement lost marketing exclusivity united states june mercks us sales proscar million decrease compared company expects decline us proscar sales continue basic patent proscar also covers propecia however propecia protected additional patents expire october v accines segment revenues sales vaccines segment increased result new product launches continued success inline vaccines following discussion vaccines includes total vaccines sales vast majority included vaccines segment remainder representing certain sales vaccines nonus subsidiaries managed included pharmaceutical segment amounts reflect sales vaccines sold major european markets sanofi pasteur msd spmsd companys joint venture sanofi pasteur results reflected equity income affiliates company announced fda approval three new breakthrough vaccines gardasil rotateq zostavax june fda approved gardasil vaccine available united states prevent cervical cancer vulvar vaginal precancers caused hpv types prevent lowgrade pre cancerous lesions genital warts caused hpv types gardasil approved yearold girls women gardasil three dose intra muscular vaccine given six months united states estimated approximately women diagnosed cervical cancer year approximately women die june us centers disease controls cdc advisory committee immunization practices acip voted unanimously recommend girls women years old vaccinated gardasil acip recommended gardasil administered yearold females females aged previously vaccinated yearold females vaccinated gardasil discretion physicians november company announced cdc added gardasil cdcs vaccines children program eligible girls women aged february managed care plans representing least privatelyinsured lives united states currently insurance plans decided reimburse gardasil covered members benefit design insurers reimbursing vaccine lowest price paid merck private nonhmo customers september gardasil approved first vaccine eu use children adolescents aged years adult females aged years prevention cervical cancer high grade cervical dysplasiasprecancers cervical intraepithelial neoplasia cin highgradeprecancerous vulvar dysplastic lesions vin genital warts caused hpv types gardasil marketed spmsd european countries including eu remaining central eastern european countries gardasil marketed merck sharp dohme either gardasil silgard total sales gardasil recorded merck million gardasil approved countries accelerated reviews regulatory applications pending approximately countries february company announced glaxosmithkline gsk entered cross license settlement agreement certain patent rights related hpv vaccines pursuant agreement gsk received upfront payment receiving royalties company based upon sales gardasil upon development launch agreement resolves competing intellectual property claims related companys gsks vaccine candidates addition merck entered license agreement collaboration csl limited relating technology used gardasil gardasil also subject thirdparty licensing agreements consequence agreements company pay royalties worldwide sales gardasil approximately aggregate clinical studies evaluate efficacy gardasil females years age males years age continue countries around world company expects submit fda indication females years age fourth quarter indication males years age company also conducting ongoing clinical studies assess potential crossprotection hpv types related hpv including hpv crossprotection proven could potentially expand vaccines prevention coverage cervical cancer february fda approved rotateq companys vaccine help protect rotavirus gastroenteritis infants children fda approval rotateq based data companys phase iii clinical trials nearly infants including data rotavirus efficacy safety trial rest one largest prelicensure vaccine clinical trials ever conducted clinical trials rotateq prevented severe cases rotavirus gastroenteritis prevented rotavirus gastroenteritis cases severity caused serotypes targeted vaccine g g g g compared placebo first full rotavirus season vaccination rotateq also reduced hospitalizations emergency room visits rotavirus gastroenteritis caused serotypes targeted vaccine first two years third dose february cdcs acip unanimously voted recommend infants starting weeks age vaccinated rotateq rotavirus vaccine available united states acip recommended oral readyto use vaccine given current routine wellbaby visits months age april rotateq made available cdc vaccines children program within united states february health insurance plans representing approximately covered lives eligible age group infants young children six weeks age added rotateq formularies rotateq approved countries applications licensure filed countries nicaragua rotateq approved company provide vaccine free charge infants born country threeyear period commencing october joint demonstration project nicaraguan ministry health rotateq sales recorded merck million february merck updated labeling information rotateq include postmarketing reports intussusception hematochezia vaccine adverse events reporting system vaers national vaccine safety surveillance program february fda reported since licensure rotateq february january cases intussusception infants received rotateq reported united states vaers number exceed number cases expected based background rate rest specifically designed evaluate vaccine safety respect intussusception rest increased risk intussuception rotateq compared placebo may fda approved zostavax companys vaccine prevention herpes zoster shingles individuals years age older also approved regulatory authorities eu australia may zostavax first medical option approved prevention shingles october cdc acip voted unanimously recommend adults years age older vaccinated zostavax help prevent shingles following acip recommendation united states february managed care plans representing approximately covered lives reimbursing zostavax sales zostavax recorded merck million june acip unanimously voted recommend children years age routinely receive second dose varicella chickenpoxcontaining vaccine mercks varivax combination vaccine proquad vaccines help protect chickenpox available united states acip also voted recommend children adolescents adults previously received one dose varicellacontaining vaccine receive catchup second dose acip voted include second dose chickenpox vaccine vaccines children program merck recently determined bulk manufacturing process companys varicella zoster virus vzvcontaining vaccines producing lower amounts bulk vzv intermediate expected vzv bulk question designated use fulfilling future quantities three vzvcontaining vaccines varivax proquad zostavax result production vzv bulk temporarily suspended company identifies cause issue situation affect quality mercks vzvcontaining vaccines currently market lots vaccine inventory ready release market vaccines filled finished existing vzv bulk company works resolve issue decreasing availability proquad increasing availability component vaccines varivax mmr ii additionally company postpone introductions outside united states proquad zostavax vzv bulk issue resolved based approach view current projections company currently expects meet anticipated market demand vzvcontaining vaccines costs expenses harebased compensation january company adopted financial accounting standards board fasb statement r sharebased payment fas r see note consolidated financial statements fas r requires sharebased payments employees expensed requisite service period based grantdate fair value awards prior adopting fas r company accounted employee stock options using intrinsic value method measures sharebased compensation expense amount market price stock date grant exceeds exercise price company elected modified prospective transition method adopting fas r therefore prior periods restated method provisions fas r apply awards granted modified january total pretax sharebased compensation expense million million million incremental pretax expense related adoption fas r million addition unrecognized expense awards yet vested date adoption shall recognized net income periods date adoption december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation expense recorded unallocated expense millions change change materials production marketing administrative research development restructuring costs equity income affiliates income expense net greater aterials production materials production costs increased compared increase sales increase primarily attributable million recorded related global restructuring program compared million recorded amount recorded million represents accelerated depreciation associated planned sale closure five companys manufacturing facilities see note consolidated financial statements remaining million represents impairment charges associated abandonment certain fixed assets longer used business result restructuring actions materials production costs also include stock option expense million additionally materials production costs included unfavorable impact inflation materials production costs increased compared decline sales increase primarily attributable million recorded related global restructuring program million represents impairment charges associated abandonment certain fixed assets longer used business result restructuring actions remaining million represents accelerated depreciation associated mercks plan sell close five owned manufacturing facilities additionally increase materials production costs attributable unfavorable effect inflation variance costs relative sales decline reflects impact items noted well unfavorable effect sales associated voluntary worldwide withdrawal vioxx gross margin compared restructuring charges noted unfavorable impact percentage points percentage points addition zocor lost us marketing exclusivity negatively affected gross margin impact voluntary worldwide withdrawal vioxx unfavorable effect gross margin arketing administrative marketing administrative expenses increased primarily reflecting million additional reserves solely legal defense costs vioxx litigation see note consolidated financial statements well costs associated launches three new vaccines new products mainly januvia united states marketing administrative expenses also included million charge establish legal defense reserve fosamax litigation see note consolidated financial statements well stock option expense million additionally marketing administrative expenses included unfavorable effect inflation marketing administrative expenses decreased primarily due costs recorded million voluntary worldwide withdrawal vioxx million establishment reserve solely legal defense costs vioxx litigation partially offsetting decrease additional reserve million vioxx legal defense costs recorded well costs required prepare launch three new vaccines additionally unfavorable effect inflation unfavorable effect exchange also partially offset declines r esearch development research development expenses increased included increase million acquired research charge related acquisition sirna well million acquired research charge resulting glycofi acquisition addition increase reflects accelerated depreciation costs million related closure research facilities connection global restructuring program well stock option expense million additionally unfavorable effect inflation also contributed increase company three drug candidates currently fda review june fda accepted standard review nda mk intravenous prodrug emend treatment cinv company anticipates decision nda second quarter july fda accepted standard review nda janumet companys investigational oral medicine combining januvia metformin designed provide additional treatment patients needing one oral agent help control blood sugar treatment type diabetes company expects fda action nda end march company also moving forward planned regulatory filings countries outside united states arcoxia companys investigational selective cox inhibitor remains standard review fda united states response fdas approvable letter merck included results medal multinational etoricoxib diclofenac arthritis longterm program showed rate confirmed thrombotic cardiovascular events similar arcoxia diclofenac widely used nonsteroidal anti inflammatory drug world company anticipates fda action april company expects fda advisory committee meeting held prior fda action arcoxia currently available countries europe latin america asiapacific region middle eastnorthern africa company anticipates filing three ndas fda company plans file nda mk fda second quarter received fast track designation indication treatmentexperienced patients interim week data doseranging phase ii trial mk companys investigational hiv integrase inhibitor patients advanced hiv infection presented th annual conference retroviruses opportunistic infections february results showed oral investigational medication three doses studied combination optimized background therapy obt greater antiretroviral activity obt alone study results also showed mk combination obt generally well tolerated patients failing antiretroviral therapy art resistant least one drug three available classes oral arts limited active arts options treatment american society microbiologys th annual international conference antimicrobial agents chemotherapy september company presented interim week data ongoing study treatmentexperienced patients demonstrated mk maintaining viral load regression august th international aids conference company presented interim week data phase ii doseranging trial mk conducted treatmentnave hivinfected patients data showed mk twice daily used combination tenofovir lamivudine achieved comparable viral load reduction efavirenz combined agents previously untreated patients september american society microbiologys th annual international conference antimicrobial agents chemotherapy company presented additional interim week data phase ii doseranging study treatmentnave patients demonstrated increase lipid levels patients taking mk tenofovir lamivudine company entered phase iii clinical trials mka support mkb investigational therapies lipid management mka represents novel approach lowering ldlc raising hdlc lowering triglycerides mkb combines mka proven benefits simvastatin potentially reduce risk coronary heart disease beyond statins provide alone company plans file mka fda file mkb november company presented data phase ii study american heart associations scientific sessions chicago showed coadministration mk er niacin significantly reduced flushing patients dyslipidemia compared patients took er niacin alone flushing characterized redness skin warming burning face neck caused dilation blood vessels near skin common niacininduced side effect cause discomfort patients significant factor leading discontinuation niacin therapy october company h lundbeck denmark announced submission nda gaboxadol novel investigational drug phase iii development treatment insomnia occur mid phase ii clinical studies gaboxadol showed improved sleep quality well increased slowwave sleep without suppressing rem sleep december merck announced gaboxadol likely scheduled compound also midyear merck expects four products phase iii development including mkb discussed company initiated targeted phase iii program investigational compound treatment obesity mk investigational cannabinoid receptor inverse agonist results early clinical studies indicate mk demonstrated significant weightloss efficacy versus placebo generally safe welltolerated however reported another cannabinoid receptor inverse agonist psychiatric adverse experiences observed announced december company plans start phase iii testing mk calcitonin gene related peptide receptor antagonist treatment migraine headaches phase iii program expected commence first quarter also announced december company anticipates mk cathepsin k inhibitor treatment osteoporosis enter phase iii testing mid august merck gilead sciences inc gilead established agreement distribution atripla oncedaily single tablet regimen treatment hiv infection adults developing countries around world atripla contains mg efavirenz nonnucleoside reverse transcriptase inhibitor mg emtricitabine mg tenofovir disoproxil fumarate nucleoside reverse transcriptase inhibitors efavirenz marketed merck tradename stocrin territories outside united states canada certain european countries commercialized bristolmyers squibb bms tradename sustiva emtricitabine tenofovir disoproxil fumarate commercialized gilead tradenames emtriva viread respectively compounds commonly prescribed together oncedaily fixeddose tablet marketed tradename truvada use part combination therapy october company along bms gilead announced submission marketing authorisation application maa atripla eu emea maa reviewed chmp subject validation emea maa atripla eu filed jointly three companies newly established threeway collaboration based ireland review maa conducted emea centralized licensing procedure finalized provides one marketing authorization member states eu discussions among three companies regarding agreements manufacturing commercialization distribution atripla eu ongoing merck continues remain focused augmenting internal efforts capitalizing growth opportunities ranging targeted acquisitions research collaborations preclinical clinical compounds technology transactions drive near longterm growth company completed transactions across broad range therapeutic categories well earlystage technology transactions merck currently evaluating opportunities actively monitoring landscape range targeted acquisitions meet companys strategic criteria highlights activities year include march neuromed pharmaceuticals ltd neuromed merck signed research collaboration license agreement research develop commercialize novel compounds treatment pain neurological disorders including neuromeds lead compound nmed mk currently phase ii development treatment pain terms agreement neuromed received upfront payment million successful development launch nmed initial single indication worldwide basis would trigger milestone payments totaling million milestones could increase approximately million indication nmed developed approved additional compound developed approved two indications neuromed would also receive royalties worldwide sales nmed additional compounds developed agreement also march merck nicox sa nicox entered new agreement collaborate development new antihypertensive drugs using nicoxs proprietary nitric oxidedonating technology agreement covers nitric oxidedonating derivatives several major classes antihypertensive agents treatment high blood pressure complications hypertension cardiovascular related disorders merck exclusive right develop commercialize antihypertensives use nicoxs nitric oxidedonating technology treatment systemic hypertension may company acquired abmaxis privatelyheld biopharmaceutical company dedicated discovery optimization monoclonal antibody products human therapeutics diagnostics june company acquired glycofi privatelyheld biotechnology company leader field yeast glycoengineering optimization biologic drug molecules connection acquisition company recorded charge million acquired research associated glycofis technology platform used research development process acquisition date technological feasibility established alternative future use existed see acquisitions october merck ambrilia biopharma inc ambrilia biopharmaceutical company developing innovative therapeutics fields cancer infectious diseases announced entered exclusive licensing agreement granting merck worldwide rights ambrilias hivaids protease inhibitor program terms agreement ambrilia granted merck exclusive worldwide rights lead compound ppl completed phase singledose pharmacokinetic study currently phase repeat dose pharmacokinetic study return ambrilia received upfront licensing fee million signing eligible cash payments totaling million upon successful completion development clinical regulatory sales milestones ambrilia receive royalties future product sales november company expanded scope existing strategic collaboration foxhollow technologies inc foxhollow atherosclerotic plaque analysis additionally merck acquired stake foxhollow purchase million newlyissued shares foxhollow common stock per share representing approximately stake existing strategic collaboration entered provided foxhollow receive upfront payment opportunity additional payments collaboration continued terms expanded collaboration agreement merck pay million foxhollow four years exchange foxhollows agreement collaborate exclusively merck specified disease areas merck also provide minimum million funding foxhollow first three years four year collaboration program term research activities conducted foxhollow mercks direction foxhollow receive milestone payments successful development drug products diagnostic tests utilizing results collaboration well royalties november merck j david gladstone institutes announced major collaboration license agreement research development drugs treat neurodegenerative diseases including alzheimers disease linked apoeregulated mechanisms body agreement provides merck affiliate worldwide exclusive license research develop commercialize compounds directed apoeregulated pathways result collaborative research discoveries made field neurodegeneration gladstone institutes also november merck advinus therapeutics p ltd advinus announced formed drug discovery clinical development collaboration area metabolic disorders advinus merck work together develop clinically validated drug candidates metabolic disorders merck retaining right advance promising candidates latestage clinical trials advinis receive upfront payment could potentially receive milestone payments million target included collaboration collaboration begin two target programs could expand include others time december merck completed acquisition sirna publiclyheld biotechnology company leader developing new class medicines based rnai technology could significantly alter treatment disease connection acquisition company recorded charge million acquired research associated sirnas compounds currently development acquisition date technological feasibility established alternative future use existed see acquisitions additionally december merck idera pharmaceuticals idera announced formed broad collaboration research develop commercialize ideras tolllike receptor tlr agonists terms agreement merck receive worldwide exclusive rights number ideras agonist compounds targeting tlr use combination mercks therapeutic prophylactic vaccines development oncology infectious diseases alzheimers disease merck idera engage twoyear research development collaboration generate novel agonists targeting tlr tlr incorporating merck idera chemistry use licensed fields merck paid upfront license fee million idera purchased million common stock per share addition merck fund research development collaboration idera eligible receive milestone payments million vaccines successfully developed three fields additional milestones million would payable followon indications oncology field successful development additional vaccines containing ideras tlr agonists limit number vaccines merck apply ideras agonists within licensed fields addition idera receive royalties products commercialized collaboration company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development programs generally designed focus development novel medicines address large unmet medical needs mercks new efforts improve drug discovery involve focusing nine priority disease areas well utilizing new research technologies building alliances external partners making targeted acquisitions complement companys strong internal research capabilities previous announced nine priority disease areas alzheimers disease atherosclerosis cardiovascular disease diabetes novel vaccines obesity oncology targeted therapies pain sleep disorders therapeutic areas carefully chosen based set criteria including unmet medical needs scientific opportunity commercial opportunity chart reflecting companys current research pipeline february set forth item business research development expenses decreased included accelerated depreciation costs million related closure research facilities addition decrease reflects impact million licensing expense initial payments certain disclosed research collaborations million acquired research expense acquisition aton pharma inc partially offsetting decrease increase research development activities supporting mercks pipeline well unfavorable effect inflation r estructuring costs restructuring costs million million respectively included restructuring costs separation costs associated mercks plan eliminate approximately positions end merck incurred million million respectively separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated related global restructuring program company eliminated positions positions comprised actual headcount reductions elimination contractors vacant positions also company recorded million separation costs associated restructuring programs restructuring costs included unallocated expense segment reporting purposes e quity income affiliates equity income affiliates reflects performance companys joint ventures partnerships increase equity income affiliates reflects successful performance vytorin zetia merckscheringplough partnership growth also attributable higher partnership returns azlp see selected joint venture affiliate information ther income expense net increase income expense net reflects increase interest income generated companys investment portfolio derived higher interest rates higher average investment portfolio balances decrease income expense net primarily reflects million gain sale companys equity stake european joint venture johnson johnson well realized gains companys investment portfolio recorded egment profits millions pharmaceutical segment profits vaccines segment profits segment profits ncome income taxes segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker company allocate vast majority indirect production costs research development expenses general administrative expenses well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits taxes paid joint venture level portion equity income additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items reflected table also included miscellaneous corporate profits operating profits related divested products businesses supply sales adjustments eliminate effect double counting certain items income expense pharmaceutical segment profits increased compared reflecting higher equity income primarily driven strong performance merckscheringplough partnership partially offset loss us marketing exclusivity zocor proscar pharmaceutical segment profits declined primarily related voluntary worldwide withdrawal vioxx vaccines segment profits increased driven launch three new vaccines successful performance inline vaccines vaccines segment profits declined primarily reflecting increased marketing administrative costs required prepare launches three new vaccines vaccines segment profits also reflect equity income spmsd axes income companys effective income tax rate higher effective tax rate reflects unfavorable impact percentage points primarily related companys decision repatriate billion foreign earnings accordance american jobs creation act ajca effective tax rate reflects unfavorable impact percentage points related non deductible acquired research development costs associated acquisitions sirna glycofi tax rate three years favorably impacted restructuring charges n et income earnings per share millions except per share amounts change change net income sales average total assets earnings per common share assuming dilution n et income earnings per common share net income decreased declined earnings per common share assuming dilution declined compared decline declines primarily reflect impact acquired research charges higher restructuring charges increased reserves legal defense costs incremental impact expensing stock options increased costs partially offset growth equity income affiliates net tax charge associated repatriation foreign earnings accordance ajca net income percentage sales decrease percentage sales ratio compared reflects factors discussed net income percentage average total assets elected joint venture affiliate information expand research base realize synergies combining capabilities opportunities assets previous years company formed number joint ventures see note consolidated financial statements erckscheringplough partnership company scheringplough corporation scheringplough collectively partners entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas agreements generally provide equal sharing development costs copromotion approved products company cholesterolmanagement partnership agreements expanded include countries world excluding japan ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states july combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside united states cholesterol agreements provide sharing operating income generated merckschering plough cholesterol partnership msp partnership based upon percentages vary product sales level country us market partners share profits zetia vytorin sales equally exception first million annual zetia sales scheringplough receives greater share profits operating income includes expenses partners contractually agreed share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services ongoing clinical research market support market research market expansion well specialty sales force physician education programs expenses incurred support msp partnership shared partners marketing administrative expenses including certain sales force costs well certain manufacturing costs included equity income affiliates however costs reflected overall results company certain research development expenses generally shared equally partners adjusting earned milestones sales joint venture products follows millions zetia vytorin global sales zetia increased global sales vytorin increased vytorin single tablet cholesterol treatment provide ldl cholesterol lowering dual inhibition cholesterol production absorption june msp partnership announced new data two clinical trials data presented international symposium atherosclerosis meeting showed vytorin significantly effective crestor reducing ldl cholesterol across study dose comparisons analysis data showed averaged across study doses vytorin brought patients high risk cardiovascular disease ldl cholesterol levels less mgdl compared crestor also june new data released american diabetes associations ada th annual scientific sessions showed recommended usual starting doses vytorin superior lipitor lowering ldl cholesterol patients type diabetes high cholesterol data also published december issue mayo clinic proceedings results companys interest msp partnership recorded equity income affiliates merck recognized equity income million million million strazeneca lp company entered agreement astra ab astra develop market astra products united states company astra formed equallyowned joint venture developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining company astra restructured joint venture whereby company acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership company maintains limited partner interest partnership renamed astrazeneca lp azlp became exclusive distributor products kbi retained rights merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns aggregated million million million respectively erial limited merck rhnepoulenc sa sanofiaventis sa combined animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species sales joint venture products follows millions fipronil products avermectin products biological products products broiler foreign turkey segments poultry genetics business sold domestic turkey segment divested transactions completed divestiture merials interest poultry genetics business comparative purposes amounts presented include revenue earned poultry genetics business anofi pasteur msd merck pasteur merieux connaught sanofi pasteur sa established owned joint venture market vaccines europe collaborate development combination vaccines distribution europe merck launched three new vaccines approved use eu marketed spmsd certain western european countries gardasil prevention cervical cancer genital warts caused certain types hpv rotateq help protect rotavirus gastroenteritis infants children zostavax help prevent shingles herpes zoster individuals years age older september spmsd entered letter undertaking lou emea due agency concerns regarding longterm efficacy hepatitis b component hexavac hepatitis b component hexavac manufactured merck lou requires relevant part suspension eu hexavac license suspension hexavac distribution recall hexavac product eu recall hexavac number noneu countries surveillance program possible future revaccination spmsd markets sells hexavac part eu notified merck reserving rights may seek damages merck defended indemnified held harmless merck event third party claims september emea initiated formal review longterm efficacy hepatitis b vaccine hbvaxpro hepatitis b component hepatitis bhib combination vaccine procomvax products marketed sold spmsd european territory sold elsewhere different names merck extensive review emea determined may vaccine continues offer effective protection hepatitis b allowed spmsd continue marketing product minor label changes sales joint venture products follows millions hepatitis vaccines viral vaccines vaccines j ohnson johnsonmerck consumer pharmaceuticals company merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture expanded europe canada march merck sold equity stake european joint venture johnson johnson million recorded million gain income expense net merck continue benefit royalties certain products also regained rights potential future products switch prescription overthecounter status europe sales joint venture products follows millions gastrointestinal products products includes sales european joint venture march c apital expenditures capital expenditures million billion expenditures united states million million expenditures included million production facilities million research development facilities million environmental projects million administrative safety general site projects capital expenditures estimated billion depreciation expense billion billion billion billion respectively applied locations united states total depreciation expense includes accelerated depreciation million million respectively associated global restructuring plan additionally depreciation expense reflects million associated closure terlings park basic research center see note consolidated financial statements nalysis liquidity capital resources mercks strong financial profile enables company fully fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders cash provided operating activities billion continues companys primary source funds finance capital expenditures treasury stock purchases dividends paid stockholders december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments elected data millions working capital total debt total liabilities equity cash provided operations total debt company began shifting mix investments shortterm longterm resulting reduction working capital line historical levels relative level december enable execution ajca repatriation company changed mix investments longterm shortterm resulting significant increase working capital december ajca created temporary incentives december us multinationals repatriate accumulated income earned outside united states december connection ajca company repatriated billion result company recorded income tax charge million taxes income related repatriation million paid remainder paid first quarter december approximately billion ajca repatriation invested fully collateralized overnight repurchase agreements included shortterm investments consolidated balance sheet early company began reinvesting repurchase agreement balances short longterm investments working capital levels adequate meet operating requirements company ratios total debt total liabilities equity cash provided operations total debt reflect strength companys operating cash flows ability company cover contractual obligations previously disclosed internal revenue service irs examining companys tax returns years issued notices deficiency respect partnership transaction entered two minority interest equity financings entered respectively irs recently concluded examination years issue final revenue agents report first quarter february company entered closing agreements irs covering several specific items including partnership transaction minority interest equity financings terms closing agreements company expects make payment approximately billion first quarter payment offset tax refund million amounts previously paid related matters ii million federal tax benefit related interest included payment resulting net cash cost company approximately billion company previously established reserves matters conclusion irs examination including closing agreements material effect companys results operations financial position liquidity material adverse effect companys cash flow first quarter payment made impact years subsequent partnership transaction minority interest equity financings included closing agreements although years remain open respects previously disclosed october company received notice reassessment canada revenue agency cra containing adjustments related certain intercompany pricing matters result additional taxes due approximately billion us dollars plus interest million us dollars see note consolidated financial statements company disagrees positions taken cra believes without merit company intends contest reassessment cra appeals process courts necessary connection appeals process notice reassessment company required post deposit one half tax interest assessed january company pledged collateral consisting cash cash equivalents million financial institution provided letter guarantee cra management believes resolution matters material adverse effect companys financial position liquidity however unfavorable resolution could material adverse effect companys results operations cash flows quarter adjustment recorded tax due companys contractual obligations december follows p ayments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt operating leases purchase obligations consist primarily goods services enforceable legally binding include obligations minimum inventory contracts research development advertising research contracts include milestone payments contingent upon future events loans payable current portion longterm debt includes million notes redeemed company february upon notification remarketing agent due overall rise interest rates would exercise annual option remarket notes loans payable current portion longterm debt also reflects million longdated notes subject repayment option holders annual basis required funding obligations relating companys pension postretirement benefit plans expected material december company increased capacity shelf registration statement filed securities exchange commission sec issue debt securities additional billion february company issued billion tenyear notes shelf november company issued million twentyyear notes million fiveyear notes shelf remaining capacity companys shelf registration statement approximately billion april company extended maturity date billion fiveyear revolving credit facility february april facility provides backup liquidity companys commercial paper borrowing facility general corporate purposes company drawn funding facility companys longterm credit ratings assigned moodys standard poors aa aa respectively negative outlook ratings continue allow access capital markets flexibility obtaining funds competitive terms company continues maintain conservative financial profile total cash investments billion exceeds sum loans payable longterm debt billion company also longterm credit ratings remain among top rated nonfinancial corporations despite strong financial profile certain contingent events realized discussed note consolidated financial statements could material adverse impact companys liquidity capital resources company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations july board directors approved purchases time billion merck shares total treasury stock purchased program billion december billion remains stock repurchase authorization approved merck board directors f inancial instruments market risk disclosures f oreign currency risk management us dollar functional currency companys foreign subsidiaries significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge anticipated thirdparty sales expected occur planning cycle typically three years future company layer hedges time increasing portion sales hedged gets closer expected date transaction probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner merck manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows fully offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows weaker us dollar would result net benefit market value companys hedges would declined million million respectively uniform weakening us dollar december market value determined using foreign exchange option pricing model holding factors except exchange rates constant merck principally uses purchased local currency put options uniform weakening us dollar yield largest overall potential loss market value options sensitivity measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets merck routinely enters contracts fully offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts limited basis deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level company uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened currency exposures company december income taxes would declined million million respectively merck net short position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows nterest rate risk management addition revenue hedging balance sheet risk management programs company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party seven payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixed rate notes one swap maturing notional amount million two swaps maturing notional amounts million one swap maturing notional amount million three swaps maturing notional amounts million swaps effectively convert fixedrate obligations floating rate instruments cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments december included repurchase agreements market values significantly impacted changes interest rates market value companys medium longterm fixedrate investments modestly impacted changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value companys investments debt related swap contracts change interest rates indicated one percentage point increase interest rates december would positively impacted net aggregate market value instruments million million respectively one percentage point decrease december would negatively impacted net aggregate market value million million respectively decreased sensitivity attributable change mix investments shortterm variable rate december longterm fixed rate december fair value companys debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair value companys investments determined using combination pricing duration models c ritical accounting policies matters consolidated financial statements include certain amounts based managements best estimates judgments estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions acquisitions taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements r evenue recognition revenues sales products recognized title risk loss passes customer revenues domestic pharmaceutical sales recognized time shipment many foreign subsidiaries well vaccine sales revenues recognized time delivery recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesale purchaser known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale provision aggregate indirect customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases directly intermediary wholesale purchaser contracted customer generally purchases product contracted price plus markup wholesaler wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid benefit providers final dispensing product pharmacy benefit plan participant provision based expected payments driven patient usage contract performance benefit provider customers company assumes firstin firstout movement inventory within supply chain purposes estimating aggregate indirect customer discount accrual addition company uses historical customer segment mix adjusted known events order estimate expected provision amounts accrued aggregate indirect customer discounts evaluated quarterly basis comparison information provided wholesalers customers amounts accrued adjustments recorded trends significant events indicate change estimated provision appropriate company continually monitors provision aggregate indirect customer discounts material adjustments estimates associated aggregate indirect customer discount provision summarized information changes aggregate indirect customer discount accrual follows millions balance january current provision adjustments prior years payments b alance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates accrued expenses accrued balances relative provisions included accounts receivable accrued current liabilities million million respectively december million billion respectively december company maintains returns policy allows customers return product within specified period prior subsequent expiration date generally six months twelve months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market additional generic competition changes formularies launch overthecounter products name product returns provision well actual returns less net sales distribution program us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories within specified levels terms program allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution program includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide mentioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns nventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support initial market demand typically capitalization inventory begin related product candidates phase iii clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory impacted stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements december inventories produced preparation product launches consisted three vaccine products new formulation existing vaccine product new compound type diabetes company launched accordingly significant inventories produced preparation product launches capitalized december buildup inventories produced preparation product launches material effect companys liquidity c ontingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december company reserve million solely future legal defense costs related vioxx lawsuits vioxx investigations company spent million aggregate including million fourth quarter legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation third fourth quarter company recorded charges million million respectively increase reserve solely future legal defense costs related vioxx million december reserve based certain assumptions best estimate amount company believes time reasonably estimate spent significant factors considered establishment ongoing review reserve vioxx legal defense costs follows actual costs incurred company time development companys legal defense strategy structure light scope vioxx litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx product liability lawsuits events scheduled trials expected occur throughout inherent inability predict ultimate outcomes trials limit companys ability reasonably estimate legal costs beyond end company anticipate need increase reserve every quarter continue monitor legal defense costs review adequacy associated reserves may determine increase reserves legal defense costs time future based upon factors set forth believes would appropriate company currently anticipates number vioxx product liability lawsuits tried trial oregon securities case scheduled company predict whether trial proceed schedule timing vioxx shareholder lawsuit trials company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations company established reserves potential liability relating vioxx litigation december company established reserve approximately million solely future legal defense costs fosamax litigation significant factors considered establishment reserve fosamax litigation legal defense costs follows actual costs incurred company thus far development companys legal defense strategy structure light creation fosamax multidistrict litigation number cases brought company anticipated timing progression related costs pretrial activities fosamax litigation company continue monitor legal defense costs review adequacy associated reserves due uncertain nature litigation company unable estimate costs beyond end unfavorable outcomes fosamax litigation could material adverse effect companys financial position liquidity results operations company established reserves potential liability relating fosamax litigation company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties prps may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs worldwide survey initially performed assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated estimates extent contamination site initially made preinvestigation stage liabilities potential cost remediation accrued time definitive information became available course investigations andor remedial efforts site estimates refined accruals adjusted accordingly estimates related accruals continue refined annually company believes compliance material respects applicable environmental laws regulations expenditures remediation environmental liabilities million estimated million years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december december respectively liabilities undiscounted consider potential recoveries insurers parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year harebased compensation company recognizes compensation cost relating sharebased payment transactions net income using fairvalue measurement method accordance fas r adopted january fas r requires sharebased payments employees including grants employee stock options recognized net income compensation expense based fair value requisite service period awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options p ensions postretirement benefit plans net pension postretirement benefit cost totaled million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated annually modified reflect prevailing market rate december portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due december company changed discount rate us pension plans us postretirement benefit plans expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well actual returns companys plan assets applies adjustments reflect recent capital market experience using reference information company develops forwardlooking return expectations asset category weighted average expected longterm rate return targeted portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate result analysis companys expected rate return remained unchanged us pension postretirement benefit plans target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent long term nature plans benefit obligation expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost company expect minimum pension funding requirement internal revenue code preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements effective december company adopted fasb statement employers accounting defined benefit pension postretirement plans amendment fasb statements r fas except requirement measure plan assets benefit obligations companys fiscal year end balance sheet effective december connection adoption fas net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component accumulated comprehensive income expected returns based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized marketrelated value assets ratably fiveyear period also net loss amounts accumulated comprehensive income excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amortization net losses companys us plans december expected increase net pension postretirement benefit cost approximately million annually cquisitions company accounts acquired businesses using purchase method accounting accordance fas business combinations requires assets acquired liabilities assumed recorded date acquisition respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill company determines acquired company development stage company commenced planned principal operations acquisition accounted acquisition assets rather business combination therefore goodwill would recorded fair value intangible assets including acquired research based significant judgments made management accordingly significant items company typically obtains assistance third party valuation specialists amounts allocated acquired research expensed date acquisition technological feasibility established alternative future use existed projects used immediately research process alternative future uses company capitalizes intangible assets amortizes appropriate useful life valuations useful life assumptions based information available near acquisition date based expectations assumptions deemed reasonable management judgments made determining estimated fair values assigned assets acquired liabilities assumed well asset lives materially impact companys results operations intangible assets including acquired research company typically uses income approach estimates fair value based projects projected cash flows future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underling patent expected revenues adjusted probability technical marketing success resulting cash flows discounted risk adjusted discount rate axes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual one time item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys effective tax rate evaluating tax positions company establishes reserves despite belief tax return positions fully supportable certain positions likely challenged may succeed see note consolidated financial statements company adjusts reserves light changing facts circumstances closing tax audit tax regulations require items included tax return different times items reflected financial statements result effective tax rate reflected financial statements different reported tax return differences permanent expenses deductible tax return timing differences depreciation expense timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements previously disclosed october ajca signed law ajca creates temporary incentive us multinationals repatriate accumulated income earned outside united states december connection ajca company repatriated billion see note consolidated financial statements result repatriation company recorded income tax charge million taxes income related repatriation charge partially offset million benefit associated decision implement certain tax planning strategies company changed intention indefinitely reinvest accumulated earnings earned subsequent december december foreign earnings billion retained indefinitely subsidiary companies reinvestment provision made income taxes would payable upon distribution earnings practicable determine amount related unrecognized deferred income tax liability r ecently issued accounting standards july fasb issued interpretation accounting uncertainty income taxes interpretation fasb statement fin effective january fin clarifies accounting uncertainty tax positions requiring companies recognize financial statements impact tax position position likely sustained audit based technical merits position among provisions fin also requires expanded disclosures end annual period presented company continues evaluate impact fin financial position results operations time effects adoption yet determined september fasb issued statement fair value measurements fas effective january statement clarifies definition fair value establishes framework measuring fair value expands disclosures fair value measurements effect adoption fas companys financial position results operations expected material c autionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forward looking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms k q k item business annual report company discusses detail various important factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties tem quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations tem financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income retained earnings comprehensive income cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows c onsolidated statement income merck co inc subsidiaries years ended december millions except per share amounts ales c osts expenses materials production marketing administrative research development restructuring costs equity income affiliates income expense net ncome taxes taxes income n et income basic earnings per common share earnings per common share assuming dilution c onsolidated statement retained earnings merck co inc subsidiaries years ended december millions b alance january n et income common stock dividends declared balance december c onsolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income ther comprehensive income loss net unrealized loss gain derivatives net tax net income realization net unrealized gain loss investments net tax net income realization minimum pension liability net tax cumulative translation adjustment relating equity investees net tax c omprehensive income accompanying notes integral part consolidated financial statements consolidated balance sheet merck co inc subsidiaries december millions ssets current assets cash cash equivalents shortterm investments accounts receivable inventories excludes inventories classified assets see note prepaid expenses taxes otal current assets nvestments p roperty plant equipment cost land buildings machinery equipment office furnishings construction progress less allowance depreciation g oodwill ther intangibles net ther assets liabilities stockholders equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable otal current liabilities l ongterm debt eferred income taxes noncurrent liabilities inority interests tockholders equity common stock one cent par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive income less treasury stock cost shares shares otal stockholders equity accompanying notes integral part consolidated financial statement consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization deferred income taxes equity income affiliates dividends distributions equity affiliates sharebased compensation acquired research net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities n et cash provided operating activities c ash flows investing activities capital expenditures purchases securities subsidiaries investments proceeds sales securities subsidiaries investments n et cash used provided investing activities c ash flows financing activities net change shortterm borrowings proceeds issuance debt payments debt redemption preferred units subsidiary purchases treasury stock dividends paid stockholders proceeds exercise stock options n et cash used financing activities e ffect exchange rate changes cash cash equivalents n et decrease increase cash cash equivalents cash cash equivalents beginning year c ash cash equivalents end year accompanying notes integral part consolidated financial statement n otes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck global researchdriven pharmaceutical company discovers develops manufactures markets broad range innovative products improve human animal health companys operations principally managed products basis comprised two reportable segments pharmaceutical segment vaccines segment pharmaceutical segment includes human health pharmaceutical products marketed either directly joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations institutions vaccines segment includes human health vaccine products marketed either directly joint venture products consist preventative pediatric adolescent adult vaccines primarily administered physician offices merck sells human health vaccines primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value pharmaceutical vaccine products health care professionals private practice group practices managed care organizations summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside stockholders interests shown minority interests investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis foreign currency translation us dollar functional currency companys foreign subsidiaries cash cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories substantially domestic inventories valued lower lastin firstout lifo cost market book tax purposes foreign inventories valued lower firstin firstout fifo cost market inventories consist currently marketed products certain products awaiting regulatory approval evaluating recoverability inventories produced preparation product launches company considers probability revenue obtained future sale related inventory together status product within regulatory approval process investments investments classified availableforsale reported fair value unrealized gains losses extent hedged reported net tax accumulated comprehensive income investments debt securities classified heldtomaturity consistent managements intent reported cost impairment losses charged income expense net otherthantemporary declines fair value company considers available evidence evaluating potential impairment investments including duration extent fair value less cost companys ability intent hold investment revenue recognition revenues sales products recognized title risk loss passes customer revenues domestic pharmaceutical sales recognized time shipment many foreign subsidiaries well vaccine sales revenues recognized time delivery recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesale purchaser known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale accruals chargebacks reflected direct reduction accounts receivable accruals rebates recorded accrued expenses accrued balances relative provisions included accounts receivable accrued current liabilities million million respectively december million billion respectively december effective january company began recognizing revenue sale vaccines federal government placement stockpiles related pediatric vaccine stockpile accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile company retrospectively applied impacts adopting interpretation reducing accrued current liabilities million increasing income taxes payable million retained earnings million respectively december impact companys results operations impacts adoption results operations increases following sales million materials production costs million taxes income million net income million earnings per common share assuming dilution depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings acquisitions company accounts acquired businesses using purchase method accounting accordance financial accounting standards board fasb statement business combinations requires assets acquired liabilities assumed recorded date acquisition respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill company determines acquired company development stage company commenced planned principal operations acquisition accounted acquisition assets rather business combination therefore goodwill would recorded accordance fasb interpretation applicability fasb statement business combinations accounted purchase method company allocates amounts acquired research expensed date acquisition technological feasibility established alternative future use existed projects used immediately research process alternative future uses company capitalizes intangible assets amortizes appropriate useful life operating results acquired business reflected companys consolidated financial statements results operations date acquisition goodwill intangibles goodwill represents excess acquisition costs fair value net assets businesses purchased goodwill assigned reporting units within companys segments evaluated impairment least annual basis using fair value based test acquired intangibles recorded cost amortized straightline basis estimated useful lives ranging years see note events circumstances warrant review company assess recoverability future operations intangibles using undiscounted cash flows derived lowest appropriate asset groupings generally subsidiary level impairments recognized operating results extent carrying value exceeds fair value determined based net present value estimated future cash flows research development research development expensed incurred upfront milestone payments made third parties connection research development collaborations prior regulatory approval expensed incurred payments made third parties subsequent regulatory approval capitalized amortized shorter remaining license product patent life sharebased compensation effective january company adopted fasb statement r sharebased payment fas r see note fas r requires sharebased payments employees expensed requisite service period based grantdate fair value awards requires unvested portion outstanding awards upon adoption recognized using fair value attribution methodologies previously determined fasb statement accounting stockbased compensation company continues use blackscholes valuation method applied requirements fas r using modified prospective method prior adoption fas r employee sharebased compensation recognized using intrinsic value method measures sharebased compensation expense amount market price stock date grant exceeds exercise price accordingly compensation expense recognized companys sharebased compensation plans performancebased awards restricted stock units options granted employees certain equity method investees legal defense costs legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation acquisitions taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently issued accounting standards fasb recently issued interpretation accounting uncertainty income taxes interpretation fasb statement fin statement fair value measurements fas fin effective january clarifies accounting uncertainty tax positions requiring companies recognize financial statements impact tax position position likely sustained audit based technical merits position among provisions fin also requires expanded disclosures end annual period presented company continues evaluate impact fin financial position results operations time effects adoption yet determined fas effective january clarifies definition fair value establishes framework measuring fair value expands disclosures fair value measurements effect adoption fas companys financial position results operations expected material voluntary product withdrawal september company announced voluntary worldwide withdrawal vioxx arthritis acute pain medication companys decision effective immediately based new threeyear data prospective randomized placebocontrolled clinical trial approve adenomatous polyp prevention vioxx connection withdrawal company recorded unfavorable adjustment net income million per share adjustment pretax income million amount million related estimated customer returns product previously sold recorded reduction sales million related writeoffs inventory held company recorded materials production expense million related estimated costs undertake withdrawal product recorded marketing administrative expense tax benefit adjustment million reflects geographical mix vioxx returns cost withdrawal adjustment include charges future legal defense costs see note vioxx withdrawal process completed costs associated withdrawal line original amounts recorded company restructuring g lobal restructuring program november company announced initial phase global restructuring program designed reduce companys cost structure increase efficiency enhance competitiveness initial steps include implementation new supply strategy merck manufacturing division intended create leaner costeffective customerfocused manufacturing model threeyear period part program merck announced plans sell close five manufacturing sites two preclinical sites end eliminate approximately positions companywide company also sold closed certain facilities sold related assets connection restructuring program pretax costs restructuring program million million expected million million end initial phase restructuring program expected substantially complete cumulative pretax costs program expected range billion billion approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities scheduled closure since inception global restructuring program december company recorded total pretax accumulated costs billion eliminated approximately positions comprised employee separations elimination contractors vacant positions following table summarizes charges related global restructuring program type cost eparation ccelerated year ended december costs depreciation total materials production research development restructuring costs year ended december aterials production research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated approximately positions eliminated approximately eliminated comprised actual headcount reductions elimination contractors vacant positions accelerated depreciation costs primarily relate five merckowned manufacturing facilities ponders end united kingdom okazaki japan kirkland canada albany georgia danville pennsylvania two preclinical sites okazaki menuma japan sold closed end actions effort reduce costs consolidate companys manufacturing research facilities end three manufacturing facilities closed sold ceased operations two preclinical sites closed sites continue operate respective closure dates since future cash flows sufficient recover respective book values merck required accelerate depreciation site assets rather writing immediately site assets include manufacturing research facilities equipment activity includes approximately million million respectively associated impairment certain fixed assets longer used business result restructuring actions must therefore written additionally activity includes million million respectively related curtailment settlement termination charges companys pension postretirement benefit plans see note activity also includes pretax gains million resulting sales facilities connection global restructuring program ther restructuring programs part costreduction initiative announced october completed end company eliminated positions company completed similar program positions eliminated december result restructuring actions company recorded restructuring costs million million amounts respectively million million related employee severance benefits million million related curtailment settlement termination charges companys pension postretirement benefit plans see note million related modification terms certain employees stock option grants following table summarizes charges spending relating global restructuring program programs eparation ccelerated costs depreciation total restructuring reserves january expense payments receipts net noncash activity restructuring reserves december expense payments receipts net noncash activity restructuring reserves december includes separation costs associated global restructuring program well amounts restructuring programs restructuring programs substantially complete end first quarter includes proceeds sales facilities connection global restructuring program company also closed basic research center terlings park united kingdom anticipation closing company incurred additional accelerated depreciation costs million recorded research development expense reflected table reduced assets research center net realizable values subsequent december research development performed site company records restructuring activities accordance fasb statement employers accounting postemployment benefits amendment fasb statement fasb statement employers accounting settlements curtailments defined benefit pension plans termination benefits fasb statement accounting impairment disposal longlived assets fasb statement accounting costs associated exit disposal activities segment reporting restructuring charges recorded unallocated expense research collaborations acquisitions license agreements merck continues strategy establishing strong external alliances complement substantial internal research capabilities including research collaborations acquisitions licensing preclinical clinical compounds technology transfers drive near longterm growth merck signed agreements december merck completed acquisition sirna therapeutics inc sirna per share cash total value approximately billion included purchase outstanding sirna shares warrants stock options aggregate purchase price billion paid january accordingly reflected liability within accrued current liabilities companys consolidated balance sheet december sirna publiclyheld biotechnology company leader developing new class medicines based rna interference rnai technology could significantly alter treatment disease rnaibased therapeutics selectively catalyze destruction rna transcribed individual gene acquisition sirna expected increase mercks ability use rnai technology turn targeted gene human cell potentially rendering inoperative gene responsible triggering specific disease transaction accounted purchase method accounting assets acquired liabilities assumed sirna date acquisition recorded respective fair values acquisition date companys consolidated financial statements determination fair values requires management make significant estimates assumptions excess purchase price fair value acquired net assets recorded goodwill million goodwill fully allocated pharmaceutical segment deductible tax purposes also company recorded charge million acquired research associated sirnas compounds currently development acquisition date technological feasibility established alternative future use existed acquired research charge related development treatments hepatitis b hepatitis c viruses preclinical development well licensing agreements held sirna charge deductible tax purposes recorded research development expense determined based upon present value expected future cash flows new product candidates resulting technology adjusted probability technical marketing success utilizing income approach reflecting appropriate riskadjusted discount rates ongoing activity respect compounds development expected material companys research development expenses allocation purchase price also resulted recognition intangible asset million related deferred tax liability million well assets liabilities net million intangible asset relates sirnas developed technology used immediately research development process alternative future uses intangible asset amortized research development expense straight line basis seven year useful life pro forma financial information required sirnas historical financial results significant compared companys financial results transaction closed december accordingly sirnas operating results reflected companys results operations also december merck idera pharmaceuticals idera announced formed broad collaboration research develop commercialize ideras tolllike receptor tlr agonists terms agreement merck receive worldwide exclusive rights number ideras agonist compounds targeting tlr use combination mercks therapeutic prophylactic vaccines development oncology infectious diseases alzheimers disease merck idera engage twoyear research development collaboration generate novel agonists targeting tlr tlr incorporating merck idera chemistry use licensed fields merck paid upfront license fee million idera recorded research development expense purchased million common stock per share addition merck fund research development collaboration idera eligible receive milestone payments million vaccines successfully developed three fields additional milestones million would payable followon indications oncology field successful development additional vaccines containing ideras tlr agonists limit number vaccines merck apply ideras agonists within licensed fields addition idera receive royalties products commercialized collaboration november company expanded scope existing strategic collaboration foxhollow technologies inc foxhollow atherosclerotic plaque analysis additionally merck acquired stake foxhollow purchase million newlyissued shares foxhollow common stock per share representing approximately stake shares recorded equity method investment consolidated balance sheet december existing strategic collaboration entered provided foxhollow receive upfront payment opportunity additional payments collaboration continued terms expanded collaboration agreement merck pay million foxhollow four years exchange foxhollows agreement collaborate exclusively merck specified disease areas merck also provide minimum million funding foxhollow first three years four year collaboration program term research activities conducted foxhollow mercks direction foxhollow receive milestone payments successful development drug products diagnostic tests utilizing results collaboration well royalties october merck ambrilia biopharma inc ambrilia biopharmaceutical company developing innovative therapeutics fields cancer infectious diseases announced entered exclusive licensing agreement granting merck worldwide rights ambrilias hivaids protease inhibitor program terms agreement ambrilia granted merck exclusive worldwide rights lead compound ppl completed phase singledose pharmacokinetic study currently phase repeat dose pharmacokinetic study return ambrilia received upfront licensing fee million signing company recorded research development expense eligible cash payments totaling million upon successful completion development clinical regulatory sales milestones ambrilia receive royalties future product sales june company acquired outstanding equity glycofi inc glycofi approximately million cash million purchase price net million shares already owned net transaction costs glycofi privatelyheld biotechnology company leader field yeast glycoengineering addition specific carbohydrate modifications proteins yeast optimization biologic drug molecules glycofis technology platform used development glycoprotein well optimization glycoprotein target connection acquisition company recorded charge million acquired research associated glycofis technology platform used research development process acquisition date technological feasibility established alternative future use existed charge deductible tax purposes company expects technology fully developed next one two years charge recorded research development expense determined based upon present value expected future cash flows new product candidates resulting technology adjusted probability technical marketing success utilizing income approach reflecting appropriate riskadjusted discount rate company also recorded million intangible asset million net deferred taxes related glycofis developed technology used immediately research development process alternative future uses intangible asset amortized research development expense straightline basis five year useful life remaining net assets acquired transaction material glycofi development stage company commenced planned principal operations transaction accounted acquisition assets rather business combination therefore goodwill recorded glycofis results operations included companys consolidated financial results since acquisition date may company acquired equity abmaxis inc abmaxis approximately million cash abmaxis privatelyheld biopharmaceutical company dedicated discovery optimization monoclonal antibody mab products human therapeutics diagnostics abmaxis developed validated breakthrough antibody engineering technology platform abmaxis insilico immunization alternative future uses company significant technological engineering risks date acquisition connection acquisition company allocated substantially purchase price abmaxis technology platform recorded intangible asset million million net deferred taxes intangible asset amortized research development expense straightline basis five year useful life remaining net assets acquired transaction material abmaxis development stage company commenced planned principal operations transaction accounted acquisition assets rather business combination therefore goodwill recorded abmaxis results operations included companys consolidated financial results since acquisition date march neuromed pharmaceuticals ltd neuromed merck signed research collaboration license agreement research develop commercialize novel compounds treatment pain neurological disorders including neuromeds lead compound nmed mk currently phase ii development treatment pain terms agreement neuromed received upfront payment million company recorded research development expense successful development launch nmed initial single indication worldwide basis would trigger milestone payments totaling million milestones could increase approximately million indication nmed developed approved additional compound developed approved two indications neuromed would also receive royalties worldwide sales nmed additional compounds developed agreement agensys inc agensys cancer biotechnology company merck announced formation global alliance jointly develop commercialize agspsca agensys fully human mab prostate stem cell antigen also merck entered agreement geron corporation develop cancer vaccine telomerase enzyme active cancer cells maintains telomere length ends chromosomes allows cancer grow metastasize long periods time company acquired aton pharma inc aton privatelyheld biotechnology company focusing development novel treatments cancer serious diseases atons clinical pipeline histone deacetylase inhibitors represents class antitumor agents potential efficacy based novel mechanism action atons lead product candidate time acquisition suberoylanilide hydroxamic acid known vorinostat treatment cutaneous tcell lymphoma approved food drug administration october marketed zolinza united states consideration acquisition consisted upfront payment well contingent payments based upon regulatory filing approval sale products connection transaction company recorded charge million included research development expense acquired research associated products development acquisition date technological feasibility established alternative future use existed remaining net assets acquired transaction material aton development stage company commenced planned principal operations transaction accounted acquisition assets rather business combination therefore goodwill recorded atons results operations included companys since acquisition date financial instruments f oreign currency risk management us dollar functional currency companys foreign subsidiaries significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge anticipated thirdparty sales expected occur planning cycle typically three years future company layer hedges time increasing portion sales hedged gets closer expected date transaction probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner merck manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows fully offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows designated hedge relationship based total changes options cash flows accordingly entire fair value change options deferred accumulated comprehensive income aoci reclassified sales hedged anticipated revenue recognized hedge relationship perfectly effective therefore hedge ineffectiveness recorded fair values currency options reported accounts receivable assets cash flows contracts reported operating activities consolidated statement cash flows primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets merck routinely enters contracts fully offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts limited basis deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level foreign currency denominated monetary assets liabilities remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year company uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates changes fair value hedged securities due fluctuations spot rates offset income expense net fair value changes forward contracts attributable spot rate fluctuations hedge ineffectiveness material changes contracts fair value due spotforward differences excluded designated hedge relationship recognized income expense net amounts significant years ended december fair values forward exchange contracts reported following four balance sheet line items accounts receivable current portion gain position assets noncurrent portion gain position accrued current liabilities current portion loss position deferred income taxes noncurrent liabilities non current portion loss position cash flows contracts reported operating activities consolidated statement cash flows nterest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party seven payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes one swap maturing notional amount million two swaps maturing notional amounts million one swap maturing notional amount million three swaps maturing notional amounts million swaps effectively convert fixedrate obligations floatingrate instruments fair value changes notes fully offset interest expense fair value changes swap contracts fair values contracts reported accounts receivable assets accrued current liabilities deferred income taxes noncurrent liabilities cash flows contracts reported operating activities consolidated statement cash flows f air value financial instruments summarized carrying values fair values companys financial instruments december fair values estimated based market prices available dealer quotes carrying value fair value carrying value fair value assets cash cash equivalents shortterm investments longterm investments purchased currency options forward exchange contracts interest rate swaps liabilities loans payable current portion longterm debt longterm debt forward exchange contracts connection american jobs creation act ajca company repatriated billion see note december billion ajca repatriation invested fully collateralized overnight repurchase agreements included shortterm investments consolidated balance sheet early company reinvested repurchase agreement balances short long term investments summary december carrying values fair values companys investments gross unrealized gains losses companys availableforsaleinvestments recorded net tax aoci follows carrying fair gross unrealized value value gains losses corporate notes bonds us government agency securities commercial paper municipal securities mortgagedbacked securities assetbacked securities foreign government bonds repurchase agreements debt securities equity securities total availableforsale substantially companys unrealized losses december continuous loss positions less months carrying fair gross unrealized value value gains losses repurchase agreements corporate notes bonds commercial paper municipal securities us government agency securities debt securities equity securities total availableforsale availableforsale debt securities maturing within one year totaled billion december remaining debt securities billion mature within five years c oncentrations credit risk part ongoing control procedures company monitors concentrations credit risk associated corporate issuers securities financial institutions conducts business credit risk minimal credit exposure limits established avoid concentration single issuer institution four us customers represented aggregate approximately onefifth companys accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost reduction lifo costs recognized inventories assets inventories valued lifo method comprised approximately inventories december amounts recognized assets comprised entirely raw materials work process inventories include inventories products expected sold within one year principally vaccines december inventories produced preparation product launches intangibles intangibles december consisted patents product rights total acquired cost patents product rights total accumulated amortization increase intangibles primarily reflects intangibles connection acquisitions sirna glycofi abmaxis see note aggregate amortization expense million million million estimated aggregate amortization expense next five years follows million million million million million joint ventures equity method affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates comprised following ears ended december merckscheringplough astrazeneca lp primarily reflects results merial limited joint ventures sanofi pasteur johnson johnson erckscheringplough company scheringplough corporation scheringplough collectively partners entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas agreements generally provide equal sharing development costs copromotion approved products company cholesterolmanagement partnership agreements expanded include countries world excluding japan ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states reported merckscheringplough cholesterol partnership msp partnership global sales zetia totaled billion billion billion july combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside united states global sales vytorin billion billion million cholesterol agreements provide sharing operating income generated msp partnership based upon percentages vary product sales level country us market partners share profits zetia vytorin equally exception first million annual zetia sales scheringplough receives greater share profits operating income includes expenses partners contractually agreed share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services ongoing clinical research market support market research market expansion well specialty sales force physician education programs expenses incurred support msp partnership shared partners marketing administrative expenses including certain sales force costs well certain manufacturing costs included equity income affiliates however costs reflected overall results company certain research development expenses generally shared equally partners adjusting earned milestones respiratory therapeutic agreements provide joint development marketing partners oncedaily fixedcombination tablet containing active ingredients montelukast sodium loratadine montelukast sodium sold merck singulair loratadine sold scheringplough claritin january respiratory partnership reported results phase iii clinical trials fixedcombination tablet containing montelukast sodium loratadine phase iii study demonstrate sufficient added benefits treatment seasonal allergic rhinitis although montelukast sodium loratadine combination tablet approval country phase iii clinical development ongoing strazeneca lp merck entered agreement astra ab astra develop market astras products royaltybearing license companys total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby company acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium prilosec addition merck earns certain partnership returns recorded equity income affiliates reflected table returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings astrazeneca merger triggers partial redemption mercks limited partnership interest upon redemption azlp distribute kbi amount based primarily multiple mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value conjunction restructuring payment million deferred astra purchased option asset option buy mercks interest kbi products excluding gastrointestinal medicines nexium prilosec asset option exercisable exercise price equal net present value march projected future pretax revenue received company kbi products appraised value merck also right require astra purchase interest appraised value addition company granted astra option buy mercks common stock interest kbi exercisable two years astras purchase mercks interest kbi products exercise option astra also provided year combined annual sales two products fall minimum amount provided case long either merck option astrazenecas option exercised exercise price based net present value estimated future net sales nexium prilosec determined time exercise astrazeneca merger constituted trigger event kbi restructuring agreements result merger exchange mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment subject trueup calculation may require repayment portion amount trueup amount directly dependent fair market value astra product rights retained company accordingly recognition contingent income deferred realizable amount determinable anticipated prior provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value trueup amount guaranteed minimum billion distribution limited partner share agreed value payment trueup amount occur astrazenecas purchase mercks interest kbi products contingent upon exercise either mercks option astrazenecas option therefore payment appraised value may may occur anofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales million million million erial limited merck rhnepoulenc sa sanofiaventis sa combined animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species merial sales billion billion billion j ohnson johnson merck consumer pharmaceuticals company merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned venture expanded europe canada march merck sold equity stake european joint venture johnson johnson million recorded million gain income expense net see note merck continue benefit royalties certain products also regained rights potential future products switch prescription overthecounter status europe sales product marketed joint venture including sales european joint venture march million million million investments affiliates accounted using equity method including joint ventures totaled billion december billion december amounts reported assets summarized information affiliates follows ears ended december sales materials production costs expense net income taxes ecember current assets noncurrent assets current liabilities noncurrent liabilities loans payable longterm debt commitments loans payable december included million million respectively longdated notes subject repayment option holders annual basis loans payable december also included million notes annual interest rate resets redeemed company february upon notification remarketing agent due overall rise interest rates would exercise annual option remarket notes loans payable december also included million fixedrate notes due million fixed rate notes due respectively december foreign subsidiary company entered month million line credit financial institution december borrowings line credit million included loans payable loans payable december included billion commercial paper borrowings issued foreign subsidiary billion commercial paper borrowing facility established october provide funding portion companys repatriation connection ajca see note commercial paper outstanding december weighted average interest rate borrowings december respectively longterm debt december consisted astra note due notes due notes due debentures due notes due debentures due notes due variablerate borrowing due notes due debentures due company party interest rate swap contracts effectively convert million fixedrate notes floatingrate instruments see note presented table december consisted primarily million borrowings variable rates averaging respectively borrowings million subject repayment option holders beginning million subject repayment option holders beginning years also included foreign borrowings varying rates aggregate maturities longterm debt next five years follows million billion million million million rental expense companys operating leases net sublease income million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made result number factors product liability insurance become less available cost increased significantly company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability products first sold date company continue evaluate insurance needs costs availability benefits product liability insurance future v ioxx litigation p roduct liability lawsuits previously disclosed individual putative class actions filed company state federal courts alleging personal injury andor economic loss respect purchase use vioxx actions filed federal court coordinated multidistrict litigation us district court eastern district louisiana mdl district judge eldon e fallon number actions filed state court coordinated separate coordinated proceedings state courts new jersey california texas counties philadelphia pennsylvania clark county nevada december company served aware named defendant approximately lawsuits include approximately plaintiff groups alleging personal injuries resulting use vioxx approximately putative class actions alleging personal injuries andor economic loss actions discussed paragraph collectively referred vioxx product liability lawsuits lawsuits approximately lawsuits representing approximately plaintiff groups slated federal mdl approximately lawsuits representing approximately plaintiff groups included coordinated proceeding new jersey superior court judge carol e higbee addition vioxx product liability lawsuits discussed claims plaintiffs dismissed december plaintiffs whose claims dismissed prejudice ie brought either plaintiffs courts additional plaintiffs claims dismissed without prejudice ie brought mdl judge fallon july indicated would schedule trial series cases period november following categories heart attack short term use ii heart attack long term use iii stroke iv cardiovascular injury involving prescription written april labeling vioxx revised include results vigor trial trials began november concluded december next scheduled trial mdl retrial barnett v merck issue damages discussed merck entered tolling agreement tolling agreement mdl plaintiffs steering committee establishes procedure halt running statute limitations tolling certain categories claims allegedly arising use vioxx nonnew jersey citizens tolling agreement applies individuals filed lawsuits may may eventually file lawsuits claimants seek toll claims alleging injuries resulting thrombotic cardiovascular event results myocardial infarction ischemic stroke tolling agreement provides counsel additional time evaluate potential claims tolling agreement requires tolled claims filed federal court december approximately claimants entered tolling agreements merck voluntarily withdrew vioxx market september many states twoyear statute limitations product liability claims requiring claims must filed within two years plaintiffs learned could learned potential cause action result may view september deadline filing vioxx cases important note however law regarding statutes limitations complex varies state state factspecific cases might affected existence pending class actions example states three year statutes limitations instances statute limitations even longer merck expects legal arguments concerning proper application statutes decisions judges presiding individual cases state federal proceedings company previously disclosed outcomes several vioxx product liability lawsuits tried prior september see chart august barnett v merck case judge fallon mdl jury new orleans louisiana returned plaintiff verdict second federal vioxx case go trial jury awarded million compensatory damages million punitive damages august judge fallon overturned excessive damages portion verdict ordered new trial damages judge fallon set retrial october issue damages merck filed motions new trial issues judgment matter law currently pending court plaintiff opposed mercks motion asked judge reduce amount award rather retry case juries found favor merck counts fourth fifth cases go trial mdl jury returned verdict merck mason v merck november dedrick v merck december november judge fallon denied motion filed mdl certify nationwide class persons allegedly suffered personal injury result taking vioxx december jury albright v merck case tried state court birmingham alabama returned verdict merck counts company previously disclosed april garza v merck jury rio grande city texas returned verdict favor plaintiff september texas state court granted companys request investigate possible jury bias juror admitted prior trial several occasions borrowed money plaintiff december court entered judgment plaintiff amount million plus interest reduced original award million texas state cap punitive damages company seeking new trial appeal verdict court grant new trial october california superior court los angeles consolidated trial began cases appell v merck arrigale v merck january judge victoria chaney declared mistrial plaintiffs jury reported deadlocked october coordinated proceeding new jersey superior court judge higbee dismissed claims united kingdom plaintiffs plaintiffs appealed first case scheduled trial texas coordinated proceeding rigby v merck scheduled begin trial november rigby case voluntarily dismissed october plaintiff filed notice nonsuit court consolidated trial hermans v merck humeston v merck began january coordinated proceeding new jersey superior court judge higbee humeston v merck first tried judge higbee set aside november jury verdict favor merck ordered new trial grounds newly discovered evidence hermanshumeston trial separated two phases general phase regarding mercks conduct plaintiffspecific phase jury questions deliberation phase regarding mercks conduct jury answers questions affirmative case move phase ii phase ii plaintiff present specific case end phase ii jury deliberate answer questions respect two plaintiffs jury answer separate verdict sheets course one deliberation case moves punitive phase single presentation side one jury deliberation plaintiffs first case scheduled trial philadelphia coordinated proceeding mccool v merck scheduled begin trial february plaintiff voluntarily dismissed prejudice case january september new jersey superior court appellate division heard argument plaintiffs appeal judge higbees dismissal sinclair v merck case putative class action originally filed december sought creation medical monitoring fund judge higbee granted companys motion dismiss may january appellate division reversed decision remanded case back judge higbee factual inquiry company petitioned new jersey supreme court review appellate divisions decision date vioxx product liability lawsuits plaintiffs whose claims scheduled trial claims seven dismissed claims seven withdrawn trial calendar plaintiffs juries decided mercks favor nine times plaintiffs favor four times addition recent california trial involving two plaintiffs jury could reach verdict either plaintiff mistrial declared new jersey state judge set aside one nine merck verdicts respect four plaintiffs verdicts merck already filed appeal sought judicial review cases one four federal judge overturned damage award shortly trial addition consolidated trial two plaintiffs currently ongoing coordinated proceeding new jersey superior court judge higbee another trial schwaller v merck commenced state court madison county illinois following chart sets forth results us vioxx product liability trials date state federal verdict date plaintiff court result comments aug ernst texas verdict plaintiff jury awarded plaintiff million court reduced amount approximately million plus interest judgment appeal nov humeston nj verdict merck judge ordered new trial currently judge overturned ongoing verdict feb plunkett federal mistrial jury merck prevailed february retrial deadlocked first trial plaintiff moved new trial verdict merck retrial april mcdarby nj verdict plaintiff plaintiff awarded million damages mercks motion new trial pending plaintiffs motion attorneys fees april cona nj verdict merck however jury awarded plaintiff nominal sum failure warn claim consumer fraud act claim mercks motion new trial consumer fraud act claim pending plaintiffs motion attorneys fees april garza texas verdict plaintiff judge reduced million jury award million plus interest merck moved new trial july doherty nj verdict merck plaintiff moved new trial aug grossberg california verdict merck plaintiff moved new trial aug barnett federal verdict plaintiff plaintiff awarded million damages judge ruled award grossly excessive scheduled new trial damages october mercks motion new trial remaining issues pending sept smith federal verdict merck nov mason federal verdict merck dec dedrick federal verdict merck plaintiff moved new trial dec albright alabama verdict merck plaintiff moved new trial jan arrigaleappell california mistrial declared jury deadlocked ther lawsuits previously disclosed july new jersey state trial court certified nationwide class third party payors unions health insurance plans paid whole part vioxx used plan members insureds named plaintiff case seeks recovery certain vioxx purchase costs plus penalties based allegations purported class members paid vioxx would known products alleged risks merck believes class improperly certified trial courts ruling procedural address merits plaintiffs allegations company intends defend vigorously march new jersey superior court appellate division affirmed class certification order july new jersey supreme court decided exercise discretion hear companys appeal appellate divisions decision august appellate division ordered stay proceedings superior court pending ruling supreme court oral argument new jersey supreme court scheduled take place march previously reported company also named defendant separate lawsuits brought attorneys general alaska louisiana mississippi montana texas utah actions allege company misrepresented safety vioxx seek recovery cost vioxx purchased reimbursed state agencies ii reimbursement sums paid state agencies medical services treatment persons injured vioxx iii damages various common law theories andor iv remedies various state statutory theories including state consumer fraud andor fair business practices medicaid fraud statutes including civil penalties hareholder lawsuits previously disclosed addition vioxx product liability lawsuits company various current former officers directors defendants various putative class actions individual lawsuits federal securities laws state securities laws vioxx securities lawsuits vioxx securities lawsuits pending federal court transferred judicial panel multidistrict litigation jpml united states district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx securities lawsuits purposes plaintiffs request certification class purchasers company stock may october complaint alleges defendants made false misleading statements regarding vioxx violation sections b securities exchange act seeks unspecified compensatory damages costs suit including attorneys fees complaint also asserts claim section securities exchange act certain defendants relating sales merck stock addition complaint includes allegations sections securities act certain defendants made incomplete misleading statements registration statement certain prospectuses filed connection merck stock investment plan dividend reinvestment plan defendants filed motion dismiss complaint oral argument motion dismiss scheduled take place march previously disclosed august complaint filed oregon state court state oregon oregon state treasurer behalf oregon public employee retirement fund company certain current former officers directors complaint brought oregon securities law alleges plaintiff suffered damages connection purchases merck common stock artificially inflated prices due companys alleged violations law related disclosures vioxx current former officers directors entered tolling agreement june dismissed without prejudice case july court denied companys motion dismiss complaint required plaintiff amend complaint plaintiff filed amended complaint september merck filed motion require plaintiffs make complaint definite certain denied court merck filed answer complaint january previously disclosed various shareholder derivative actions filed federal court transferred shareholder mdl consolidated purposes judge chesler vioxx derivative lawsuits consolidated complaint arose substantially factual allegations made vioxx securities lawsuits vioxx derivative lawsuits purportedly brought assert rights company assert claims certain members board past present certain executive officers breach fiduciary duty waste corporate assets unjust enrichment abuse control gross mismanagement may judge chesler granted defendants motion dismiss denied plaintiffs request leave amend complaint plaintiffs appeal district courts decision refusing leave amend complaint currently pending united states court appeals third circuit previously disclosed october two individual shareholders made demand board directors company take legal action mr raymond gilmartin former chairman president chief executive officer individuals allegedly causing damage company respect allegedly improper marketing vioxx july board received another shareholder letter demanding board take legal action board management merck allegedly causing damage company relating companys allegedly improper marketing vioxx december demands rejected board directors previously announced board directors appointed special committee review companys actions prior voluntary withdrawal vioxx act board responding shareholder litigation matters related withdrawal vioxx advise board respect action taken result review december special committee retained honorable john martin jr debevoise plimpton llp conduct independent investigation senior managements conduct respect cardiovascular safety profile vioxx period vioxx developed marketed review completed third quarter full report including appendices made public september addition previously disclosed various putative class actions filed federal court employee retirement income security act erisa company certain current former officers directors vioxx erisa lawsuits together vioxx securities lawsuits vioxx derivative lawsuits vioxx shareholder lawsuits transferred shareholder mdl consolidated purposes consolidated complaint asserts claims behalf certain companys current former employees participants certain companys retirement plans breach fiduciary duty lawsuits make similar allegations allegations contained vioxx securities lawsuits october defendants moved dismiss erisa complaint july judge chesler granted part denied part defendants motion dismiss nternational lawsuits previously disclosed addition lawsuits discussed company named defendant litigation relating vioxx various countries collectively vioxx foreign lawsuits europe well canada brazil argentina australia turkey israel dditional lawsuits based media reports sources company anticipates additional vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits filed andor certain current former officers directors future nsurance previously disclosed company product liability insurance claims brought vioxx product liability lawsuits stated upper limits approximately million deductibles coinsurance insurance provides coverage legal defense costs potential damage amounts incurred connection vioxx product liability lawsuits company believes insurance coverage extends additional vioxx product liability lawsuits may filed future company directors officers insurance coverage applicable vioxx securities lawsuits vioxx derivative lawsuits stated upper limits approximately million company fiduciary insurance vioxx erisa lawsuits stated upper limits approximately million additional insurance coverage claims may also available upperlevel excess policies provide coverage variety risks disputes certain insurers availability insurance coverage likely additional disputes companys insurance coverage respect vioxx lawsuits adequate cover defense costs losses previously disclosed companys upper level excess insurers provide excess insurance potentially applicable vioxx lawsuits commenced arbitration seeking among things cancel policies void obligations policies raise coverage issues respect vioxx lawsuits merck intends contest vigorously insurers claims attempt enforce rights applicable insurance policies amounts actually recovered policies discussed section may less amounts specified preceding paragraph nvestigations previously disclosed november company advised staff sec commencing informal inquiry concerning vioxx january company announced received notice sec issued formal notice investigation also company received subpoenas us department justice doj requesting information related companys research marketing selling activities respect vioxx federal health care investigation criminal statutes addition previously disclosed investigations conducted local authorities certain cities europe order determine whether criminal charges brought concerning vioxx company cooperating governmental entities respective investigations vioxx investigations company predict outcome inquiries however could result potential civil andor criminal dispositions previously disclosed company received number civil investigative demands cid group attorneys general states district columbia investigating whether company violated state consumer protection laws marketing vioxx company cooperating attorneys general responding cids addition company received subpoena september state california attorney general seeking documents information related placement vioxx californias medical formulary company cooperating attorney general responding subpoena r eserves company currently anticipates number vioxx product liability lawsuits tried throughout trial oregon securities case scheduled company predict whether trial proceed schedule timing vioxx shareholder lawsuit trials company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits company established reserves potential liability relating vioxx lawsuits vioxx investigations including cases verdicts judgments entered company postverdict proceedings appeal cases company believes strong points raise appeal therefore unfavorable outcomes cases probable unfavorable outcomes vioxx litigation defined could material adverse effect companys financial position liquidity results operations legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december company reserve million solely future legal defense costs related vioxx litigation company spent million aggregate including million fourth quarter legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation third quarter fourth quarter company recorded charges million million respectively increase reserve solely future legal defense costs related vioxx litigation million december increasing reserve company considered factors considered previously established reserves vioxx litigation management believes better estimate companys expenses reasonably estimate costs significant factors considered establishment ongoing review reserve vioxx legal defense costs follows actual costs incurred company development companys legal defense strategy structure light scope vioxx litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx product liability lawsuits events scheduled trials expected occur throughout inherent inability predict ultimate outcomes trials limit companys ability reasonably estimate legal costs beyond end company continue monitor legal defense costs review adequacy associated reserves ther product liability litigation previously disclosed company defendant product liability lawsuits united states involving fosamax fosamax litigation december cases filed merck either federal state court including cases seek class action certification well damages medical monitoring actions plaintiffs allege among things suffered osteonecrosis jaw generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax august jpml ordered fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax mdl coordinated pretrial proceedings fosamax mdl transferred judge john keenan united states district court southern district new york result jpml order cases judge keenan judge keenan issued case management order setting forth schedule governing proceedings focuses primarily upon resolving class action certification motions company intends defend lawsuits december company established reserve approximately million solely future legal defense costs fosamax litigation significant factors considered establishment reserve fosamax litigation legal defense costs follows actual costs incurred company thus far development companys legal defense strategy structure light creation fosamax mdl number cases brought company anticipated timing progression related costs pretrial activities fosamax litigation company continue monitor legal defense costs review adequacy associated reserves due uncertain nature litigation company unable estimate costs beyond end unfavorable outcomes fosamax litigation could material adverse effect companys financial position liquidity results operations c ommercial litigation beginning company named number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states company settled federal class action represented single largest group claims settled substantially remaining cases satisfactory terms remaining cases inactive several years company engaged conspiracy admission wrongdoing made included settlement agreements previously disclosed company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels jpml ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case may court granted companys motion dismiss consolidated class action dismissed company class action case subsequent companys dismissal plaintiffs filed amended consolidated class action complaint name company defendant company many pharmaceutical manufacturers defendants similar complaints pending federal state court brought individually number counties state new york company defendants awaiting final ruling motion dismiss suffolk county case first new york county cases filed addition december company defendant state cases brought attorneys general kentucky illinois alabama wisconsin mississippi arizona hawaii alaska defended previously disclosed company named defendant antitrust cases federal court minnesota state court california alleging unlawful conspiracy among different sets pharmaceutical manufacturers protect high prices united states impeding importation united states lowerpriced pharmaceuticals canada court dismissed federal claims minnesota case prejudice plaintiffs filed notice appeal federal court appeals eighth circuit affirmed dismissal federal claims state claims action dismissed without prejudice refiled jurisdiction california antitrust action parties engaged discovery defendant manufacturers filed summary judgment december court granted summary judgment favor merck defendants dismissed case plaintiffs filed notice appeal california state appeals court previously disclosed suit federal court alabama two providers health services needy patients alleges pharmaceutical companies overcharged plaintiffs class similarly situated pharmaceuticals purchased plaintiffs program established section b public health service act company defendants filed motion dismiss complaint numerous grounds recently denied court denial motion dismiss case dismissed voluntarily parties previously disclosed january doj notified federal court new orleans louisiana going intervene time pending federal false claims act case filed seal december company court issued order unsealing complaint filed physician louisiana ordered complaint served complaint alleged companys discounting pepcid certain louisiana hospitals led increases costs medicaid dismissed amended complaint filed seal case administratively closed court seal lifted state louisiana filed amended complaint incorporating allegations contained sealed amended complaint allegations contained sealed amended complaint unknown april company named qui tam lawsuit nevada false claims act suit nevada attorney general intervened alleges company inappropriately offered nominal pricing marketing pricing inducements certain customers also failed comply obligations medicaid best price scheme related arrangements may companys motion dismiss action denied district court company defending lawsuit g overnmental proceedings previously disclosed company received subpoena doj connection investigation companys marketing selling activities including nominal pricing programs samples company also reported received cid attorney general texas regarding companys marketing selling activities relating texas previously disclosed company received another cid attorney general texas asking additional information regarding companys marketing selling activities related texas including respect certain nominal pricing programs samples april company received subpoena office inspector general district columbia connection investigation companys interactions physicians district columbia maryland virginia november company received letter request doj connection investigation companys pricing pepcid september company received subpoena illinois attorney general subpoena seeks information related repackaging prescription drugs activity relating merck illinois matter previously disclosed company received letter doj advising existence qui tam complaint alleging company violated certain rules related calculations best price federal pricing benchmark calculations certain may affect companys medicaid rebate obligation doj informed company intend intervene action closed investigation lawsuit continues however company cooperating investigations company predict outcome investigations however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations addition time time federal state foreign regulators authorities may seek information practices pharmaceutical industry companys business practices inquiries investigations discussed section feasible predict outcome inquiries previously disclosed february italian antitrust authority ica adopted measure commencing formal investigation merck sharp dohme italia spa msd italy company article italian competition law article ec ascertain whether company msd italy committed abuse dominant position refusing grant acs dobfar spa dobfar italian company voluntary license companys italian supplementary protection certificate spc pursuant domestic legislation passed permit dobfar manufacture imipenem cilastatin ic active ingredients tienam italy sale outside italy countries patent protection expired never existed hearing ica held may june ica found preliminary basis companys refusal grant license abuse dominant position imposed interim measures requiring company grant license manufacture ic italy stockpiling purposes expiration spc november italian administrative court denied companys appeal icas order companys spc expired january proceedings ica continued merits article investigation effort resolve matter company offered commitment ica pursuant company would grant nonexclusive licenses italian spc finasteride respect finasteride mg treatment benign prostate hyperplasia deadline ica adopt final decision whether companys commitment warrants closure case march v accine litigation previously disclosed company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella andor trivalent vaccines measles mumps rubella including companys mmr ii conditions include autism without inflammatory bowel disease epilepsy encephalitis encephalopathy guillainbarre syndrome transverse myelitis claimants proceeding companys knowledge intending proceed company company defend lawsuits previously disclosed company also party individual class action product liability lawsuits claims united states involving pediatric vaccines eg hepatitis b vaccine contained thimerosal preservative used vaccines merck distributed thimerosalcontaining pediatric vaccines united states since fall december approximately active thimerosal related lawsuits approximately plaintiffs defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines two cases scheduled trial dismissed one state court case ohio voluntarily dismissed plaintiffs second federal district court case texas court entered summary judgment favor defendants plaintiffs ultimately voluntarily dismissed appeal company defend lawsuits however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations company successful cases type either dismissed stayed ground action prohibited national childhood vaccine injury act vaccine act vaccine act prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court vaccine act filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods company party vaccine court proceedings petitions brought united states department health human services cases trial dates referred preceding paragraph dismissed brought plaintiffs claimed made timely withdrawal vaccine court petitions company aware approximately cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders thimerosalcontaining vaccines involved vaccine court proceeding company vaccines company sole source mmr ii vaccine domestically june special masters presiding vaccine court proceedings scheduled begin hearing petitioners government present evidence issue whether vaccines cause autism spectrum disorders hearing expected last number weeks since party company participate proceedings p atent litigation time time generic manufacturers pharmaceutical products file abbreviated new drug applications andas fda seeking market generic forms companys products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic form fosamax prilosec nexium propecia trusopt cosopt prior expiration companys astrazenecas case prilosec nexium patents concerning products generic companies andas generally include allegations non infringement invalidity unenforceability patents generic manufacturers received fda approval market generic form prilosec company filed patent infringement suits federal court companies filing andas generic alendronate fosamax finasteride propecia dorzolamide trusopt dorzolamidetimolol cosopt astrazeneca company filed patent infringement suits federal court companies filing andas generic omeprazole prilosec esomeprazole nexium similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products february schering plough corporation schering plough received notice generic company indicating filed anda zetia challenging us patents listed zetia merck schering plough market zetia joint venture considering appropriate response february company received notice generic company indicating filed anda montelukast challenging us patent listed singulair company considering appropriate response previously disclosed january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid company exhausted options appeal decision based court appeals decision fosamax fosamax plus lose market exclusivity united states february april respectively company expects significant decline us fosamax fosamax plus sales products respective loss market exclusivity may federal court canada trial division issued decision refusing bar approval generic alendronate ground mercks patent weekly alendronate likely invalid decision appealed generic alendronate launched canada june july merck sued federal court canada apotex seeking damages lost sales generic weekly alendronate due patent proceeding previously disclosed september company appealed decision opposition division opposition division european patent office epo revoked companys patent europe covers onceweekly administration alendronate march board appeal epo upheld decision opposition division thus presently company entitled market exclusivity fosamax major european markets addition mercks basic patent covering use alendronate challenged several european countries company received adverse decisions germany holland united kingdom decision united kingdom upheld appeal company appealed decisions germany holland june company filed lawsuits federal court barr laboratories inc teva pharmaceutical industries ltd teva asserting respective manufacturing processes making alendronate products would infringe one process patents company october action australia challenging validity companys australian patent onceweekly administration alendronate patent found invalid decision upheld appeal addition previously disclosed japan proceeding filed challenging validity companys japanese patent onceweekly administration alendronate january company sued hitech pharmacal co inc hitech amityville new york patent infringement response hitechs application fda seeking approval generic version mercks ophthalmic drugs trusopt cosopt used treating elevated intraocular pressure people ocular hypertension glaucoma lawsuit merck sued enforce patent covering active ingredient dorzolamide present trusopt cosopt case district court entered judgment mercks favor hitech appealed hearing appeal conducted december decision pending merck elected enforce two us patents listed fda cover combination dorzolamide timolol two active ingredients cosopt lawsuit automatically stays fda approval hitechs andas months january adverse court decision whichever may occur earlier patent covering dorzolamide provides exclusivity trusopt cosopt october including six months pediatric exclusivity time company expects sales products decline case omeprazole trial court united states rendered opinion october upholding validity companys astrazenecas patents covering stabilized formulation omeprazole ruling one defendants omeprazole product infringe patents three defendants products found infringe formulation patents december us court appeals federal circuit affirmed decision trial court respect companys patent infringement claims certain generic manufacturers omeprazole products trial concluded june decision pending company astrazeneca received notice october ranbaxy laboratories limited ranbaxy filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium november company astrazeneca sued ranbaxy united states district court new jersey accordingly fda approval ranbaxys anda stayed months april adverse court decision whichever may occur earlier company astrazeneca received notice january ivax pharmaceuticals inc subsequently acquired teva filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium march company astrazeneca sued teva united states district court new jersey accordingly fda approval tevas anda stayed months september adverse court decision whichever may occur earlier case finasteride anda filed seeking approval generic version propecia alleging invalidity companys patents company filed patent infringement lawsuit district court delaware september company reached settlement generic company dr reddys laboratories drl drl may sell generic mg finasteride product beginning january europe company aware various companies seeking registration generic losartan active ingredient cozaar company patent rights losartan via license ei du pont de nemours company du pont company du pont filed patent infringement proceedings various companies portugal spain norway ther litigation july merck served shareholder derivative suit filed new jersey superior court hunterdon county company certain current former officers directors lawsuit seeks recover cancel compensation awarded companys executive officers asserts claims breach fiduciary duty waste unjust enrichment july court granted defendants motion dismiss based plaintiffs failure make presuit demand mercks board directors denied plaintiffs request leave amend thus case terminated november individual shareholder delivered letter board alleging company sustained damages companys adoption change control separation benefits plan cic plan november shareholder made demand board take legal action boards current former members allegedly causing damage company respect adoption cic plan response demand letter independent members board determined november board meeting board would take shareholders request consideration remains consideration previously disclosed august united states district court district new jersey granted motion company medco health solutions inc medco health certain officers directors dismiss shareholder derivative action involving claims related companys revenue recognition practice retail copayments paid individuals medco health provides pharmaceutical benefits well allegations complaint dismissed prejudice plaintiffs appealed decision december us court appeals third circuit upheld district courts decision dismissing suit sent issue whether companys board directors properly refused shareholder demand relating companys treatment retail copayments back district court reconsideration different legal standard plaintiffs moved remand action state court august district court granted motion february shareholder derivative suit currently pending superior court new jersey chancery division hunterdon county previously disclosed prior spinoff medco health company medco health agreed settle class action basis series lawsuits asserting violations erisa gruer cases company medco health certain plaintiffs counsel filed settlement agreement federal district court new york cases commenced number plaintiffs including participants number pharmaceutical benefit plans medco health pharmacy benefit manager well trustees plans consolidated medco health company agreed proposed settlement order avoid significant cost distraction prolonged litigation proposed class settlement agreed plaintiffs five cases filed medco health company proposed settlement company medco health agreed pay total million medco health agreed modify certain business practices continue certain specified business practices period five years financial compensation intended benefit members settlement class includes erisa plans medco health administered pharmacy benefit time since december district court held hearings hear objections fairness proposed settlement approved settlement yet determined number class member plans properly elected participate settlement settlement becomes final appeals resolved certain class member plans indicated participate settlement cases initiated three plans two individuals remain pending southern district new york plaintiffs cases asserted claims based erisa well federal state laws similar claims asserted settling class members gruer cases company medco health named defendants cases three notices appeal filed appellate court heard oral argument may december appellate court issued decision vacating district courts judgment remanding cases district court allow district court resolve certain jurisdictional issues hearing held address issues february district court issued ruling august resolving jurisdictional issues favor settling plaintiffs class members party previously appealed district courts judgment renewed appeals renewed appeals presently briefed spinoff medco health medco health assumed substantially liability exposure matters discussed foregoing two paragraphs cases defended medco health various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed note opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided note e nvironmental matters company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs insurers former site owners operators recalcitrant potentially responsible parties june potassium thiocyanate accidentally discharged companys plant west point pennsylvania upper gwynedd township authoritys wastewater treatment plant wissahickon creek causing fishkill federal state agencies investigating discharge company currently cooperating investigations managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries insurers parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year preferred stock subsidiary companies december company redeemed variablerate preferred units subsidiary billion par value plus accrued dividends preferred securities held subsidiary level previously included minority interests consolidated financial statements connection restructuring ami see note company assumed billion par value preferred stock obligation dividend rate per annum carried kbi included minority interests small portion preferred stock carried kbi convertible kbi common shares none preferred securities convertible companys common shares therefore included common shares issuable purposes computing earnings per common share assuming dilution see note stockholders equity paidin capital increased million million decreased million changes primarily reflect impact shares issued upon exercise stock options related income tax benefits well issuance restricted shares addition increase reflects impact recognizing sharebased compensation expense result adoption fas r see note summary treasury stock transactions shares millions follows shares cost shares cost shares cost b alance january purchases issuances b alance december issued primarily stock option plans december million shares preferred stock without par value authorized none issued sharebased compensation plans company sharebased compensation plans employees nonemployee directors employees certain companys equity method investees may granted options purchase shares company common stock fair market value time grant addition stock options company grants performance share units psus restricted stock units rsus certain management level employees plans approved companys shareholders december million shares authorized future grants companys sharebased compensation plans company settles employee sharebased compensation awards primarily treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest onethird year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest well nonforfeitable dividend equivalents fair value awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued company recognize compensation expense connection psus psu rsu payouts shares company stock end threeyear period subject terms applicable awards effective january company adopted fas r employee sharebased compensation expense previously recognized using intrinsic value method measures sharebased compensation expense amount market price stock date grant exceeds exercise price fas r requires recognition fair value sharebased compensation net income company recognizes straight line basis requisite service period additionally company elected modified prospective transition method adopting fas r therefore prior periods retrospectively adjusted method provisions fas r apply awards granted modified january addition unrecognized expense awards yet vested date adoption recognized net income relevant period date adoption also effective january company adopted fasb staff position r transition election related accounting tax effects sharebased payment awards provides company optional short cut method calculating historical pool windfall tax benefits upon adopting fas r following table provides amounts sharebased compensation cost recorded consolidated statement income substantially amounts related rsus ears ended december p retax sharebased compensation expense income tax benefits otal sharebased compensation expense net tax result adoption fas r effective january incremental impact companys sharebased compensation expense reduced companys results operations follows ear ended december income taxes net income earnings per common share assuming dilution fas r requires company present pro forma information periods prior adoption company accounted employee sharebased compensation fair value method statement purposes pro forma disclosure estimated fair value awards date grant including granted retirementeligible employees amortized expense requisite service period following table illustrates effect net income earnings per common share company applied fair value method recognizing employee sharebased compensation years ended december ears ended december net income reported compensation expense net tax reported fair value method pro forma net income earnings per common share basic reported basic pro forma assuming dilution reported assuming dilution pro forma pro forma amounts fair value option grant estimated date grant using blackscholes option pricing model upon adoption fas r compensation expense recognized immediately awards granted retirementeligible employees period grant date date retirement eligibility achieved approach known nonsubstantive vesting period approach company applying approach stock options granted retirementeligible employees effect pro forma earnings per share assuming dilution years ended december provided table would significant pro forma compensation expense calculated using blackscholes model utilizing assumptions based historical data expense determined using separate expected term assumptions vesting tranche result pro forma compensation expense stock options granted january prior january calculated using accelerated amortization method prescribed fasb interpretation accounting stock appreciation rights variable stock option award plans upon adoption fas r effective january company recognizes compensation expense using straightline method company continues use blackscholes option pricing model option grants adoption fas r applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected term options riskfree rate volatility dividend yield expected term represents expected amount time options granted expected outstanding based historical forecasted exercise behavior riskfree rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options weighted average fair value options granted per option respectively determined using following assumptions ear ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative companys stock option plans options thousands follows weighted weighted average aggregate average remaining intrinsic number exercise contractual value options price term balance december granted exercised forfeited outstanding december exercisable december additional information pertaining companys stock option plans provided table ear ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options summary companys nonvested rsus psus shares thousands december follows r sus p sus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested december granted vested forfeited n onvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation recorded unallocated expense pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries pension benefits united states based formula considers final average pay years credited service addition company provides medical dental life insurance benefits principally eligible us retirees similar benefits dependents postretirement benefit plans company uses december measurement date substantially pension plans postretirement benefit plans net cost companys pension postretirement benefit plans consisted following components po stretir e ent pension benefits benefits years ended december service cost interest cost expected return plan assets net amortization termination benefits curtailments settlements n et pension postretirement cost net pension cost attributable us plans included table million million million cost health care life insurance benefits active employees million million million connection companys restructuring actions see note merck recorded termination charges pension postretirement benefit plans related expanded eligibility certain employees exiting company also connection restructuring activities company recorded curtailment losses pension postretirement benefit plans amendments changed participant contributions service recognized eligibility postretirement benefit plans generated curtailment gains addition company recorded settlement losses settlement gain certain domestic pension plans resulting employees electing receive pension benefits lump sum payments effective december company adopted fasb statement employers accounting defined benefit pension postretirement plans amendment fasb statements r fas except requirement measure plan assets benefit obligations companys fiscal year end effective december fas required company fully recognize funded status benefit plans overfunded plan recognized asset underfunded plan recognized liability previously unrecognized net losses unrecognized plan changes recognized component aoci december see note effects applying fas december follows application fas application fas adjustments fas prepaid expenses taxes assets accrued current liabilities deferred income taxes noncurrent liabilities accumulated comprehensive income loss summarized information changes plan assets benefit obligation funded status amounts recorded december follows ther po treti rement pension benefits benefits fair value plan assets january actual return plan assets company contributions benefits paid plan assets f air value plan assets december benefit obligation january service cost interest cost actuarial losses gains benefits paid plan amendments curtailments termination benefits b enefit obligation december funded status december unrecognized net loss unrecognized plan changes n et amount recorded recognized assets accrued current liabilities deferred income taxes noncurrent liabilities accumulated comprehensive loss fair value us pension plan assets included preceding table billion billion pension benefit obligation us plans included table billion billion weighted average asset allocations investment portfolio pension postretirement benefit plans december follows ther pension postretirement benefits benefits us equities international equities fixedincome investments real estate investments cash cash equivalents target investment portfolios companys pension plans determined country based nature liabilities considering demographic composition plan participants average age years service active versus retiree status accordance local regulations weighted average target allocation us equities international equities fixedincome investments real estate investments cash cash equivalents investments include insurance contracts certain international pension plans target investment portfolio companys postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios asset allocation consistent longterm nature plans benefit obligation well diversified among asset classes portfolio invests contributions pension plans postretirement benefit plans expected million million respectively expected benefit payments follows pension postretirement benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service december accumulated benefit obligation billion billion respectively pension plans billion billion respectively us pension plans company recorded minimum pension liability representing extent accumulated benefit obligation exceeded plan assets certain companys pension plans million prior adoption fas december minimum pension liability million december pension plans benefit obligations excess plan assets december fair value plan assets million million respectively benefit obligation billion billion respectively plans accumulated benefit obligations excess plan assets december fair value plan assets million million respectively accumulated benefit obligation million million respectively effective adoption fas net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aoci net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees estimated net loss prior service cost credit amounts amortized aoci net pension postretirement benefit cost million million respectively pension plans million million respectively postretirement benefit plans company reassesses benefit plan assumptions regular basis weighted average assumptions used determining pension plan us pension postretirement benefit plan information follows us pe n sion postretirement pension plans benefit plans december net cost iscount rate expected rate return plan assets salary growth rate b enefit obligation iscount rate salary growth rate used postretirement benefit plans expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined country basis developing expected rate return within country longterm historical returns data considered well actual returns plan assets capital markets experience using reference information longterm return expectations asset category weighted average expected return countrys target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate companys expected rate return remain unchanged us pension postretirement benefit plans health care cost trend rate assumptions postretirement benefit plans follows ecember health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects one p e rcen tage point increase decrease effect total service interest cost components effect benefit obligation income expense net ears ended december interest income interest expense exchange gains minority interests net increase interest income reflects interest income generated companys investment portfolio derived higher interest rates higher average investment portfolio balances interest paid million million million reduced minority interest attributable redemption subsidiary variablerate preferred units see note net primarily reflects million gain sale companys equity stake european joint venture johnson johnson well realized gains companys investment portfolio taxes income reconciliation companys effective tax rate us statutory rate follows ta x rat e amount us statutory rate applied income taxes differential arising foreign earnings tax exemption puerto rico operations acquired research state taxes ajca includes tax effect minority interests contingency reserves research credits export incentives miscellaneous items domestic companies contributed approximately consolidated income taxes taxes income consisted ears ended december current provision federal foreign state eferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation advance payment equity investments pensions opeb compensation related vioxx legal defense costs reserve net operating losses subtotal valuation allowance otal deferred taxes n et deferred income taxes recognized prepaid expenses taxes assets income taxes payable deferred income taxes noncurrent liabilities company net operating loss nol carryforwards number jurisdictions significant united kingdom nol carryforwards million expiration date valuation allowance years primarily relates certain canadian nol carryforwards resulting legal entity reorganization income taxes paid billion billion billion respectively stock option exercises significant impact taxes paid stock option exercises reduced income taxes paid million previously disclosed internal revenue service irs examining companys tax returns years issued notices deficiency respect partnership transaction entered two minority interest equity financings entered respectively irs recently concluded examination years issue final revenue agents report first quarter february company entered closing agreements irs covering several specific items including partnership transaction minority interest equity financings terms closing agreements company expects make payment approximately billion first quarter payment offset tax refund million amounts previously paid related matters ii million federal tax benefit related interest included payment resulting net cash cost company approximately billion company previously established reserves matters conclusion irs examination including closing agreements material effect companys results operations financial position liquidity material adverse effect companys cash flow first quarter payment made impact years subsequent partnership transaction minority interest equity financings included closing agreements although years remain open respects previously disclosed mercks canadian tax returns years examined canada revenue agency cra october cra issued company notice reassessment containing adjustments related certain intercompany pricing matters result additional tax due approximately billion us dollars plus interest million us dollars company disagrees positions taken cra believes without merit company intends contest assessment cra appeals process courts necessary connection appeals process notice reassessment company required post deposit one half tax interest assessed january company pledged collateral consisting cash cash equivalents million financial institution provided letter guarantee cra management believes resolution matters material adverse effect companys financial position liquidity however unfavorable resolution could material adverse effect companys results operations cash flows quarter adjustment recorded tax due previously disclosed october ajca signed law ajca created temporary incentives us multinationals repatriate accumulated income earned outside united states december accordance ajca company repatriated billion company recorded income tax charge million taxes income related repatriation million paid remainder paid first quarter charge partially offset million benefit associated decision implement certain tax planning strategies company changed intention indefinitely reinvest accumulated earnings earned subsequent december december foreign earnings billion retained indefinitely subsidiary companies reinvestment provision made income taxes would payable upon distributions earnings practicable determine amount related unrecognized deferred income tax liability addition company subsidiaries operating puerto rico singapore tax incentive grants expire respectively earnings per share weighted average common shares used computations basic earnings per common share earnings per common share assuming dilution shares millions follows ears ended december average common shares outstanding common shares issuable verage common shares outstanding assuming dilution issuable primarily sharebased compensation plans million million million common shares issuable companys sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive comprehensive income components comprehensive income loss follows pr etax tax fter tax year ended december n et unrealized loss derivatives net loss realization erivatives n et unrealized gain investments net loss realization nvestments inimum pension liability c umulative translation adjustment related equity investees year ended december n et unrealized gain derivatives net loss realization erivatives n et unrealized loss investments net loss realization nvestments inimum pension liability c umulative translation adjustment related equity investees pr etax tax fter tax year ended december n et unrealized loss derivatives net loss realization erivatives n et unrealized loss investments net income realization nvestments inimum pension liability c umulative translation adjustment related equity investees net applicable minority interest components accumulated comprehensive income loss follows ecember net unrealized loss gain derivatives net unrealized gain investments minimum pension liability pension plan net loss postretirement benefit plan net loss pension plan changes postretirement benefit plan changes cumulative translation adjustment related equity investees december million net unrealized loss derivatives associated options maturing next months hedge anticipated foreign currency denominated sales period segment reporting companys operations principally managed products basis comprised two reportable segments pharmaceutical segment vaccines segment fourth quarter vaccines segment previously included met reportable segment criteria pursuant fasb statement disclosures segments enterprise related information prior periods recast reflect vaccines reportable segment pharmaceutical segment includes human health pharmaceutical products marketed either directly joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations institutions vaccines segment includes human health vaccine products marketed either directly joint venture products consist preventative pediatric adolescent adult vaccines primarily administered physician offices merck sells human health vaccines primarily physicians wholesalers physician distributors government entities vaccines segment includes vast majority companys vaccine sales excludes certain sales vaccines nonus subsidiaries managed included pharmaceutical segment large component pediatric adolescent vaccines funded us government us centers disease control prevention vaccines children program includes nonreportable human animal health segments accounting policies segments described described note revenues profits segments follows p harmaceutical v accines total year ended december egment revenues segment profits included segment profits equity income affiliates depreciation amortization ear ended december egment revenues segment profits included segment profits equity income affiliates depreciation amortization ear ended december egment revenues segment profits included segment profits equity income affiliates depreciation amortization accordance segment reporting requirements vaccines segment revenues exclude million million million respectively vaccine sales certain nonus subsidiaries managed included pharmaceutical segment segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker company allocate vast majority indirect production costs research development expenses general administrative expenses well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits reconciliation total segment revenues consolidated sales follows ears ended december segment revenues revenues revenues primarily comprised miscellaneous corporate revenues sales related divested products businesses supply sales included segment results sales companys products follows ears ended december singulair cozaarhyzaar fosamax zocor primaxin cosopttrusopt proscar vasotecvaseretic cancidas maxalt propecia vioxx vaccinesbiologicals presented net discounts returns amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates primarily includes sales human pharmaceuticals pharmaceutical animal health supply sales companys joint ventures revenue companys relationship azlp primarily relating sales nexium prilosec revenue azlp billion billion billion respectively consolidated revenues geographic area derived follows ears ended december united states europe middle east africa japan reconciliation total segment profits consolidated income taxes follows ears ended december segment profits profits adjustments unallocated interest income interest expense equity income affiliates depreciation amortization research development expenses net profits primarily comprised miscellaneous corporate profits well operating profits related divested products businesses supply sales adjustments represent elimination effect double counting certain items income expense equity income affiliates includes taxes paid joint venture level portion equity income reported segment profits expenses net include expenses corporate manufacturing cost centers miscellaneous income expense net longlived assets geographic area located follows ears ended december united states europe middle east africa japan longlived assets comprised property plant equipment net goodwill intangible assets net company disaggregate assets products services basis internal management reporting therefore information presented r eport independent registered public accounting firm stockholders board directors merck co inc w e completed integrated audits merck co incs consolidated financial statements internal control financial reporting december accordance standards public company accounting oversight board united states opinions based audits presented c onsolidated financial statements n opinion accompanying consolidated balance sheets related consolidated statements income retained earnings comprehensive income cash flows present fairly material respects financial position merck co inc subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits statements accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit financial statements includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion discussed note consolidated financial statements company changed manner accounts sharebased compensation discussed note consolidated financial statements company changed manner accounts defined benefit pension postretirement plans effective december nternal control financial reporting lso opinion managements assessment included accompanying managements report internal control financial reporting company maintained effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso fairly stated material respects based criteria furthermore opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinions managements assessment effectiveness companys internal control financial reporting based audit conducted audit internal control financial reporting accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit internal control financial reporting includes obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures consider necessary circumstances believe audit provides reasonable basis opinions companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements b ecause inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate p ricewaterhousecoopers llp florham park new jersey february b supplementary data selected quarterly financial data contained condensed interim financial data table c ondensed interim financial data unaudited millions except per share amounts h q rd q n q st q ales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income taxes net income basic earnings per common share earnings per common share assuming dilution ales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income taxes net income basic earnings per common share earnings per common share assuming dilution amounts include acquired research expenses associated acquisitions amounts fourth third quarter fourth quarter include impact additional vioxx legal defense reserves see note amounts fourth quarter include impact fosamax legal defense reserves see note amounts include impact net tax charge primarily associated ajca repatriation see note amounts include impact restructuring actions see note amounts reflect incremental impact expensing stock options tem changes disagreements accountants accounting financial disclosure applicable tem controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission coso based evaluation management concluded internal control financial reporting effective december based criteria internal control integrated framework issued coso managements assessment effectiveness internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm pricewaterhousecoopers llp issued report managements assessment effectiveness companys internal control financial reporting changes internal control financial reporting period covered report materially affected reasonably likely materially affect companys internal control financial reporting anagements report anagements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices company periodically conducts managements stewardship program key management financial personnel program reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing addition may company submitted new york stock exchange nyse certificate ceo certifying aware violation company nyse corporate governance listing standards anagements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined exchange act rule af management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission coso based evaluation management concluded internal control financial reporting effective december based criteria internal control integrated framework issued coso managements assessment effectiveness internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm pricewaterhousecoopers llp issued report managements assessment effectiveness companys internal control financial reporting included herein richard clark judy c lewent chief executive officer executive vice president president chief financial officer tem b information none part iii tem directors executive officers corporate governance required information directors nominees incorporated reference discussion item election directors companys proxy statement annual meeting stockholders held april information executive officers set forth part document pages required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting stockholders held april company adopted code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer code conduct available companys website wwwmerckcomaboutcorporategovernance company intends post website amendments waivers code conduct printed copy sent without charge stockholder requests writing chief ethics officer merck co inc one merck drive whitehouse station nj required information identification audit committee audit committee financial expert incorporated reference discussion heading board committees companys proxy statement annual meeting stockholders held april tem executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards fiscal year end table option exercises stock vested table retirement plan benefits related pension benefits table nonqualified deferred compensation related tables potential payments termination change control including discussion subheadings separation separation plan payment benefit estimates table individual agreements change control change control payment benefit estimates table well footnote information various tables companys proxy statement annual meeting stockholders held april required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting stockholders held april required information headings compensation committee interlocks insider participation compensation committee report incorporated reference companys proxy statement annual meeting stockholders held april tem security ownership certain beneficial owners management related stockholder matters information respect securities authorized issuance equity compensation plans incorporated reference discussion heading equity compensation plan information companys proxy statement annual meeting stockholders held april information respect security ownership certain beneficial owners management incorporated reference discussion heading security ownership certain beneficial owners management companys proxy statement annual meeting stockholders held april tem certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading relationships outside firms discussion respect loan dr kim subheading perquisities compensation discussion analysis companys proxy statement annual meeting stockholders held april required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting stockholders held april tem principal accountant fees services information required item incorporated reference discussion audit committee beginning caption preapproval policy services independent registered public accounting firm fees companys proxy statement annual meeting stockholders held april part iv tem exhibits financial statement schedules following documents filed part financial statements consolidated statement income years ended december consolidated statement retained earnings years ended december consolidated statement comprehensive income years ended december consolidated balance sheet december consolidated statement cash flows years ended december notes consolidated financial statements report pricewaterhousecoopers llp independent registered public accounting firm financial statement schedules schedules omitted either required applicable financial statements affiliates carried equity basis omitted considered individually aggregate affiliates constitute significant subsidiary exhibits ex hib number description master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june agreement plan merger among merck co inc spinnaker acquisition corp wholly owned subsidiary merck co inc sirna therapeutics inc dated october incorporated reference current report form k dated october restated certificate incorporation merck co inc october incorporated reference form q quarterly report period ended september bylaws merck co inc amended effective may incorporated reference current report form k dated may indenture dated april merck co inc morgan guaranty trust company new york trustee incorporated reference exhibit registration statement form first supplemental indenture merck co inc first trust new york national association trustee incorporated reference exhibit b registration statement form executive incentive plan amended effective february incorporated reference annual report fiscal year ended december base salary deferral plan adopted october effective january incorporated reference annual report fiscal year ended december merck co inc deferral program amended restated september incorporated reference current report form k dated september incentive stock plan amended restated december incentive stock plan amended restated december incentive stock plan amended restated december incentive stock plan amended effective december merck co inc change control separation benefits plan incorporated reference current report form k dated november merck co inc separation benefits plan nonunion employees amended restated effective july incorporated reference current report form k dated july nonemployee directors stock option plan amended restated february incorporated reference annual report fiscal year ended december nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june ex hib number description nonemployee directors stock option plan effective april amended restated february supplemental retirement plan amended effective january incorporated reference annual report fiscal year ended december retirement plan directors merck co inc amended restated june incorporated reference form q quarterly report period ended june plan deferred payment directors compensation amended restated october incorporated reference current report form k dated september offer letter merck co inc peter kim dated december incorporated reference annual report fiscal year ended december offer letter merck co inc peter loescher dated march incorporated reference form q quarterly report period ended march letter agreement merck co inc per woldolsen dated july incorporated reference current report form k dated july letter agreement merck co inc bradley sheares dated august letter agreement merck co inc david w anstice dated december amended restated license option agreement dated july astra ab astra merck inc incorporated reference form q quarterly report period ended june kbi shares option agreement dated july among astra ab merck co inc merck holdings inc incorporated reference form q quarterly report period ended june kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc incorporated reference form q quarterly report period ended june kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc incorporated reference quarterly report period ended june limited partnership agreement dated july kb usa lp kbi sub inc incorporated reference form q quarterly report period ended june distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june form voting agreement made entered october merck co inc sirna therapeutics inc incorporated reference current report form k dated october computation ratios earnings fixed charges subsidiaries merck co inc ex hib number description consent independent registered public accounting firm contained report power attorney certified resolution board directors rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer management contract compensatory plan arrangement copies exhibits may obtained stockholders upon written request directed stockholder services department merck co inc po box ws ab whitehouse station new jersey signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized ated february merck co inc richard clark chief executive officer president celia colbert celia colbert attorneyinfact pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signatures title date richard clark chief executive officer president february principal executive officer director judy c lewent executive vice president chief february financial officer principal financial officer john canan vice president controller principal february accounting officer lawrence bossidy director february william g bowen director february johnnetta b cole director february william b harrison jr director february william n kelley director february rochelle b lazarus director february thomas e shenk director february anne tatlock director february samuel thier director february wendell p weeks director february peter c wendell director february celia colbert signing name hereto hereby sign document pursuant powers attorney duly executed persons named filed securities exchange commission exhibit document behalf persons capacities date stated persons including majority directors company celia colbert celia colbert attorneyinfact exhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form nos form nos merck co inc report dated february relating consolidated financial statements managements assessment effectiveness internal control financial reporting effectiveness internal control financial reporting incorporated reference annual report p ricewaterhousecoopers llp f lorham park new jersey february exhibit index ex hib number description master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june agreement plan merger among merck co inc spinnaker acquisition corp wholly owned subsidiary merck co inc sirna therapeutics inc dated october incorporated reference current report form k dated october restated certificate incorporation merck co inc october incorporated reference form q quarterly report period ended september bylaws merck co inc amended effective may incorporated reference current report form k dated may indenture dated april merck co inc morgan guaranty trust company new york trustee incorporated reference exhibit registration statement form first supplemental indenture merck co inc first trust new york national association trustee incorporated reference exhibit b registration statement form executive incentive plan amended effective february incorporated reference annual report fiscal year ended december base salary deferral plan adopted october effective january incorporated reference annual report fiscal year ended december merck co inc deferral program amended restated september incorporated reference current report form k dated september incentive stock plan amended restated december incentive stock plan amended restated december incentive stock plan amended restated december incentive stock plan amended effective december merck co inc change control separation benefits plan incorporated reference current report form k dated november merck co inc separation benefits plan nonunion employees amended restated effective july incorporated reference current report form k dated july nonemployee directors stock option plan amended restated february incorporated reference annual report fiscal year ended december nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june nonemployee directors stock option plan effective april amended restated february supplemental retirement plan amended effective january incorporated reference annual report fiscal year ended december retirement plan directors merck co inc amended restated june incorporated reference form q quarterly report period ended june plan deferred payment directors compensation amended restated october incorporated reference current report form k dated september ex hib number description offer letter merck co inc peter kim dated december incorporated reference annual report fiscal year ended december offer letter merck co inc peter loescher dated march incorporated reference form q quarterly report period ended march letter agreement merck co inc per woldolsen dated july incorporated reference current report form k dated july letter agreement merck co inc bradley sheares dated august letter agreement merck co inc david w anstice dated december amended restated license option agreement dated july astra ab astra merck inc incorporated reference form q quarterly report period ended june kbi shares option agreement dated july among astra ab merck co inc merck holdings inc incorporated reference form q quarterly report period ended june kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc incorporated reference form q quarterly report period ended june kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc incorporated reference quarterly report period ended june limited partnership agreement dated july kb usa lp kbi sub inc incorporated reference form q quarterly report period ended june distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june form voting agreement made entered october merck co inc sirna therapeutics inc incorporated reference current report form k dated october computation ratios earnings fixed charges subsidiaries merck co inc consent independent registered public accounting firm contained report power attorney certified resolution board directors rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer management contract compensatory plan arrangement exhibit merck co inc incentive stock plan amended restated december incentive stock plan incentive stock plan isp effective january established encourage employees merck co inc company subsidiaries affiliates joint ventures merck institute therapeutic research acquire common stock company believed isp stimulate employees efforts companys behalf tend maintain strengthen desire remain company interest company stockholders encourage employees greater personal financial investment company ownership common stock administration isp shall administered compensation benefits committee board directors company committee committee authorized subject provisions isp establish rules regulations deems necessary proper administration isp make determinations take action connection therewith relation isp deems necessary advisable consistent isp committee may delegate power authority hereunder chief executive officer senior member management committee deems appropriate provided however committee may delegate authority regard matter action affecting officer subject section securities exchange act purpose section subsequent sections isp shall deemed include plan comparable subplans established subsidiaries aggregate shall constitute one plan governed terms set forth herein eligibility regular fulltime parttime employees company subsidiaries affiliates joint ventures merck institute therapeutic research including officers whether directors company employees joint venture partner affiliate company provide services joint venture partner affiliate directors officers company purposes section securities exchange act shall eligible participate isp eligible employees designated committee delegate directors regular employees eligible incentives incentives isp may granted one combination incentive stock options statutory stock option b nonqualified stock options c stock appreciation rights restricted stock grants e performance shares together incentives incentives shall subject terms conditions set forth herein terms conditions may established committee determinations committee isp including without limitation determinations eligible employees form amount timing incentives terms provisions incentives agreements evidencing incentives need uniform may made selectively among eligible employees receive eligible receive incentives hereunder whether eligible employees similarly situated shares available incentives shares subject issuance transfer subject adjustment provided section c hereof hereby reserved issuance isp million shares companys common stock common stock shares available granting awards shall increased number shares options benefits granted plan lapsed expired terminated cancelled addition shares reserved issuance companys incentive stock plan incentive stock plan prior plans excess number shares options benefits awarded thereunder plus shares options benefits granted prior plans may lapse expire terminate cancelled shall also reserved available issuance reissuance isp shares plan may delivered company authorized unissued shares common stock common stock held treasury b limit individuals incentives given year eligible employee may receive incentives covering three million shares companys common stock number shares may adjusted accordance section c c adjustment shares event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination shares merger consolidation rights offering spin split split similar change capital structure company committee shall make equitable adjustments number kind shares authorized issuance isp ii number kind shares subject outstanding incentives iii option price stock options iv grant value stock appreciation rights determination shall final binding conclusive parties stock options committee may grant options qualifying incentive stock options internal revenue code amended successor code thereto code statutory options code nonqualified options collectively stock options stock options shall subject following terms conditions terms conditions committee may prescribe option price option price per share respect stock option shall determined committee shall less fair market value common stock date stock option granted determined committee b period option period stock option shall fixed committee shall exceed ten years c payment option price shall payable cash time stock option exercised shares shall issued full payment therefore made grantee stock option shall none rights stockholder shares issued exercise option shares covered stock option may purchased installments exercise dates committee delegate may determine shares purchased applicable exercise date may purchased thereafter time prior final expiration stock option event including specified paragraphs e f g section shall stock option exercisable specified expiration period e termination employment upon termination stock option grantees employment reason retirement death termination deliberate willful gross misconduct stock option privileges shall limited shares immediately exercisable date termination committee however discretion may provide stock options outstanding yet exercisable upon termination stock option grantees employment may become exercisable accordance schedule determined committee stock option privileges shall expire unless exercised surrendered stock appreciation right within period time date termination employment may established committee event later expiration date stock option stock option grantees employment terminated deliberate willful gross misconduct determined company rights stock option shall expire upon receipt notice termination f retirement upon retirement stock option grantee stock option privileges shall apply shares immediately exercisable date retirement committee however discretion may provide stock options outstanding yet exercisable upon retirement stock option grantee may become exercisable accordance schedule determined committee stock option privileges shall expire unless exercised within period time may established committee event later expiration date stock option g death upon death stock option grantee stock option privileges shall apply shares immediately exercisable time death committee however discretion may provide stock options outstanding yet exercisable upon death stock option grantee may become exercisable accordance schedule determined committee privileges shall expire unless exercised legal representatives within period time determined committee event later expiration date stock option h limits incentive stock options except may otherwise permitted code committee shall grant eligible employee incentive stock options aggregate first exercisable one calendar year extent aggregate fair market value common stock time incentive stock options granted exceeds stock appreciation rights committee may discretion grant right receive appreciation fair market value shares common stock stock appreciation right either singly combination underlying stock option granted hereunder prior plans stock appreciation rights shall subject following terms conditions terms conditions committee may prescribe time period grant stock appreciation right granted respect underlying stock option may granted time stock option grant time thereafter prior expiration stock option grant stock appreciation right granted respect underlying stock option time stock appreciation right granted committee may limit exercise period stock appreciation right period stock appreciation right shall attach underlying stock option event shall exercise period stock appreciation right granted respect underlying stock option exceed exercise period stock option stock appreciation right granted without underlying stock option period exercise stock appreciation right shall set committee b value stock appreciation right stock appreciation right granted respect underlying stock option grantee entitled surrender stock option exercisable receive exchange therefore amount equal excess fair market value common stock date election surrender received company stock option price multiplied number shares covered stock option surrendered stock appreciation right granted without underlying stock option grantee receive upon exercise stock appreciation right amount equal excess fair market value common stock date election surrender stock appreciation right received company fair market value common stock date grant multiplied number shares covered grant stock appreciation right c payment stock appreciation right payment stock appreciation right shall form shares common stock cash combination shares cash form payment upon exercise right shall determined committee either time grant stock appreciation right time exercise stock appreciation right performance share awards committee may grant awards payment may made shares common stock cash combination shares cash performance company subsidiary division affiliate company selected committee award period meets certain goals established committee performance share awards performance share awards shall subject following terms conditions terms conditions committee may prescribe award period performance goals committee shall determine include performance share award grant period time performance share award made award period committee shall also establish performance objectives performance goals met company subsidiary division award period condition payment performance share award performance goals may include earnings per share return stockholders equity return assets net income financial measurement established committee performance goals may include minimum optimum objectives single set objectives b payment performance share awards committee shall establish method calculating amount payment made performance share award performance goals met including fixing maximum payment performance share award shall expressed terms shares common stock referred performance shares completion award period performance company subsidiary division shall measured performance goals committee shall determine whether none portion performance share award shall paid committee discretion may elect make payment shares common stock cash combination shares cash cash payment shall based fair market value performance shares soon practicable prior date payment c revision performance goals time prior end award period committee may revise performance goals computation payment unforeseen events occur substantial effect performance company subsidiary division judgment committee make application performance goals unfair unless revision made requirement employment grantee performance share award must remain employ company completion award period order entitled payment performance share award provided committee may sole discretion provide partial payment exception deemed equitable e dividends committee may discretion time granting performance share award provide dividends declared common stock award period would paid respect performance shares owned grantee paid grantee ii accumulated benefit grantee used increase number performance shares grantee f limit performance share awards incentives granted performance share awards section restricted stock grants section shall exceed aggregate million shares common stock number shares may adjusted accordance section c restricted stock grants committee may award shares common stock grantee shares shall subject following terms conditions terms conditions committee may prescribe restricted stock grant requirement employment grantee restricted stock grant must remain employment company period designated committee restriction period order retain shares restricted stock grant grantee leaves employment company prior end restriction period restricted stock grant shall terminate shares common stock shall returned immediately company provided committee may time grant provide employment restriction lapse respect portion portions restricted stock grant different times restriction period committee may discretion also provide complete partial exceptions employment restriction deems equitable b restrictions transfer legend stock certificates restriction period grantee may sell assign transfer pledge otherwise dispose shares common stock except successor section hereof certificate shares common stock issued hereunder shall contain legend giving appropriate notice restrictions grant c escrow agreement committee may require grantee enter escrow agreement providing certificates representing restricted stock grant remain physical custody escrow holder restrictions removed expire lapse restrictions restrictions imposed restricted stock grant shall lapse upon expiration restriction period conditions employment set forth met grantee shall entitled legend removed certificates e dividends committee shall discretion time restricted stock grant provide dividends declared common stock restriction period shall either paid grantee ii accumulated benefit grantee paid grantee expiration restriction period f limit restricted stock grant incentives granted restricted stock grants section performance share awards section shall exceed aggregate million shares common stock number shares may adjusted accordance section c discontinuance amendment plan board directors may discontinue isp time may time time amend revise terms isp permitted applicable statutes except may revoke alter manner unfavorable grantees incentives hereunder incentives outstanding may board amend isp without stockholder approval absence approval would cause plan fail comply rule b securities exchange act requirement applicable law regulation incentive shall granted isp december incentives granted theretofore may extend beyond date nontransferability incentive stock option granted isp shall transferable laws descent distribution incentive granted isp may transferable subject terms conditions may established committee accordance regulations promulgated securities exchange act applicable law regulation right employment isp incentives granted hereunder shall confer upon eligible employee right continued employment company subsidiaries affiliates joint ventures merck institute therapeutic research affect way right entities terminate employment eligible employee time reason taxes company shall entitled withhold amount tax attributable option granted amount payable shares deliverable isp giving person entitled receive amount shares notice far advance practicable merck change control options vesting options key rd options upon occurrence change control stock option outstanding immediately prior change control key rd options shall immediately become fully vested exercisable vesting key rd options subject aii schedule upon occurrence change control key rd option shall continue subject performancebased vesting schedule applicable thereto immediately prior change control ii notwithstanding ai schedule stock options continue outstanding following change control exchanged converted options purchase securities successor entity successor options upon occurrence change control portion key rd option shall immediately vest become exercisable following percentages key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited b key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited c key rd options first second milestones reached date change control thenunvested portion key rd option shall vest become exercisable posttermination exercise period stock options continue outstanding following change control exchanged converted successor options portion stock options successor options applicable vested exercisable immediately following termination employment holder thereof change control shall remain exercisable following termination five years date termination beyond remainder term thereof provided however termination reason gross misconduct death retirement terms applied awards granted plans provisions plan applicable termination reason gross misconduct death retirement shall apply termination effect vesting pursuant section would cause stock option successor stock option terminate earlier accelerated vesting occurred term stock option shall expire earlier accelerated vesting occurred cashout stock options stock options continue outstanding following change control exchanged converted successor options holder vested exercisable option shall entitled receive soon practicable following change control share common stock subject vested exercisable option amount cash determined committee prior change control event less excess change control price exercise price thereof subject existing deferral elections effect consideration paid change control entirely shares common stock acquiring resulting corporation committee may prior change control provide cancellation outstanding stock options time change control whole part cash pursuant provision may provide exchange conversion outstanding stock options time change control whole part connection provision may shall obligated permit holders stock options make elections related thereto determines appropriate incentive stock options amended section apply incentive stock option within meaning section internal revenue code b restricted stock units performance share units vesting restricted stock units upon occurrence change control unvested restricted stock unit award outstanding immediately prior change control plan shall immediately become fully vested vesting performance share units upon occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately become vested amount equal psu pro rata amount settlement restricted stock units performance share units common stock continues widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid shares common stock securities soon practicable date change control subject existing deferral elections effect ii common stock continue widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid cash soon practicable date change control subject existing deferral elections effect c provisions except extent required applicable law entirety protection period material terms plan shall modified manner materially adverse qualifying participants understood section c schedule shall require specific type levels equity awards granted qualifying participants following change control protection period plan may amended modified reduce eliminate protections set forth section c schedule may terminated company shall pay legal fees related expenses including costs experts evidence counsel reasonably good faith incurred qualifying participant qualifying participant prevails claim relief action x qualifying participant claiming provisions section c c schedule violated avoidance doubt excluding claims plan benefits ordinary course applicable company qualifying participants employer enforce post termination covenants qualifying participant section apply incentive stock option within meaning section internal revenue code anything plan amended schedule notwithstanding company reserves right make changes may required extent required avoid adverse consequences american jobs creation act amended definitions purposes schedule following terms shall following meanings change control shall meaning set forth companys change control separation benefits plan provided however award plan consists deferred compensation subject section code definition change control shall deemed modified extent necessary comply section code change control price shall mean respect share common stock higher highest reported sales price regular way share transaction reported new york stock exchange composite tape national exchange shares listed nasdaq national market day period prior including date change control b change control result tender exchange offer merger similar corporate transaction highest price per share paid tender exchange offer merger similar corporate transaction provided extent part consideration paid transaction consists securities noncash consideration value securities noncash consideration shall determined committee key rd options shall mean performancebased options granted employees key research development program described applicable schedule rules regulations plan protection period shall mean period beginning date change control ending second anniversary date change control psu pro rata amount shall mean performance share unit award amount determined multiplying x x number target shares subject performance share unit award times assumed performance percentage fraction numerator number whole partial calendar months elapsed applicable performance period counting partial month whole month purpose denominator total number months applicable performance period assumed performance percentage shall determined averaging ranks award period follows completed performance year change control actual rank except fewer days elapsed since completion performance year target rank shall used b performance year incomplete yet begun change control target rank rounding average rank calculated pursuant foregoing clause nearest whole number using ordinary numerical rounding using final award percentage associated number determined foregoing clause target rank rank associated chart final award percentages qualifying participants shall mean individuals participate plan whether current former employees immediately prior change control e application schedule shall apply stock options restricted stock unit awards performance share unit awards plans granted prior november exhibit merck co inc incentive stock plan amended restated december incentive stock plan incentive stock plan isp effective january established encourage employees merck co inc company subsidiaries affiliates joint ventures acquire common stock company common stock believed isp stimulate employees efforts companys behalf tend maintain strengthen desire remain company interest company stockholders encourage employees greater personal financial investment company ownership common stock incentives incentives isp may granted one combination incentive stock options statutory stock options b nonqualified stock options c stock appreciation rights restricted stock grants e performance shares collectively incentives incentives shall subject terms conditions set forth herein terms conditions may established compensation benefits committee board directors committee eligibility regular fulltime parttime employees company subsidiaries affiliates joint ventures including officers whether directors company employees joint venture partner affiliate company provide services joint venture partner affiliate shall eligible participate isp eligible employees designated committee directors company regular employees eligible participate isp administration isp shall administered committee committee shall responsible administration isp including without limitation determining eligible employees receive incentives kind incentives made isp number shares terms conditions incentives determinations committee isp including without limitation determinations eligible employees form amount timing incentives terms provisions incentives agreements evidencing incentives need uniform may made selectively among eligible employees receive eligible receive incentives hereunder whether eligible employees similarly situated committee shall responsibility construing interpreting isp establishing amending rules regulations may deem necessary desirable proper administration isp decision action taken taken committee arising connection construction administration interpretation effect isp rules regulations shall maximum extent permitted applicable law within absolute discretion except otherwise specifically provided herein shall conclusive binding upon company eligible employees person claiming eligible employee committee may delegate power authority hereunder chief executive officer senior member management committee deems appropriate provided however committee may delegate authority regard matter action affecting officer subject section securities exchange act purpose section subsequent sections isp shall deemed include plan comparable subplans established subsidiaries aggregate shall constitute one plan governed terms set forth herein shares available incentives shares subject issuance transfer subject adjustment provided section c hereof hereby reserved issuance isp million shares common stock shares available granting awards shall increased number shares options benefits granted isp lapsed expired terminated canceled addition shares reserved issuance companys incentive stock plan incentive stock plan prior plans excess number shares options benefits awarded thereunder plus shares options benefits granted prior plans may lapse expire terminate canceled shall also reserved available issuance reissuance isp shares isp may delivered company authorized unissued shares common stock common stock held treasury b limit individuals incentives given year eligible employee may receive incentives covering three million shares companys common stock number shares shall adjusted accordance section c c adjustment shares event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination shares merger consolidation rights offering spin split split similar change capital structure company committee shall make equitable adjustments number kind shares authorized issuance isp ii number kind shares subject outstanding incentives iii option price stock options iv grant value stock appreciation rights determination shall final binding conclusive parties stock options committee may grant options qualifying incentive stock options internal revenue code amended successor code thereto code statutory options code nonqualified options collectively stock options stock options shall subject following terms conditions terms conditions committee may prescribe option price option price per share respect stock option shall determined committee shall less fair market value common stock date stock option granted determined committee b period option period stock option shall fixed committee shall exceed ten years c payment shares shall issued full payment option price made option prices may paid cash committee determines shares common stock combination cash shares committee approves use shares common stock payment method committee shall establish conditions deems appropriate use common stock exercise stock option stock options awarded isp shall exercised companys brokerassisted stock option exercise program provided program available time option exercise means committee may determine time time committee may establish rules procedures permit optionholder defer recognition gain upon exercise stock option exercise option committee shall determine shares covered stock option may purchased committee may establish waiting periods dates options become exercisable vested exercise periods provided event including specified paragraphs e f g section shall stock option exercisable specified expiration period e termination employment upon termination stock option grantees employment reason retirement death termination deliberate willful gross misconduct stock option privileges shall limited shares immediately exercisable date termination committee however discretion may provide stock options outstanding yet exercisable upon termination stock option grantees employment may become exercisable accordance schedule may determined committee stock option privileges shall expire unless exercised surrendered stock appreciation right within period time date termination employment may established committee event later expiration date stock option f retirement upon retirement stock option grantee stock option privileges shall apply shares immediately exercisable date retirement committee however discretion may provide stock options outstanding yet exercisable upon retirement stock option grantee may become exercisable accordance schedule may determined committee stock option privileges shall expire unless exercised within period time may established committee event later expiration date stock option g death upon death stock option grantee stock option privileges shall apply shares immediately exercisable time death committee however discretion may provide stock options outstanding yet exercisable upon death stock option grantee may become exercisable accordance schedule may determined committee privileges shall expire unless exercised legal representatives within period time determined committee event later expiration date stock option h termination due misconduct stock option grantees employment terminated deliberate willful gross misconduct determined company rights stock option shall expire upon receipt notice termination limits incentive stock options except may otherwise permitted code committee shall grant eligible employee incentive stock options aggregate first exercisable one calendar year extent aggregate fair market value common stock time incentive stock options granted exceeds amount internal revenue service may decide time time stock appreciation rights committee may discretion grant right receive appreciation fair market value shares common stock stock appreciation right either singly combination underlying stock option granted hereunder prior plans stock appreciation rights shall subject following terms conditions terms conditions committee may prescribe time period grant stock appreciation right granted respect underlying stock option may granted time stock option grant time thereafter prior expiration stock option grant stock appreciation right granted respect underlying stock option time stock appreciation right granted committee may limit exercise period stock appreciation right period stock appreciation right shall attach underlying stock option event shall exercise period stock appreciation right granted respect underlying stock option exceed exercise period stock option stock appreciation right granted without underlying stock option period exercise stock appreciation right shall set committee b value stock appreciation right stock appreciation right granted respect underlying stock option grantee entitled surrender stock option exercisable receive exchange therefor amount equal excess fair market value common stock date election surrender received company stock option price multiplied number shares covered stock option surrendered stock appreciation right granted without underlying stock option grantee receive upon exercise stock appreciation right amount equal excess fair market value common stock date election surrender stock appreciation right received company fair market value common stock date grant multiplied number shares covered grant stock appreciation right c payment stock appreciation right payment stock appreciation right shall form shares common stock cash combination shares cash form payment upon exercise right shall determined committee either time grant stock appreciation right time exercise stock appreciation right performance share awards committee may grant awards payment may made shares common stock cash combination shares cash performance company subsidiary division affiliate joint venture company selected committee award period meets certain goals established committee performance share awards performance share awards shall subject following terms conditions terms conditions committee may prescribe award period performance goals committee shall determine include performance share award grant period time performance share award made award period committee shall also establish performance objectives performance goals met company subsidiary division joint venture award period condition payment performance share award performance goals may include earnings per share return stockholders equity return assets net income financial measurement established committee performance goals may include minimum optimum objectives single set objectives b payment performance share awards committee shall establish method calculating amount payment made performance share award performance goals met including fixing maximum payment performance share award shall expressed terms shares common stock referred performance shares completion award period performance company subsidiary division joint venture shall measured performance goals committee shall determine whether none portion performance share award shall paid committee discretion may elect make payment shares common stock cash combination shares cash cash payment shall based fair market value performance shares soon practicable prior date payment c revision performance goals time prior end award period committee may revise performance goals computation payment unforeseen events occur substantial effect performance company subsidiary division joint venture judgment committee make application performance goals unfair unless revision made requirement employment grantee performance share award must remain employ company completion award period order entitled payment performance share award provided committee may discretion provide full partial payment exception deemed equitable e dividends committee may discretion time granting performance share award provide dividends declared common stock award period would paid respect performance shares owned grantee paid grantee ii accumulated benefit grantee used increase number performance shares grantee f limit performance share awards incentives granted performance share awards section restricted stock grants section shall exceed aggregate six million shares common stock number shares shall adjusted accordance section c restricted stock grants committee may award shares common stock grantee shares shall subject following terms conditions terms conditions committee may prescribe restricted stock grant requirement employment grantee restricted stock grant must remain employment company period designated committee restriction period order retain shares restricted stock grant grantee leaves employment company prior end restriction period restricted stock grant shall terminate shares common stock shall returned immediately company provided committee may time grant provide employment restriction lapse respect portion portions restricted stock grant different times restriction period committee may discretion also provide complete partial exceptions employment restriction deems equitable b restrictions transfer legend stock certificates restriction period grantee may sell assign transfer pledge otherwise dispose shares common stock certificate shares common stock issued hereunder shall contain legend giving appropriate notice restrictions grant c escrow agreement committee may require grantee enter escrow agreement providing certificates representing restricted stock grant remain physical custody escrow holder restrictions removed expire lapse restrictions restrictions imposed restricted stock grant shall lapse upon expiration restriction period conditions employment set forth met grantee shall entitled legend removed certificates e dividends committee shall discretion time restricted stock grant provide dividends declared common stock restriction period shall either paid grantee ii accumulated benefit grantee paid grantee expiration restriction period f limit restricted stock grant incentives granted restricted stock grants section performance share awards section shall exceed aggregate six million shares common stock number shares shall adjusted accordance section c transferability incentive stock option granted isp shall transferable laws descent distribution incentive granted isp transferable assignable recipient may made subject execution attachment similar procedures laws descent distribution determined committee accordance regulations promulgated securities exchange act applicable law regulation discontinuance amendment plan board directors may discontinue isp time may time time amend revise terms isp permitted applicable statutes except may revoke alter manner unfavorable grantees incentives hereunder incentives outstanding may board amend isp without stockholder approval absence approval would cause plan fail comply rule b securities exchange act requirement applicable law regulation unless approved companys stockholders adjustments reduction exercise price outstanding incentives shall made cancellation outstanding incentives subsequent regranting incentives lower price individual incentive shall granted isp december incentives granted theretofore may extend beyond date right employment participation isp incentives granted hereunder shall confer upon eligible employee right continued employment company subsidiaries affiliates joint ventures affect way right entities terminate employment eligible employee time reason individual shall right granted incentive granted incentive receive future incentives limitation compensation nothing isp shall construed limit right company establish plans pay compensation employees cash property manner expressly authorized isp impact benefits except may otherwise specifically stated employee benefit plan policy program amount payable respect incentive shall treated compensation purposes calculating employees right plan policy program constraint corporate action nothing isp shall construed limit impair otherwise affect companys right power make adjustments reclassifications reorganizations changes capital business structure merge consolidate dissolve liquidate sell transfer part business assets ii except provided section limit right power company subsidiary take action entity deems necessary appropriate withholding taxes company shall entitled deduct payment isp regardless form payment amount applicable income employment taxes required law withheld respect payment may require eligible employee pay tax prior condition making payment accordance applicable administrative guidelines establishes committee may allow eligible employee pay amount taxes required law withheld incentive withholding payment common stock due result incentive permitting eligible employee deliver company shares common stock fair market value determined committee equal amount required withholding taxes governing law isp agreements hereunder shall construed accordance governed laws state new jersey merck change control options vesting options key rd options upon occurrence change control stock option outstanding immediately prior change control key rd options shall immediately become fully vested exercisable vesting key rd options subject aii schedule upon occurrence change control key rd option shall continue subject performancebased vesting schedule applicable thereto immediately prior change control ii notwithstanding ai schedule stock options continue outstanding following change control exchanged converted options purchase securities successor entity successor options upon occurrence change control portion key rd option shall immediately vest become exercisable following percentages key rd options first milestone reached date change control unvested portion key rd option shall vest become exercisable remainder shall forfeited b key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited c key rd options first second milestones reached date change control thenunvested portion key rd option shall vest become exercisable posttermination exercise period stock options continue outstanding following change control exchanged converted successor options portion stock options successor options applicable vested exercisable immediately following termination employment holder thereof change control shall remain exercisable following termination five years date termination beyond remainder term thereof provided however termination reason gross misconduct death retirement terms applied awards granted plans provisions plan applicable termination reason gross misconduct death retirement shall apply termination effect vesting pursuant section would cause stock option successor stock option terminate earlier accelerated vesting occurred term stock option shall expire earlier accelerated vesting occurred cashout stock options stock options continue outstanding following change control exchanged converted successor options holder vested exercisable option shall entitled receive soon practicable following change control share common stock subject vested exercisable option amount cash determined committee prior change control event less excess change control price exercise price thereof subject existing deferral elections effect consideration paid change control entirely shares common stock acquiring resulting corporation committee may prior change control provide cancellation outstanding stock options time change control whole part cash pursuant provision may provide exchange conversion outstanding stock options time change control whole part connection provision may shall obligated permit holders stock options make elections related thereto determines appropriate incentive stock options amended section apply incentive stock option within meaning section internal revenue code b restricted stock units performance share units vesting restricted stock units upon occurrence change control unvested restricted stock unit award outstanding immediately prior change control plan shall immediately become fully vested vesting performance share units upon occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately become vested amount equal psu pro rata amount settlement restricted stock units performance share units common stock continues widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid shares common stock securities soon practicable date change control subject existing deferral elections effect ii common stock continue widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid cash soon practicable date change control subject existing deferral elections effect c provisions except extent required applicable law entirety protection period material terms plan shall modified manner materially adverse qualifying participants understood section c schedule shall require specific type levels equity awards granted qualifying participants following change control protection period plan may amended modified reduce eliminate protections set forth section c schedule may terminated company shall pay legal fees related expenses including costs experts evidence counsel reasonably good faith incurred qualifying participant qualifying participant prevails claim relief action x qualifying participant claiming provisions section c c schedule violated avoidance doubt excluding claims plan benefits ordinary course applicable company qualifying participants employer enforce posttermination covenants qualifying participant section apply incentive stock option within meaning section internal revenue code anything plan amended schedule notwithstanding company reserves right make changes may required extent required avoid adverse consequences american jobs creation act amended definitions purposes schedule following terms shall following meanings change control shall meaning set forth companys change control separation benefits plan provided however award plan consists deferred compensation subject section code definition change control shall deemed modified extent necessary comply section code change control price shall mean respect share common stock higher highest reported sales price regular way share transaction reported new york stock exchange composite tape national exchange shares listed nasdaq national market day period prior including date change control b change control result tender exchange offer merger similar corporate transaction highest price per share paid tender exchange offer merger similar corporate transaction provided extent part consideration paid transaction consists securities noncash consideration value securities non cash consideration shall determined committee key rd options shall mean performancebased options granted employees key research development program described applicable schedule rules regulations plan protection period shall mean period beginning date change control ending second anniversary date change control psu pro rata amount shall mean performance share unit award amount determined multiplying x x number target shares subject performance share unit award times assumed performance percentage fraction numerator number whole partial calendar months elapsed applicable performance period counting partial month whole month purpose denominator total number months applicable performance period assumed performance percentage shall determined averaging ranks award period follows completed performance year change control actual rank except fewer days elapsed since completion performance year target rank shall used b performance year incomplete yet begun change control target rank rounding average rank calculated pursuant foregoing clause nearest whole number using ordinary numerical rounding using final award percentage associated number determined foregoing clause target rank rank associated chart final award percentages qualifying participants shall mean individuals participate plan whether current former employees immediately prior change control e application schedule shall apply stock options restricted stock unit awards performance share unit awards plans granted prior november exhibit merck co inc incentive stock plan amended restated december merck co inc incentive stock plan amended december purpose incentive stock plan plan effective may established encourage employees merck co inc company subsidiaries affiliates joint ventures acquire common stock company common stock believed plan serve interests company stockholders allows employees greater personal financial interest company ownership right acquire common stock turn stimulate employees efforts companys behalf maintain strengthen desire remain company believed plan also assist recruitment employees administration plan shall administered compensation benefits committee board directors company committee director company may serve committee nonemployee director purposes rule b securities exchange act amended exchange act ii satisfies requirements outside director purposes section internal revenue code code committee shall responsible administration plan including without limitation determining eligible employees receive incentives types incentives receive plan number shares covered incentives granted plan terms conditions incentives determinations committee plan including without limitation determinations eligible employees form amount timing incentives terms provisions incentives writings evidencing incentives need uniform may made selectively among eligible employees receive eligible receive incentives hereunder whether eligible employees similarly situated committee shall responsibility construing interpreting plan including right construe disputed doubtful plan provisions establishing amending construing rules regulations may deem necessary desirable proper administration plan decision action taken taken committee arising connection construction administration interpretation effect plan rules regulations shall maximum extent permitted applicable law within absolute discretion except otherwise specifically provided herein shall final binding conclusive upon company eligible employees person claiming eligible employee committee permitted applicable state law may delegate power authority hereunder chief executive officer senior member management committee deems appropriate provided however committee may delegate authority regard matter action affecting officer subject section exchange act delegation shall made case incentives intended qualified section code purpose section subsequent sections plan shall deemed include plan comparable subplans established subsidiaries aggregate shall constitute one plan governed terms set forth herein eligibility employees regular fulltime parttime employees employed company parent subsidiaries affiliates joint ventures including officers whether directors company employees joint venture partner affiliate company provide services joint venture partner affiliate person employee shall eligible participate plan designated committee eligible employees b nonemployees term employee shall include following collectively excluded persons director employee officer person independent contractor agrees agreed heshe independent contractor person agreement understanding company affiliates joint venture partners heshe employee eligible employee even heshe previously employee eligible employee person employed temporary employment agency regardless amount control supervision training provided company affiliates leased employee defined section n code excluded person eligible employee receive incentives even court agency authority rules heshe commonlaw employee company affiliates c right continued employment nothing plan shall interfere limit way right company parent subsidiaries affiliates joint ventures terminate employment participant time confer upon participant right continue employ company parent subsidiaries affiliates joint ventures eligible employee shall right receive incentive benefit plan granted incentive benefit receive additional incentive benefit neither award incentive benefits arising incentives shall constitute employment contract company parent subsidiaries affiliates joint ventures accordingly plan benefits hereunder may terminated time sole exclusive discretion company without giving rise liability part company parent subsidiaries affiliates joint ventures severance except may otherwise specifically stated employee benefit plan policy program neither incentive plan amount realized incentive shall treated compensation purposes calculating employees benefit plan policy program term plan plan shall effective may subject approval plan affirmative vote stockholders company entitled vote thereon time approval incentive shall granted plan april term exercise incentives granted theretofore may extend beyond date incentives incentives plan may granted one combination incentive stock options b nonqualified stock options c stock appreciation rights restricted stock grants e performance shares f share awards g phantom stock awards collectively incentives incentives shall subject terms conditions set forth herein terms conditions may established committee shares available incentives shares available subject provisions section c maximum number shares common stock company may issued plan million shares plan predecessor incentive stock plans purchased awarded incentive lapsed expired terminated cancelled may used grant incentives plan incentives similar awards issued entity merged company acquired company otherwise involved similar corporate transaction company considered issued plan shares plan may delivered company authorized unissued shares common stock issued reacquired common stock held treasury stock event shall fractional shares common stock issued plan b limit individuals incentives calendar year eligible employee may receive incentives covering million shares companys common stock number shares shall adjusted accordance section c ii incentive person owns percent stock company within meaning section code iii incentive stock option defined section code would result person receiving grant incentive stock options stock would aggregate fair market value excess determined time incentive stock option granted would exercisable first time person calendar year c adjustment shares event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination shares merger consolidation rights offering spin split split similar change capital structure company committee shall make equitable adjustments number kind shares authorized issuance plan ii number kind shares subject outstanding incentives iii option price stock options iv grant value stock appreciation rights determination shall final binding conclusive parties stock options committee may grant options qualifying incentive stock options defined section code options incentive stock options nonqualified options collectively stock options stock options shall subject following terms conditions terms conditions committee may prescribe stock option price option price per share respect stock option shall determined committee shall less percent fair market value common stock date stock option granted determined committee b period stock option period stock option shall fixed committee provided period stock options shall exceed ten years grant provided however event death optionee prior expiration nonqualified option nonqualified option may committee determines exercisable eleven years date grant committee may subsequent granting stock option extend term thereof event shall extended term exceed ten years original grant date c exercise stock option payment therefore shares shall issued full payment option price made option price may paid cash committee determines shares common stock combination cash shares common stock committee approves use shares common stock payment method committee shall establish conditions deems appropriate use common stock exercise stock option stock options awarded plan shall exercised procedure program committee may establish define time time may include designated broker must used exercising stock options committee may establish rules procedures permit optionholder defer recognition gain upon exercise stock option first exercisable date committee shall determine shares covered stock option may purchased committee may establish waiting periods dates stock options become exercisable vested subject paragraph b section exercise periods committee may accelerate exercisability stock option portion thereof e termination employment unless determined otherwise committee upon termination stock option grantees employment reason gross misconduct stock option privileges shall limited shares immediately exercisable date termination committee however discretion may provide stock options outstanding yet exercisable upon termination stock option grantees employment may become exercisable accordance schedule determined committee stock option privileges shall expire unless exercised within period time date termination employment may established committee event later expiration date stock option f termination due misconduct stock option grantees employment terminated gross misconduct determined company rights stock option shall expire upon date termination g limits incentive stock options except may otherwise permitted code eligible employee may receive grant incentive stock options stock would aggregate fair market value excess amount internal revenue service may decide time time determined time incentive stock option granted would exercisable first time person calendar year stock appreciation rights committee may discretion grant right receive appreciation fair market value shares common stock stock appreciation right either singly combination underlying stock option granted hereunder stock appreciation right shall subject following terms conditions terms conditions committee may prescribe time period grant stock appreciation right granted respect underlying stock option may granted time stock option grant time thereafter prior expiration stock option grant stock appreciation right granted respect underlying stock option time stock appreciation right granted committee may limit exercise period stock appreciation right period stock appreciation right shall attach underlying stock option event shall exercise period stock appreciation right granted respect underlying stock option exceed exercise period stock option stock appreciation right granted without underlying stock option period exercise stock appreciation right shall set committee b value stock appreciation right stock appreciation right granted respect underlying stock option grantee entitled surrender stock option exercisable receive exchange therefor amount equal excess fair market value common stock date election surrender received company accordance exercise procedures established company stock option price spread multiplied number shares covered stock option surrendered stock appreciation right granted without underlying stock option grantee receive upon exercise stock appreciation right amount equal excess fair market value common stock date election surrender stock appreciation right received company accordance exercise procedures established company fair market value common stock date grant multiplied number shares covered grant stock appreciation right notwithstanding foregoing sole discretion committee time grants stock appreciation right may provide spread covered stock appreciation right may exceed specified amount c payment stock appreciation right payment stock appreciation right shall form shares common stock cash combination shares cash form payment upon exercise right shall determined committee either time grant stock appreciation right time exercise stock appreciation right performance share awards committee may grant awards payment may made shares common stock cash combination shares cash performance company parent subsidiary division affiliate joint venture company selected committee award period meets certain goals established committee performance share awards performance share awards shall subject following terms conditions terms conditions committee may prescribe award period performance goals committee shall determine include performance share award grant period time performance share award made award period committee also shall establish performance objectives performance goals met company parent subsidiary division affiliate joint venture company award period condition payment performance share award performance goals may include share price pretax profits earnings per share return stockholders equity return assets sales net income combination foregoing solely award intended constitute performancebased compensation section code financial measurement established committee performance goals may include minimum optimum objectives single set objectives b payment performance share awards committee shall establish method calculating amount payment made performance share award performance goals met including fixing maximum payment performance share award shall expressed terms shares common stock referred performance shares completion award period performance company parent subsidiary division affiliate joint venture company shall measured performance goals committee shall determine accordance terms performance share award whether none portion performance share award shall paid committee discretion may elect make payment shares common stock cash combination shares cash cash payment shall based fair market value performance shares soon practicable prior date payment committee may establish rules procedures permit grantee defer recognition income upon attainment performance share award c revision performance goals award intended constitute performancebased compensation section code time prior end award period committee may revise performance goals computation payment unforeseen events occur substantial effect performance company parent subsidiary division affiliate joint venture company judgment committee make application performance goals unfair unless revision made requirement employment grantee performance share award must remain employ company parent subsidiary affiliate joint venture completion award period order entitled payment performance share award provided committee may discretion provide full partial payment exception deemed equitable e dividends committee may discretion time granting performance share award provide dividends declared common stock award period would paid respect performance shares owned grantee paid grantee ii accumulated benefit grantee used increase number performance shares grantee f limit performance share awards incentives granted performance share awards section restricted stock grants section share based awards section shall exceed aggregate million shares common stock number shares shall adjusted accordance section c restricted stock grants committee may award shares common stock eligible employee shares shall subject following terms conditions terms conditions committee may prescribe restricted stock grant requirement employment grantee restricted stock grant must remain employment company period designated committee restriction period order retain shares restricted stock grant grantee leaves employment company prior end restriction period restricted stock grant shall terminate shares common stock shall returned immediately company provided committee may time grant provide employment restriction lapse respect portion portions restricted stock grant different times restriction period committee may discretion also provide complete partial exceptions employment restriction deems equitable b restrictions transfer legend stock certificates restriction period grantee may sell assign transfer pledge otherwise dispose shares common stock certificate shares common stock issued hereunder shall contain legend giving appropriate notice restrictions grant c escrow agreement committee may require grantee enter escrow agreement providing certificates representing restricted stock grant remain physical custody escrow holder restrictions removed expire lapse restrictions restrictions imposed restricted stock grant shall lapse upon expiration restriction period conditions employment set forth met grantee shall entitled legend removed certificates committee may establish rules procedures permit grantee defer recognition income upon expiration restriction period e dividends committee shall discretion time restricted stock grant provide dividends declared common stock restriction period shall either paid grantee ii accumulated benefit grantee paid grantee expiration restriction period f performance goals committee may designate whether restricted stock grant intended performancebased compensation term used section code restricted stock grant designated performancebased compensation shall conditioned achievement one performance goals defined section extent required section g limit restricted stock grant incentives granted restricted stock grants section performance share awards section share based awards section shall exceed aggregate million shares common stock number shares shall adjusted accordance section c sharebased awards committee may grant award shares common stock share award eligible employee terms conditions committee may determine sole discretion share awards may made additional compensation services rendered eligible employee may lieu cash compensation eligible employee entitled company incentives granted share based awards section performance share awards section restricted stock grants section shall exceed aggregate million shares common stock number shares shall adjusted accordance section c transferability incentive stock option granted plan shall transferable laws descent distribution incentive granted plan transferable assignable recipient may made subject execution attachment similar procedures laws descent distribution determined committee accordance regulations promulgated securities exchange act applicable law regulation notwithstanding foregoing committee discretion may adopt rules permitting transfer solely gifts grantees lifetime stock options incentive stock options members grantees immediate family trusts family partnerships similar entities benefit immediate family members purpose immediate family member means grantees spouse parent child stepchild grandchild spouses family members terms stock option shall final binding conclusive upon beneficiaries executors administrators heirs successors grantee discontinuance amendment plan board directors may discontinue plan time may time time amend revise terms plan permitted applicable statutes except may without consent grantees affected revoke alter manner unfavorable grantees incentives hereunder incentives outstanding may board amend plan without stockholder approval absence approval would cause plan fail comply rule b exchange act requirement applicable law regulation unless approved companys stockholders otherwise specifically provided plan adjustments reduction exercise price outstanding incentives shall made event decline stock price either reducing exercise price outstanding incentives cancellation outstanding incentives connection regranting incentives lower price individual limitation compensation nothing plan shall construed limit right company establish plans pay compensation employees cash property manner expressly authorized plan constraint corporate action nothing plan shall construed limit impair otherwise affect companys right power make adjustments reclassifications reorganizations changes capital business structure merge consolidate dissolve liquidate sell transfer part business assets ii except provided section limit right power company parent subsidiary affiliate joint venture take action entity deems necessary appropriate withholding taxes company shall entitled deduct payment plan regardless form payment amount applicable income employment taxes required law withheld respect payment may require eligible employee pay tax prior condition making payment accordance applicable administrative guidelines establishes committee may allow eligible employee pay amount taxes required law withheld incentive withholding payment common stock due result incentive permitting eligible employee deliver company shares common stock fair market value determined committee equal amount required withholding taxes compliance section respect eligible employees subject section exchange act section officers transactions plan intended comply applicable conditions rule b successor exchange act extent compliance plan provision applicable solely section officers required order bring transaction section officer compliance rule b shall deemed null void transaction extent permitted law deemed advisable committee delegees extent provision plan action plan administrators involving section officers deemed comply applicable condition rule b shall deemed null void section officers extent permitted law deemed advisable plan administrators use proceeds proceeds received company sale stock plan shall added general funds company shall used corporate purposes board directors shall direct governing law plan agreements hereunder shall construed accordance governed laws state new jersey without giving effect principles conflicts laws offset suspension exercise anything contrary plan notwithstanding plan administrators may offset incentive amounts reasonably believed owed company grantee ii disallow incentive exercised otherwise payable time company investigating reasonably reliable allegations gross misconduct grantee effect change control options vesting options key rd options upon occurrence change control stock option outstanding immediately prior change control key rd options shall immediately become fully vested exercisable vesting key rd options subject section aii upon occurrence change control key rd option shall continue subject performancebased vesting schedule applicable thereto immediately prior change control ii notwithstanding section ai stock options continue outstanding following change control exchanged converted options purchase securities successor entity successor options upon occurrence change control portion key rd option shall immediately vest become exercisable following percentages key rd options first milestone reached date change control thenunvested portion keyrd option shall vest become exercisable remainder shall forfeited b key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited c key rd options first second milestones reached date change control thenunvested portion key rd option shall vest become exercisable posttermination exercise period stock options continue outstanding following change control exchanged converted successor options portion stock options successor options applicable vested exercisable immediately following termination employment holder thereof change control shall remain exercisable following termination five years date termination beyond remainder term thereof provided however termination reason gross misconduct death retirement terms applied awards granted plan provisions plan applicable termination reason gross misconduct death retirement shall apply termination cashout stock options stock options continue outstanding following change control exchanged converted successor options holder vested exercisable option shall entitled receive soon practicable following change control share common stock subject vested exercisable option amount cash determined committee prior change control event less excess change control price exercise price thereof subject existing deferral elections effect consideration paid change control entirely shares common stock acquiring resulting corporation committee may prior change control provide cancellation outstanding stock options time change control whole part cash pursuant section may provide exchange conversion outstanding stock options time change control whole part connection provision may shall obligated permit holders stock options make elections related thereto determines appropriate b restricted stock units performance share units vesting restricted stock units upon occurrence change control unvested restricted stock unit award outstanding immediately prior change control plan shall immediately become fully vested vesting performance share units upon occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately become vested amount equal psu pro rata amount settlement restricted stock units performance share units common stock continues widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid shares common stock securities soon practicable date change control subject existing deferral elections effect ii common stock continue widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid cash soon practicable date change control subject existing deferral elections effect c provisions except extent required applicable law entirety protection period material terms plan shall modified manner materially adverse qualifying participants understood section c shall require specific type levels equity awards granted qualifying participants following change control protection period plan may amended modified reduce eliminate protections set forth section c may terminated company shall pay legal fees related expenses including costs experts evidence counsel reasonably good faith incurred qualifying participant qualifying participant prevails claim relief action x qualifying participant claiming provisions section c c plan violated avoidance doubt excluding claims plan benefits ordinary course applicable company qualifying participants employer enforce posttermination covenants qualifying participant definitions purposes section following terms shall following meanings change control shall meaning set forth companys change control separation benefits plan provided however award plan consists deferred compensation subject section code definition change control shall deemed modified extent necessary comply section code change control price shall mean respect share common stock higher highest reported sales price regular way share transaction reported new york stock exchange composite tape national exchange shares listed nasdaq national market tenday period prior including date change control b change control result tender exchange offer merger similar corporate transaction highest price per share paid tender exchange offer merger similar corporate transaction provided extent part consideration paid transaction consists securities noncash consideration value securities noncash consideration shall determined committee key rd options shall mean performancebased options granted employees key research development program described applicable schedule rules regulations plan protection period shall mean period beginning date change control ending second anniversary date change control psu pro rata amount shall mean performance share unit award amount determined multiplying x x number target shares subject performance share unit award times assumed performance percentage fraction numerator number whole partial calendar months elapsed applicable performance period counting partial month whole month purpose denominator total number months applicable performance period assumed performance percentage shall determined averaging ranks award period follows completed performance year change control actual rank except fewer days elapsed since completion performance year target rank shall used b performance year incomplete yet begun change control target rank rounding average rank calculated pursuant foregoing clause nearest whole number using ordinary numerical rounding using final award percentage associated number determined foregoing clause target rank rank associated chart final award percentages qualifying participants shall mean individuals participate plan whether current former employees immediately prior change control e application section shall apply stock options restricted stock unit awards performance share unit awards granted november note incentives granted november see merck change control schedule merck change control options vesting options key rd options upon occurrence change control stock option outstanding immediately prior change control key rd options shall immediately become fully vested exercisable vesting key rd options subject aii schedule upon occurrence change control key rd option shall continue subject performancebased vesting schedule applicable thereto immediately prior change control ii notwithstanding ai schedule stock options continue outstanding following change control exchanged converted options purchase securities successor entity successor options upon occurrence change control portion key rd option shall immediately vest become exercisable following percentages key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited b key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited c key rd options first second milestones reached date change control unvested portion key rd option shall vest become exercisable posttermination exercise period stock options continue outstanding following change control exchanged converted successor options portion stock options successor options applicable vested exercisable immediately following termination employment holder thereof change control shall remain exercisable following termination five years date termination beyond remainder term thereof provided however termination reason gross misconduct death retirement terms applied awards granted plans provisions plan applicable termination reason gross misconduct death retirement shall apply termination effect vesting pursuant section would cause stock option successor stock option terminate earlier accelerated vesting occurred term stock option shall expire earlier accelerated vesting occurred cashout stock options stock options continue outstanding following change control exchanged converted successor options holder vested exercisable option shall entitled receive soon practicable following change control share common stock subject vested exercisable option amount cash determined committee prior change control event less excess change control price exercise price thereof subject existing deferral elections effect consideration paid change control entirely shares common stock acquiring resulting corporation committee may prior change control provide cancellation outstanding stock options time change control whole part cash pursuant provision may provide exchange conversion outstanding stock options time change control whole part connection provision may shall obligated permit holders stock options make elections related thereto determines appropriate incentive stock options amended section apply incentive stock option within meaning section internal revenue code b restricted stock units performance share units vesting restricted stock units upon occurrence change control unvested restricted stock unit award outstanding immediately prior change control plan shall immediately become fully vested vesting performance share units upon occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately become vested amount equal psu pro rata amount settlement restricted stock units performance share units common stock continues widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid shares common stock securities soon practicable date change control subject existing deferral elections effect ii common stock continue widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid cash soon practicable date change control subject existing deferral elections effect c provisions except extent required applicable law entirety protection period material terms plan shall modified manner materially adverse qualifying participants understood section c schedule shall require specific type levels equity awards granted qualifying participants following change control protection period plan may amended modified reduce eliminate protections set forth section c schedule may terminated company shall pay legal fees related expenses including costs experts evidence counsel reasonably good faith incurred qualifying participant qualifying participant prevails claim relief action x qualifying participant claiming provisions section c c schedule violated avoidance doubt excluding claims plan benefits ordinary course applicable company qualifying participants employer enforce posttermination covenants qualifying participant section apply incentive stock option within meaning section internal revenue code anything plan amended schedule notwithstanding company reserves right make changes may required extent required avoid adverse consequences american jobs creation act amended definitions purposes schedule following terms shall following meanings change control shall meaning set forth companys change control separation benefits plan provided however award plan consists deferred compensation subject section code definition change control shall deemed modified extent necessary comply section code change control price shall mean respect share common stock higher highest reported sales price regular way share transaction reported new york stock exchange composite tape national exchange shares listed nasdaq national market day period prior including date change control b change control result tender exchange offer merger similar corporate transaction highest price per share paid tender exchange offer merger similar corporate transaction provided extent part consideration paid transaction consists securities noncash consideration value securities non cash consideration shall determined committee key rd options shall mean performancebased options granted employees key research development program described applicable schedule rules regulations plan protection period shall mean period beginning date change control ending second anniversary date change control psu pro rata amount shall mean performance share unit award amount determined multiplying x x number target shares subject performance share unit award times assumed performance percentage fraction numerator number whole partial calendar months elapsed applicable performance period counting partial month whole month purpose denominator total number months applicable performance period assumed performance percentage shall determined averaging ranks award period follows completed performance year change control actual rank except fewer days elapsed since completion performance year target rank shall used b performance year incomplete yet begun change control target rank rounding average rank calculated pursuant foregoing clause nearest whole number using ordinary numerical rounding using final award percentage associated number determined foregoing clause target rank rank associated chart final award percentages qualifying participants shall mean individuals participate plan whether current former employees immediately prior change control e application schedule shall apply stock options restricted stock unit awards performance share unit awards plans granted prior november exhibit merck co inc incentive stock plan amended effective december merck co inc incentive stock plan effective december purpose incentive stock plan plan effective may established encourage employees merck co inc company subsidiaries affiliates joint ventures acquire common stock company common stock believed plan serve interests company stockholders allows employees greater personal financial interest company ownership right acquire common stock turn stimulate employees efforts companys behalf maintain strengthen desire remain company believed plan also assist recruitment employees administration plan shall administered compensation benefits committee board directors company committee director company may serve committee nonemployee director purposes rule b securities exchange act amended exchange act ii satisfies requirements outside director purposes section internal revenue code code committee shall responsible administration plan including without limitation determining eligible employees receive incentives types incentives receive plan number shares covered incentives granted plan terms conditions incentives determinations committee plan including without limitation determinations eligible employees form amount timing incentives terms provisions incentives writings evidencing incentives need uniform may made selectively among eligible employees receive eligible receive incentives hereunder whether eligible employees similarly situated committee shall responsibility construing interpreting plan including right construe disputed doubtful plan provisions establishing amending construing rules regulations may deem necessary desirable proper administration plan decision action taken taken committee arising connection construction administration interpretation effect plan rules regulations shall maximum extent permitted applicable law within absolute discretion except otherwise specifically provided herein shall final binding conclusive upon company eligible employees person claiming eligible employee committee permitted applicable state law may delegate power authority hereunder chief executive officer senior member management committee deems appropriate provided however committee may delegate authority regard matter action affecting officer term defined rule af exchange act section officer delegation shall made case incentives intended qualified section code purpose section subsequent sections plan shall deemed include plan comparable subplans established subsidiaries aggregate shall constitute one plan governed terms set forth herein eligibility employees regular fulltime parttime employees employed company parent subsidiaries affiliates joint ventures including officers whether directors company employees joint venture partner affiliate company provide services joint venture partner affiliate person employee shall eligible participate plan designated committee eligible employees b nonemployees term employee shall include following collectively excluded persons director employee officer person independent contractor agrees agreed heshe independent contractor person agreement understanding company affiliates joint venture partners heshe employee eligible employee even heshe previously employee eligible employee person employed temporary employment agency regardless amount control supervision training provided company affiliates leased employee defined section n code excluded person eligible employee receive incentives even court agency authority rules heshe commonlaw employee company affiliates c right continued employment nothing plan shall interfere limit way right company parent subsidiaries affiliates joint ventures terminate employment participant time confer upon participant right continue employ company parent subsidiaries affiliates joint ventures eligible employee shall right receive incentive benefit plan granted incentive benefit receive additional incentive benefit neither award incentive benefits arising incentives shall constitute employment contract company parent subsidiaries affiliates joint ventures accordingly plan benefits hereunder may terminated time sole exclusive discretion company without giving rise liability part company parent subsidiaries affiliates joint ventures severance except may otherwise specifically stated employee benefit plan policy program neither incentive plan amount realized incentive shall treated compensation purposes calculating employees benefit plan policy program term plan plan shall effective may subject approval plan majority votes cast annual meeting stockholders company april incentive shall granted plan april earlier date plan may terminated board term exercise incentives granted theretofore may extend beyond date incentives incentives plan may granted one combination incentive stock options isos b nonqualified options together isos stock options c stock appreciation rights restricted stock grants e performance awards f share awards g phantom stock awards collectively incentives incentives shall subject terms conditions set forth herein terms conditions may established committee general incentives may vest stock options stock appreciation rights may exercisable earlier one year grant date except case intervening event example change control company grantees death retirement termination employment caused company event established committee required applicable law shares available incentives shares available subject provisions section c maximum number shares common stock company may issued plan million stock option stock appreciation right shall counted one share purposes limit set forth section time grant combination tandem sar stock option exercise tandem sar stock option results cancellation shall counted one share purposes limit set forth section time grant ii restricted stock grant performance share share award phantom stock award shall counted four shares purposes limit set forth section time grant iii shares plan incentive stock plans purchased awarded incentive incentive lapsed expired terminated canceled may used grant incentives plan iv notwithstanding anything contrary shares tendered payment exercise price stock option shall added maximum share limitations described b shares withheld company satisfy tax withholding obligation shall added maximum share limitations described c shares covered stock appreciation right extent exercised whether shares common stock actually upon exercise right shall considered issued transferred pursuant plan v incentives similar awards issued entity merged company acquired company otherwise involved similar corporate transaction company considered issued plan shares plan may delivered company authorized unissued shares common stock issued reacquired common stock held treasury stock event shall fractional shares common stock issued plan b limit individuals incentives calendar year eligible employee may receive respect incentives denominated respect shares common stock incentives covering million shares companys common stock number shares shall counted provided section shall adjusted accordance section c ii respect incentives denominated cash incentives fair market value exceeding million shares common stock determined date incentive granted c adjustment shares event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination shares merger consolidation rights offering spin split split similar change capital structure company committee shall make equitable adjustments number kind shares authorized issuance plan ii number kind shares subject outstanding incentives iii option price stock options iv grant value stock appreciation rights determination shall final binding conclusive parties stock options committee may grant options qualifying isos defined section code options isos nonqualified options stock options shall subject following terms conditions terms conditions committee may prescribe stock option price option price per share respect stock option shall determined committee shall less percent fair market value common stock date stock option granted determined committee b period stock option period stock option shall fixed committee provided period stock options shall exceed ten years grant provided however event death optionee prior expiration nonqualified option nonqualified option may committee determines exercisable eleven years date grant committee may subsequent granting stock option extend term thereof event shall extended term exceed ten years original grant date c exercise stock option payment therefore shares shall issued full payment option price made option price may paid cash committee determines shares common stock combination cash shares common stock cashless exercise procedure allows grantees sell immediately shares underlying exercised portion option order generate sufficient cash pay option price committee approves use shares common stock payment method committee shall establish conditions deems appropriate use common stock exercise stock option stock options awarded plan shall exercised procedure program committee may establish define time time may include designated broker must used exercising stock options committee may establish rules procedures permit option holder defer recognition gain upon exercise stock option first exercisable date committee shall determine shares covered stock option may purchased committee may establish waiting periods dates stock options become exercisable vested subject paragraph b section exercise periods committee may accelerate exercisability stock option portion thereof e termination employment unless determined otherwise committee upon termination stock option grantees employment reason gross misconduct stock option privileges shall limited shares immediately exercisable date termination committee however discretion may provide stock options outstanding yet exercisable upon termination stock option grantees employment may become exercisable accordance schedule determined committee stock option privileges shall expire unless exercised within period time date termination employment may established committee event later expiration date stock option f termination due misconduct stock option grantees employment terminated gross misconduct determined company rights stock option shall expire upon date termination g limits isos except may otherwise permitted code eligible employee may receive grant isos stock would aggregate fair market value excess amount internal revenue service may decide time time determined time iso granted would exercisable first time person calendar year grant made excess limits provided code grant shall automatically become nonqualified option h dividend equivalents anything plan contrary notwithstanding dividends dividend equivalents may paid stock options stock appreciation rights committee may discretion grant right receive appreciation fair market value shares common stock stock appreciation right either singly combination underlying stock option granted hereunder stock appreciation right shall subject following terms conditions terms conditions committee may prescribe time period grant stock appreciation right granted respect underlying stock option tandem sar may granted time stock option grant time thereafter prior expiration stock option grant time tandem sar granted committee may limit exercise period stock appreciation right period stock appreciation right shall attach underlying stock option event shall exercise period tandem sar exceed exercise period stock option stock appreciation right granted without underlying stock option stand alone sar period exercise stock appreciation right shall set committee b value stock appreciation right grantee tandem sar entitled surrender stock option exercisable receive exchange therefore amount equal excess fair market value common stock date election surrender received company accordance exercise procedures established company stock option price spread multiplied number shares covered stock option surrendered grantee stand alone sar receive upon exercise stock appreciation right amount equal excess fair market value common stock date election surrender stand alone sar received company accordance exercise procedures established company fair market value common stock date grant multiplied number shares covered grant stand alone sar notwithstanding foregoing sole discretion committee time grants stock appreciation right may provide spread covered stock appreciation right may exceed specified amount c payment stock appreciation right payment stock appreciation right shall form shares common stock cash combination shares cash form payment upon exercise right shall determined committee either time grant stock appreciation right time exercise stock appreciation right dividend equivalents anything plan contrary notwithstanding dividends dividend equivalents may paid stock appreciation rights performance awards committee may grant awards denominated shares common stock performance shares denominated dollarsperformance units performance company parent subsidiary division affiliate joint venture company selected committee award period meets certain goals established committee performance awards performance awards shall subject following terms conditions terms conditions committee may prescribe award period performance goals committee shall determine include performance share award grant period time performance share award made award period committee also shall establish performance objectives performance goals met company parent subsidiary division affiliate joint venture company award period condition payment performance award performance goals may include share price pretax profits earnings per share return stockholders equity return assets sales net income total shareholder return combination foregoing solely award intended constitute performancebased compensation section code financial measurement established committee performance goals may include minimum optimum objectives single set objectives b payment performance awards committee shall establish method calculating amount payment made performance award performance goals met including fixing maximum payment completion award period performance company parent subsidiary division affiliate joint venture company shall measured performance goals committee shall determine accordance terms performance award whether none portion performance award shall paid committee discretion may elect make payment shares common stock cash combination shares cash cash payment shall based fair market value shares common stock soon practicable prior date payment committee may establish rules procedures permit grantee defer recognition income upon attainment performance award c revision performance goals award intended constitute performancebased compensation section code time prior end award period committee may revise performance goals computation payment unforeseen events occur substantial effect performance company parent subsidiary division affiliate joint venture company judgment committee make application performance goals unfair unless revision made requirement employment grantee performance award must remain employ company parent subsidiary affiliate joint venture completion award period order entitled payment performance award provided committee may discretion provide full partial payment exception deemed equitable e dividends committee may discretion time granting performance award provide dividends declared common stock award period would paid respect performance shares owned grantee paid grantee ii accumulated benefit grantee used increase number performance shares grantee iii paid accumulated restricted stock grants committee may award actual shares common stock restricted stock phantom shares common stock restricted stock units eligible employee shares shall subject following terms conditions terms conditions committee may prescribe restricted stock grants requirement employment grantee restricted stock grant must remain employment company period designated committee restricted period order receive shares cash combination thereof restricted stock grant grantee leaves employment company prior end restricted period restricted stock grant shall terminate shares common stock shall returned immediately company provided committee may time grant provide employment restriction lapse respect portion portions restricted stock grant different times restricted period committee may discretion also provide complete partial exceptions employment restriction deems equitable b restrictions transfer legend stock certificates restricted period grantee may sell assign transfer pledge otherwise dispose restricted stock grant including limited shares common stock certificate shares common stock issued hereunder shall contain legend giving appropriate notice restrictions grant c escrow agreement committee may require grantee enter escrow agreement providing certificates representing restricted stock grant remain physical custody escrow holder restrictions removed expire lapse restrictions restrictions imposed restricted stock grant shall lapse upon expiration restricted period conditions employment set forth met grantee shall entitled legend removed certificates restricted stock restricted stock units may paid form shares common stock cash combination shares cash determined committee committee may establish rules procedures permit grantee defer recognition income upon expiration restricted period e dividends committee may discretion time restricted stock grant provide dividends declared common stock restricted period dividend equivalents paid grantee ii accumulated benefit grantee paid grantee expiration restricted period iii paid accumulated f performance goals committee may designate whether restricted stock grant intended performancebased compensation term used section code restricted stock grant designated performancebased compensation shall conditioned achievement one performance goals defined section extent required section sharebased awards committee may grant award actual shares common stock share award phantom shares common stock phantom stock award eligible employee terms conditions committee may determine sole discretion share awards may made additional compensation services rendered eligible employee may lieu cash compensation eligible employee entitled company transferability iso granted plan shall transferable laws descent distribution incentive granted plan transferable assignable recipient may made subject execution attachment similar procedures laws descent distribution determined committee accordance exchange act applicable law regulation notwithstanding foregoing committee discretion may adopt rules permitting transfer solely gifts grantees lifetime stock options isos members grantees immediate family trusts family partnerships similar entities benefit immediate family members purpose immediate family member means grantees spouse parent child stepchild grandchild spouses family members terms stock option shall final binding conclusive upon beneficiaries executors administrators heirs successors grantee discontinuance amendment plan board directors may discontinue plan time may time time amend revise terms plan permitted applicable statutes except may without consent grantees affected revoke alter manner unfavorable grantees incentives hereunder incentives outstanding may board amend plan without stockholder approval absence approval would cause plan fail comply rule b exchange act requirement applicable law regulation notwithstanding foregoing without consent affected grantees incentives may amended revised revoked necessary avoid penalties section internal revenue code amended unless approved companys stockholders otherwise specifically provided plan adjustments reduction exercise price outstanding incentives shall made event decline stock price either reducing exercise price outstanding incentives cancellation outstanding incentives connection regranting incentives lower price individual limitation compensation nothing plan shall construed limit right company establish plans pay compensation employees cash property manner expressly authorized plan constraint corporate action nothing plan shall construed limit impair otherwise affect companys right power make adjustments reclassifications reorganizations changes capital business structure merge consolidate dissolve liquidate sell transfer part business assets ii except provided section limit right power company parent subsidiary affiliate joint venture take action entity deems necessary appropriate withholding taxes company shall entitled deduct payment plan regardless form payment amount applicable income employment taxes required law withheld respect payment may require eligible employee pay tax prior condition making payment accordance applicable administrative guidelines establishes committee may allow eligible employee pay amount taxes required law withheld incentive withholding payment common stock due result incentive permitting eligible employee deliver company shares common stock fair market value determined committee equal amount required withholding taxes compliance section respect eligible employees section officers transactions plan intended comply applicable conditions rule b successor exchange act extent compliance plan provision applicable solely section officers required order bring transaction section officer compliance rule b shall deemed null void transaction extent permitted law deemed advisable committee delegees extent provision plan action plan administrators involving section officers deemed comply applicable condition rule b shall deemed null void section officers extent permitted law deemed advisable plan administrators use proceeds proceeds received company plan shall added general funds company shall used corporate purposes board directors shall direct governing law plan agreements hereunder shall construed accordance governed laws state new jersey without giving effect principles conflicts laws offset suspension exercise anything contrary plan notwithstanding plan administrators may offset incentive amounts reasonably believed owed company grantee ii disallow incentive exercised otherwise payable time company investigating reasonably reliable allegations gross misconduct grantee effect change control options vesting options key rd options upon occurrence change control stock option outstanding immediately prior change control key rd options shall immediately become fully vested exercisable vesting key rd options subject section aii upon occurrence change control key rd option shall continue subject performancebased vesting schedule applicable thereto immediately prior change control ii notwithstanding section ai stock options continue outstanding following change control exchanged converted options purchase securities successor entity successor options upon occurrence change control portion key rd option shall immediately vest become exercisable following percentages key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited b key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited c key rd options first second milestones reached date change control thenunvested portion key rd option shall vest become exercisable posttermination exercise period stock options continue outstanding following change control exchanged converted successor options portion stock options successor options applicable vested exercisable immediately following termination employment holder thereof change control shall remain exercisable following termination five years date termination beyond remainder term thereof provided however termination reason gross misconduct death retirement terms applied awards granted plan provisions plan applicable termination reason gross misconduct death retirement shall apply termination cashout stock options stock options continue outstanding following change control exchanged converted successor options holder vested exercisable option shall entitled receive soon practicable following change control share common stock subject vested exercisable option amount cash determined committee prior change control event less excess change control price exercise price thereof subject existing deferral elections effect consideration paid change control entirely shares common stock acquiring resulting corporation committee may prior change control provide cancellation outstanding stock options time change control whole part cash pursuant section may provide exchange conversion outstanding stock options time change control whole part connection provision may shall obligated permit holders stock options make elections related thereto determines appropriate b restricted stock grants performance share awards vesting restricted stock grants upon occurrence change control unvested restricted stock grant outstanding immediately prior change control plan shall immediately become fully vested vesting performance award upon occurrence change control unvested performance award outstanding immediately prior change control plan shall immediately become vested amount equal psu pro rata amount settlement restricted stock grants performance awards common stock continues widely held freely tradeable following change control exchanged converted securities successor entity widely held freely tradeable vested incentives shall paid shares common stock securities soon practicable date change control form cash respect performance units subject existing deferral elections effect ii common stock continue widely held freely tradeable following change control exchanged converted securities successor entity widely held freely tradeable vested incentives shall paid cash soon practicable date change control subject existing deferral elections effect c provisions except extent required applicable law entirety protection period material terms plan shall modified manner materially adverse qualifying participants understood section c shall require specific type levels equity awards granted qualifying participants following change control protection period plan may amended modified reduce eliminate protections set forth section c may terminated company shall pay legal fees related expenses including costs experts evidence counsel reasonably good faith incurred qualifying participant qualifying participant prevails claim relief action x qualifying participant claiming provisions section c c plan violated avoidance doubt excluding claims plan benefits ordinary course applicable company qualifying participants employer enforce posttermination covenants qualifying participant definitions purposes section following terms shall following meanings change control shall meaning set forth companys change control separation benefits plan provided however award plan consists deferred compensation subject section code definition change control shall deemed modified extent necessary comply section code change control price shall mean respect share common stock higher highest reported sales price regular way share transaction reported new york stock exchange composite tape national exchange shares listed nasdaq national market tenday period prior including date change control b change control result tender exchange offer merger similar corporate transaction highest price per share paid tender exchange offer merger similar corporate transaction provided extent part consideration paid transaction consists securities noncash consideration value securities noncash consideration shall determined committee key rd options shall mean performancebased options granted employees key research development program described applicable schedule rules regulations plan protection period shall mean period beginning date change control ending second anniversary date change control psu pro rata amount shall mean performance award amount determined committee grants performance awards qualifying participants shall mean individuals participate plan whether current former employees immediately prior change control exhibit merck co inc nonemployee directors stock option plan effective april amended restated february nonemployee directors stock option plan nonemployee directors stock option plan plan established attract retain compensate service members board directors merck co inc company merck highly qualified individuals current former employees company enable increase ownership companys common stock plan beneficial company stockholders since allow directors greater personal financial stake company ownership company stock addition underscoring common interest stockholders increasing value company stock longer term eligibility members companys board directors current former employees company subsidiaries non employee directors shall participate plan awards nonqualified stock options purchase shares merck common stock nqsos restricted stock grants collectively incentives may granted plan shares available number shares available hereby reserved issuance plan million shares merck common stock par value per share may authorized unissued shares treasury shares shares purchased open market b recapitalization adjustment event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination shares merger consolidation rights offering similar change capital structure shares company adjustments number kind shares authorized plan number kind shares covered incentives option price outstanding nqsos plan shall made manner adjustments made incentives issued companys current incentive stock plan subject required action board directors stockholders company compliance applicable securities laws annual grant nonqualified stock options year first friday following companys annual meeting stockholders individual elected reelected continuing nonemployee director shall automatically receive nqso purchase shares merck common stock amount may determined board time time notwithstanding foregoing first friday general counsel company determines herhis sole discretion company possession material undisclosed information company annual grant nqsos nonemployee directors shall suspended second business day public dissemination information price exercisability date option period shall determined reference later date merck common stock traded new york stock exchange date grant would otherwise awarded grant shall made next day thereafter merck common stock traded option price price nqso shall closing price merck common stock date grant quoted new york stock exchange option period nqso granted plan shall become exercisable three equal installments subject rounding first second third anniversaries date grant shall expire pm day tenth anniversary thereof option period used plan times shall mean time new york ny payment nqso price required tax withholding shall paid cash us dollars time nqso exercised manner permitted option exercises companys incentive stock plan isp applicable officers defined rule securities exchange act exchange act merck affiliates compensation benefits committee board directors company approves use previously owned shares common stock portion exercise price nqsos granted isp provision also shall apply plan nqsos shall exercised companys brokerassisted stock option exercise program provided program available time option exercise means effect time time isp cessation service upon cessation service nonemployee director reasons retirement death nqsos immediately exercisable date cessation service shall exercisable grantee nqsos must exercised pm day day third month cessation service event expiration option period shall forfeited example service ends january section applies nqsos would expire later pm april nqsos shall expire pm day cessation service retirement grantee ceases service nonemployee director least age ten years service age five years service cessation service retirement begins first day service ends hisher outstanding nqsos shall continue become exercisable service continued outstanding nqsos must exercised expiration option period nqsos shall forfeited notwithstanding foregoing grantee dies nqsos forfeited section shall control death upon death grantee unvested nqsos shall become immediately exercisable nqsos become exercisable upon date death nqsos exercisable date death may exercised grantees legal representatives heirs earlier pm day third anniversary date death ii expiration option period exercised earlier ii nqsos shall forfeited notwithstanding foregoing local law applicable deceased grantee requires longer shorter exercise period provisions shall comply law restricted stock grant board may award actual shares common stock restricted stock phantom shares common stock restricted stock units nonemployee director shares shall subject terms conditions board may prescribe time time administration amendment plan plan shall administered board directors merck board may delegate person group may delegate boards powers obligations hereunder relate day day administration exercise process plan may terminated amended board directors deems advisable however amendment revising price date exercisability option period amount shares nqso shall made frequently every six months unless necessary comply applicable laws regulations unless approved companys stockholders adjustments reduction exercise price outstanding nqso shall made directly cancellation outstanding nqsos subsequent regranting nqsos lower price individual amendment may revoke alter manner unfavorable grantees incentives outstanding may board amend plan without stockholder approval absence approval would cause plan fail comply rule b exchange act requirement applicable law regulation incentive may granted plan december nqsos granted prior date shall continue become exercisable may exercised restricted stock grants shall continue vest according terms transferability except set forth section nqsos granted plan shall exercisable grantees lifetime anyone grantee grantees legal guardian grantees legal representative shall transferable laws descent distribution incentives granted plan shall transferable grantees lifetime accordance following provisions grantee may transfer nqso serving nonemployee director company within one year ceasing service nonemployee director due retirement defined section nqso may transferred grantees spouse children including adopted children stepchildren grandchildren collectively family members one trusts benefit family members discretion board directors one partnerships grantee family members partners accordance rules set forth section grantee shall receive payment consideration transfer except transfer partnership grantee shall permitted receive interest partnership consideration transfer nqso transferred accordance section shall continue subject terms conditions hands transferee applicable nqso prior transfer except grantees right transfer nqso accordance section shall apply transferee however transferee natural person upon transferees death nqso privileges may exercised legal representatives beneficiaries transferee within exercise periods otherwise applicable nqso purported transfer nqso section shall effective unless prior transfer grantee met minimum stock ownership target place directors company notified company transferees name address number shares option transferred grant date exercise price shares demonstrated requested board directors proposed transferee qualifies permitted transferee rules set forth section addition transferee must sign agreement bound rules regulations plan insider trading restrictions apply grantee provide additional documents requested company order effect transfer transfer shall effective unless company effect registration statement filed securities act covering securities acquired transferee upon exercise nqso general counsel merck determined registration shares necessary compliance sec regulations companys intent plan comply respects rule b exchange act regulations promulgated thereunder provision plan later found compliance rule provision shall deemed null void grants exercises nqsos plan shall executed accordance requirements section exchange act amended regulations promulgated thereunder miscellaneous except provided plan nonemployee director shall claim right granted nqso plan neither plan action thereunder shall construed giving director right retained service company effective date plan shall effective april later date stockholder approval obtained constraint corporate action nothing plan shall construed limit impair otherwise affect companys right power make adjustments reclassifications reorganizations changes capital business structure merge consolidate liquidate sell transfer part business assets ii except provided section limit right power company subsidiary take action entity deems necessary appropriate governing law plan agreements hereunder shall construed accordance governed laws state new jersey exhibit august dear brad letter agreement agreement supersedes peter loeschers letter dated july concerning employment status merck co inc merck company incorporates revisions earlier letter discussed attorneys mercks attorneys peter discussed part general restructuring mercks worldwide human health business current position president us human health eliminated close business september separated employment merck offering severance arrangements set forth contingent timely acceptance nonrevocation terms set forth agreement employment status transition assignment effective july relieved operational responsibilities sole assignment effectuate full transition responsibilities president us human health direction status officer defined rule af defined securities exchange act ended close business july agree use best efforts perform assignment duties may assign otherwise conduct best interests company grade base salary remain current level continue eligible participate companys employee benefit plans programs may amended time time terms conditions applicable company employees grade level sole discretion employment status may converted time paid inactive status prior september paid inactive status grade base salary unchanged continue receive monthly salary payments continue accrue pension credit eligible participate plans elected flexible benefits program provided however eligible participate short term long term disability benefit plans benefits agree waive b termination employment employment terminate september separation date provided terminated employment resignation prior separation date resignation deemed occur event engage conduct inconsistent responsibilities obligations merck employee voluntarily terminate employment quitting commencing employment elsewhere termination employment separation date separation service separation merck co inc separation benefits plan nonunion employees separation plan eligible benefits applicable bridged employee described brochure entitled special separation program bridged employees bridged employee brochure separation plan summary plan description spd describes benefits available separation plan bridged employee brochure describes effect separation benefits bridgedpage employee provided incorporated herein reference conflict spd agreement bridged employee brochure agreement spd bridged employee brochure case may shall govern separation benefits upon separation receive following separation benefits accordance spd bridged employee brochure separation pay subject paragraph b receive seventyeight weeks pay described spd payable periodic installments accordance companys normal payroll periods minus applicable deductions withholdings b retirement plan receive bridged pension benefit described bridged employee brochure subject paragraph b c medical dental benefits eligible select retiree medical dental benefits described bridged employee brochure life insurance eligible considered retiree life insurance plan purposes described bridged employee brochure e outplacement eligible receive senior executive service outplacement services period twelve months f equity grants considered retired purposes outstanding unexercised stock options restricted stock units leader shares performance share units case responsibility familiarize terms individual equity grants g special payment lieu eip bonus subject paragraph b receive special payment minus applicable deductions withholdings lieu eip bonus performance deferral election respect eip bonus apply special payment event die special payment made payment made estate payments generally payments made pursuant agreement based current base salary subject applicable deductions withholding upon separation except payments described agreement attached bridged employee brochure compensation paid behalf b section payments generally may made account separation service six months following termination employment specified employee defined prop treas reg sec ai successor thereto general includes top employees company ranked compensation specified employee thus payments characterized agreement subject paragraph payments made prior first day seventh month following termination employment instead amounts would otherwise payable six months immediately following separation accumulated paid lump sum without interest soon administratively practicable following six month period ie april deferral program account deferred program account applicable paid accordance terms conditions merck deferral program applicable separated employees subject paragraph b agreement lump sum payment soon practicable separation merck pay subject appropriate tax withholding gross lump sum amount lump sum payment subject delay described paragraph b agreement condition receiving lump sum payment agree execute return release claims attached hereto attachment soon september mercks obligation pay lump sum arise revocation period executed release passed without revocation thereof financial counseling may continue participate companys executive financial services program end level established management committee members time time currently reimbursement per calendar year nondisparagement agree disparage merck affiliates subsidiaries joint ventures products officers directors employees former employees representatives agents way whatsoever provided however nothing set forth herein prohibit making statement engaging conduct extent statement conduct required law court order legal process company agrees neither employees executive officers company july members companys board directors disparage performance merck employee noncompete period eighteen months following separation date agree conduct business competition merck conduct business competition merck means purposes agreement become connected manner competitor defined directly indirectly individual director trustee officer employee debt equity investor consultant independent contractor competitor ownership management operation control person entity competitor provided event shall ownership less outstanding equity securities issuer whose securities registered securities exchange act amended standing alone prohibited subparagraph long exercise rights manage operate control business issuer b individually partnership conjunction person entity engage work work employee consultant advise manage lead employed affiliated operate enterprise endeavor defined competitor discovers develops markets sells pharmaceutical biological products vaccines unless first obtained consent mercks general counsel request consent must include name company would like work otherwise become associated nature proposed employment association relationship company information requested general counsel consent general counsel required hereunder unreasonably withheld provided however understand agree decision whether grant requested consent determined general counsel exercise sole discretion consent effective unless set forth signed written communication general counsel c competitor means following companies well parents subsidiaries affiliates successors abbott laboratories amgen astrazeneca bristol myers squibb glaxo smith kline genentech johnson johnson eli lilly novartischiron pfizer rochehoffmannla roche sanofiadventis schering plough wyeth nonsolicitation period eighteen months following separation date agree solicit entice persuade induce otherwise attempt influence person employed merck subsidiaries joint ventures date agreement leave employ merck subsidiaries joint ventures making initial contact merck employee purpose engaging discussion merck employee purpose result causing third party make initial contact merck employee purpose soliciting enticing persuading inducing leave employ merck providing third party information merck employee purpose recruitment employee confidential information acknowledge agree course employment company access trade secrets confidential proprietary business information confidential information owned pertinent company subsidiaries joint ventures agree disclose confidential information except determine good faith advice counsel required law legal process subpoena court order provided prior required disclosure use reasonable best efforts provide sufficient notice company enable company interpose effective objection disclosure litigation connection litigation investigation inquiry proceedings court arbitrator government administrative agency tribunal may asked merck testify witness provide information concerning matters might involved course employment merck agree cooperate fully mercks counsel making available counsel upon reasonable advance notice discuss information review testimony reasonably advance litigation proceedings making available testify depositions trial required requested merck notifying merck immediately upon becoming aware litigation investigation inquiry proceedings involving merck travel expenses applicable statutorily mandated witness fees agree paid connection testimony appearance participation pursuant paragraph litigation proceedings agree participate lawsuit legal action administrative proceeding initiated third party involving merck except participation solicited merck authorized merck unless commanded valid lawfully issued subpoena agree subjected subpoena requiring bear witness matters concerning employment knowledge merck contact company soon reasonably practicable cooperate fully company chosen manner proceeding nothing provision shall construed precluding cooperating law enforcement regulatory agencies connection lawful government inquiries breach agreement forfeiture benefits forfeiture benefits provision set forth spd incorporated reference agreement respect amounts benefits payable hereunder b separate apart remedy merck may event merck reasonably determines breached violated paragraph agreement mercks obligation pay amounts described paragraphs g agreement immediately cease date breach violation merck bepage relieved obligation make payments ii entitled demand agree immediately tender benefits payments previously made hereunder c agree breach paragraph agreement cause immediate irreparable injury merck impossible estimate determine damage suffered merck event breach agree breach paragraphs cause immediate irreparable injury merck impossible estimate determine damage suffered event breach separate apart remedy merck may agree event breach merck entitled addition available remedies temporary permanent injunctive relief breach employers employees partners agents associates terms set forth paragraph without necessity proving actual damages immediate irreparable harm posting bond ii award liquidated damages equal monies paid received accordance paragraphs g agreement iii associated attorneys fees costs reformation agree portions paragraphs determined invalid determination affect enforceability remaining portions paragraphs paragraphs interpreted invalid portions inserted agree invalidity caused length period time size area period time area without need action party deemed reduced period area cure invalidity confidentiality agree hold existence agreement terms conditions agreement strict confidence agree disclose except may required law legal process information third party members immediate family former spouse financial advisors outplacement firm tax authorities tax consultants anyone preparing tax returns legal advisors notwithstanding foregoing may disclose executive search firms prospective employers provisions agreement related agreement conduct business competition merck release consideration promises company set forth agreement intent bound legally agree irrevocably release forever discharge merck co inc together benefit plans subsidiaries affiliates officers directors employees agents predecessors partners successors fiduciaries assigns releasees respect manner actions suits debts claims demands whatsoever law equity arising way relating employment company termination employment arising way relating transaction occurrence act omission loss damage injury occurring time including date time sign agreement claims including limited claims based upon law statute ordinance regulation constitution executive order based contract tort common law legal equitable theory relief b claims based employee retirement income security act c claims arising civil rights laws federal state local jurisdiction including limited title vii civil rights act americans disabilities act sections rehabilitation act family medical leave act age discrimination employment act pennsylvania human relations act new jersey law discrimination claims whistleblower laws whistleblower provisions laws including limited new jersey conscientious employee protection act e claims counsel fees costs understand signing agreement waiving claims releasees released agreement greatest extent allowable law nothing paragraph shall read waiver vested rights savings pension plan foregoing release release waive claims rights waived law release waive claims rights indemnification mercks bylaws applicable law mercks directors officers insurance may future representation acknowledge promise promises agreement made signing agreement relying upon statement representation made behalf releasees concerning merits claims nature amount extent duration damages relating claims amount money benefits compensation due claimed concerning agreement concerning thing matter voluntariness agree relying solely upon judgment legally competent sign agreement signing agreement free read understood agreement signing signing agreement exchange consideration believe satisfactory adequate admissions agree acknowledge neither offer arrangements agreement construed admission evidence merck agents failed way act properly connection employment termination thereof contrary company specifically denies wrongful unlawful treatment towards agreement proposed company solely purpose reaching mutually acceptable resolution issues raised arising termination employment applicable law acknowledge agree employment relationship merck governed solely exclusively laws state new jersey united states question scope interpretation effect agreement resolved substantive procedural laws state new jersey without giving effect conflict laws provisions severability provisions portions agreement severable provision portion agreement application provision portion agreement determined invalid unenforceable extent reason provisions portions agreement remain full force effect continue enforceable fullest greatest extent permitted law amendment termination plans merck retains right extent permitted law amend terminate separation plan benefit plan described spd andor bridged employee brochure otherwise time nothing agreement affects alters right current intention merck also may extend enhance separation plan future sign return agreement later amendment termination decrease amount separation pay separation benefits eligible receive described agreement complete agreement agreement constitutes complete final agreement parties supersedes replaces prior contemporaneous agreements negotiations discussions relating subject matter agreement accordance federal older workers benefit protection act fortyfive days initial receipt agreement within consider whether sign agreement choose sign agreement entitled revoke acceptance time within seven calendar days signing revoked within time period agreement null void purposes agreement become effective enforceable revocation period expired lastly right consult attorney signing agreement please indicate acceptance agreement signing dating letter returning duplicate letter signed enclosed records truly richard clark richard clark chief executive officer president accepted dated b radley shearespage attachment release waiver claims consideration lump sum paid merck co inc merck company set forth paragraph agreement merck dated august agreement intent bound legally agree irrevocably release forever discharge merck co inc together benefit plans subsidiaries affiliates officers directors employees agents predecessors partners successors fiduciaries assigns releasees respect manner actions suits debts claims demands whatsoever law equity arising way relating employment company termination employment arising way relating transaction occurrence act omission loss damage injury occurring time including date time sign release claims including limited claims based upon law statute ordinance regulation constitution executive order based contract tort common law legal equitable theory relief b claims based employee retirement income security act c claims arising civil rights laws federal state local jurisdiction including limited title vii civil rights act americans disabilities act sections rehabilitation act family medical leave act age discrimination employment act pennsylvania human relations act new jersey law discrimination claims whistleblower laws whistleblower provisions laws including limited new jersey conscientious employee protection act e claims counsel fees costs understand signing release waiving claims releasees released release greatest extent allowable law nothing release shall read waiver vested rights savings pension plan release release waive claims rights waived law release waive claims rights indemnification mercks bylaws applicable law mercks directors officers insurance ii arising agreement may future days consider terms release advised right counsel review release sign right revoke agreement terms release notifying merck writing within calendar days executing release accepted datedexhibit december david w anstice dear david letter agreement agreement confirm discussions sets forth arrangements made concerning employment status merck co inc merck company agreed follows employment status job assignment effective september appointed newly created position executive vice president strategic initiatives reporting new assignment new assignment serve executive committee continue officer defined rule af securities exchange act b job duties duties new assignment include functioning primary sustaining sponsor companys end toend global support function initiatives full accountability successful realization two elements companys plan win ii helping refine companys strategic direction key pharmaceutical emerging markets particular china india iii serving member human health operating committee research strategic review committee iv assisting successors transitions former roles president asia pacific human health leader merckschering plough joint venture necessary v performing duties may assigned agree devote full business time attention best efforts abilities performance duties without consent company serve employee director consultant independent contractor respect business company affiliates c compensation benefits employed new assignment remain eligible salary increases bonus subject section longterm incentives continue eligible participate companys employee benefit plans programs may amended time time terms conditions applicable company employees grade level bonus eligible award companys executive incentive plan eip certain cases amount lieu award follows performance year unless employment terminated cause defined section company agrees grant eip award amount lieu award employment ends prior payout award amount less amount eip award paid performance year amount payable time eip awards generally paid employees ii calendar year subsequent employed entire calendar year ie close business december eligible eip award determined accordance manner company makes determinations employees level including without limitation companys performance divisions performance scope impact complexity individual contributions award payable calendar year following performance year question time eip awards generally paid employees iii severance year defined section c entitled amount lieu eip award accordance section b e separation agree appointment new assignment separation service within meaning companys separation benefits plan nonunion employees f length assignment employment continue basis means either company may terminate employment relationship time without notice lawful reason definitions big pharmaceutical competitor term big pharmaceutical competitor means following companies well parents subsidiaries affiliates joint ventures successors abbott laboratories amgen astrazeneca bristol myers squibb glaxo smith kline genentech johnson johnson eli lilly novartischiron pfizer rochehoffmannla roche sanofiaventis schering plough wyeth b cause term cause means intentional repeated failure refusal perform reasonably assigned duties ii dishonesty willful misconduct gross insubordination gross negligence performance duties iii involvement transaction connection performance duties company affiliates transaction adverse interests company affiliates engaged personal profit iv willful violation law rule regulation connection performance duties traffic violations similar minor offenses v indictment conviction plea contest respect x felony crime involving moral turpitude whether felony vi action inaction materially adversely affecting reputation company affiliates vii breach covenants contained section agreement breach agreement company parties c competitor term competitor means person company entity discovers develops markets sells pharmaceutical biological products vaccines anywhere world ii big pharmaceutical competitor severance event term severance event means cessation employment company whether result decision decision company except severance event occur cessation employment occurs result decision company terminate employment cause ii decision leave employment company presence circumstances would supported decision company terminate employment cause iii employment termination entitles receive severance benefits merck co inc change control separation benefits plan effect time time e severance year term severance year means calendar year severance event occurs consideration acknowledge exchange agreement accept abide terms agreement receiving benefits provided solely pursuant agreement otherwise would entitled specifically consideration ofpage initial execution company agreed offer new assignment guaranteed eip award amount lieu award set forth section terms agreement b consideration reexecution agreement company providing severance benefits set forth section terms agreement severance benefits consideration agreement accept abide terms agreement company provide following benefits severance benefits condition employment ends result severance event defined section b condition upon presentation company severance event reaffirm acceptance agreement reexecuting agreement within time period set forth section subsequently revoking acceptance severance pay subject section b receive severance pay form continued monthly salary payments minus applicable deductions withholdings period beginning day severance event ending earlier date eighteen months severance event ii july iii breach conditions set forth section b severance year bonus subject section b entitled payment amount lieu eip award employment end severance year amount equal product obtained multiplying amount eip award performance year immediately preceding severance year times fraction numerator number complete months service provided severance year ie number complete months worked severance year immediately preceding severance event denominator amount payable accordance section b payable calendar year following severance year time eip awards generally paid employees notwithstanding anything contrary section b apply severance year occur calendar year case amount payable lieu eip award set forth section di c financial counseling eligible continue participate companys executive financial services program balance severance year current level established executive committee members time time currently reimbursement per calendar year addition company provide reimbursement tax counseling required relative tax obligations laws country period commencing january st calendar year immediately following severance year ending december st third calendar year following severance year total cost taxfinancial counseling payable merck section c exceed relocation benefits decide relocate primary residence outside united states merck accordance company policy provide oneway return trip airfare temporary living maximum sixty days accompanying dependents ship household goods point mutually agreed upon area consider eligible home sale assistance buyout companys current relocation policy provided relocation completed prior twoyear anniversary severance event provided mercks payments benefits reduced relocation reimbursementexpenses move may entitled arrangement another employer understand agree eligibility benefits section contingent compliance procedures current company relocation policy related company policies payments generally severance payments made pursuant section agreement based current base salary time severance event subject applicable deductions withholding subject section b severance payments pursuant section made electronic transfer mail accordance normal manner payment regularly scheduled paydays merck salaried employees within thirty days reexecuted agreement revocation period section elapsed whichever later b section payments generally may made account separation service six months following termination employment specified employee defined prop reg sec ai successor thereto general includes top employees company ranked compensation specified employee thus extent required section internal revenue code amended payments made prior first day sixth month following termination employment instead amounts would otherwise payable accumulated paid without interest soon administratively practicable following six month period benefits entitlement benefits companys pension health welfare plans governed relevant plan documents andor company policies avoidance doubt acknowledge eligible severance benefits companys current successor separation benefits plan release consideration promises company set forth agreement intent bound legally agree irrevocably release forever discharge merck co inc together benefit plans subsidiaries affiliates joint ventures officers directors employees agents predecessors partners successors fiduciaries assigns released parties respect manner actions suits debts claims demands whatsoever law equity arising way relating employment company transfer new assignment cessation employment arising way relating transaction occurrence act omission loss damage injury occurring time including date time sign agreement claims including limited claims based upon law statute ordinance regulation constitution executive order based contract tort common law legal equitable theory relief b claims based employee retirement income security act c claims arising civil rights laws federal state local jurisdiction including limited title vii civil rights act americans disabilities act sections rehabilitation act family medical leave act age discrimination employment act pennsylvania human relations act new jersey law discrimination claims whistleblower laws whistleblower provisions laws including limited new jersey conscientious employee protection act e claims counsel fees costs understand signing agreement waiving claims released parties released agreement greatest extent allowable law nothing paragraph shall read waiver vested rights savings pension plan conditions agreement terms conditions agreement conditioned abiding terms conditions agreement terms conditions set forth companys conditions employment agreement incorporated herein reference b confidentiality agree hold existence agreement terms conditions agreement circumstances surrounding employment merck including without limitation transfer new assignment cessation thereof strict confidence agree disclose except may required law legal process information third party members immediate family tax authorities tax consultants legal advisors agree subjected subpoena court process order requiring bear witness matters concerning employment knowledge merck shall contact company immediately unless notification prohibited law order court nothing provision shall construed precluding cooperating federal state law enforcement regulatory agencies connection lawful government inquiries c non disparagement agree communicate negatively otherwise disparage merck products released parties way whatsoever agreement compete agree continued employment company period eighteen months cessation employment company conduct business competition merck conduct business competition merck means purposes agreement become connected manner big pharmaceutical competitor directly indirectly individual director trustee officer employee debt equity investor consultant independent contractor big pharmaceutical competitor ownership management operation control person entity big pharmaceutical competitor provided event shall ownership less outstanding equity securities issuer whose securities registered securities exchange act amended standing alone prohibited subparagraph long exercise rights manage operate control business issuer ii become employee consultant independent contractor director trustee officer competitor without prior consent mercks general counsel request consent must include name company would like work otherwise become associated nature proposed employment association relationship company information requested general counsel decision whether consent request made accordance subparagraph within sole discretion mercks general counsel consent unreasonably withheld consent effective unless set forth signed written communication general counsel e non solicitation agree continued employment company period eighteen months cessation employment company solicit entice persuade induce otherwise attempt influence merck employee defined leave employ merck subsidiaries affiliates joint ventures making initial contact merck employee purpose engaging discussion merck employee purpose result ii causing person make initial contact merck employee forpage purpose soliciting enticing persuading inducing leave employ merck subsidiaries affiliates joint ventures iii providing person information merck employee purpose recruitment employee purposes section e merck employee means person time action anytime preceding six months employed merck subsidiaries affiliates joint ventures f non disclosure acknowledge course employment company access trade secrets confidential andor proprietary information owned company agree disclose information third parties g extension time period time prohibited engaging activities described subsections e section extended length time breach subsections h reformation agree portion section determined invalid determination affect enforceability remaining portions section section interpreted invalid portions inserted agree invalidity caused length period time size area paragraph period time area without need action party deemed reduced period area cure invalidity remedy agree violation agreements contained section cause immediate irreparable injury merck impossible estimate determine damage suffered merck event breach separate apart remedy merck may agree event violate agreements section merck entitled temporary permanent injunctive relief breach employers employees partners agents associates without necessity proving actual damages immediate irreparable harm posting bond b cease desist providing benefits agreement c award liquidated damages equal monies paid received accordance sections b agreement associated attorneys fees costs merck covenant merck agrees instruct executive officers members board directors disparage third parties litigation connection litigation investigation inquiry proceedings court arbitrator government administrative agency tribunal may asked merck testify witness provide information concerning matters involved course employment merck agree cooperate fully mercks counsel making reasonably available counsel discuss information review testimony reasonably advance litigation proceedings making available testify depositions trial required requested merck travel expenses applicable statutorily mandated witness fees agree paid connection testimony appearance participation pursuant paragraph litigation proceedings paragraph affect right may indemnification mercks corporate bylaws policies eligibility merck advance reasonable costs disbursements counsel fees certain circumstances connection proceedings related arising activities merck employee merck continue pay legal counsel bills incurred course litigation subject terms existing arrangement subject representation acknowledge promise promises agreement made signing agreement relying upon statement representation made behalf released parties concerning merits claims nature amount extent duration damages relating claims amount money benefits compensation due claimed concerning agreement concerning thing matter voluntariness agree relying solely upon judgment eighteen years age legally competent sign agreement signing agreement free read understood agreement signing signing agreement exchange consideration believe satisfactory adequate legal counsel acknowledge informed right consult legal counsel encouraged fact engaged legal counsel represent respect agreement counsel negotiated terms agreement behalf complete agreement agreement constitutes complete final agreement parties supersedes replaces prior contemporaneous agreements negotiations discussions relating subject matter agreement applicable law acknowledge agree employment relationship merck governed solely exclusively laws state new jersey united states question scope interpretation effect agreement resolved substantive procedural laws state new jersey without giving effect conflict laws provisions severance pay agree neither merck released parties owes severance pay termination indemnity amounts payable upon termination employment nature severance unemployment compensation severance pay laws regulations state country event court administrative agency authority rules owed severance pay amounts payable section agreement reduced amount severance pay agree constructive trustee amounts carry purposes section severability provisions portions agreement severable provision portion agreement application provision portion agreement determined invalid unenforceable extent reason provisions portions agreement remain full force effect continue enforceable fullest greatest extent permitted law initial execution initial execution agreement acknowledge acceptance terms conditions agreement initial execution acknowledge acceptance given period twentyone days within consider initial execution agreement may accept agreement time within period time signing agreement returning b revocability informed upon initial execution agreement become effective enforceable seven calendar days execution may revoke acceptance agreement time within seven calendar day period sending written notice notice must received within seven calendar day period order effective received would void agreement purposes reexecution upon companys determination severance event occurred present agreement execution agree must reexecute agreement condition precedent entitlement severance benefits set forth section reexecution agreement acknowledge acceptance given period twentyone days within consider whether reexecute agreement may accept agreement time within period time signing agreement returning b revocability informed upon reexecution agreement reexecuted become effective enforceable seven calendar days reexecution may revoke acceptance agreement reexecuted time within seven calendar day period sending written notice notice must received within seven calendar day period order effective received would void agreement reexecuted affect agreement initially executed c release upon reexecution date reexecution date sign agreement purposes agreement including without limitation purposes release set forth section intent bound company entered agreement intent legally bound signature follows please indicate initial acceptance agreement signing dating letter returning duplicate letter signed enclosed records truly richard clark richard clark president ceo merck co inc accepted david w anstice dated december avid w anstice reexecuted dated avid w ansticeexhibit merck co inc subsidiaries computation ratios earnings fixed charges millions except ratio data twelve months ended december years ended december income continuing operations taxes add subtract onethird rents interest expense gross interest capitalized net amortization equity income loss affiliates net distributions preferred stock dividends net tax earnings continuing operations onethird rents interest expense gross preferred stock dividends fixed charges continuing operations ratio earnings fixed charges continuing operations purposes computing ratios earnings consist income continuing operations taxes onethird rents deemed company representative interest factor inherent rents interest expense net amounts capitalized equity income loss affiliates net distributions dividends preferred stock subsidiary companies fixed charges consist onethird rents interest expense reported companys consolidated financial statements dividends preferred stock subsidiary companiesexhibit merck co inc subsidiaries following list subsidiaries company business name stated country state name incorporation abmaxis inc delaware amrad pharmaceuticals pty ltd australia banyu pharmaceutical company ltd japan blue jay investments cv netherlands brc ltd bermuda charles e frosst uk limited united kingdom chibret denmark chibret pharmazeutische gmbh germany chinamsd hivaids public private partnership inc china chippewa holdings llc delaware cloverleaf international holdings sa luxembourg cm delaware llc delaware comsort inc delaware coophavet sas france crosswinds bv netherlands dieckmann arzneimittel gmbh germany european insurance risk excess limited ireland farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal financiere msd sas france fontelaborprodutos farmaceuticos lda portugal fregenal holdings sa panama frosst iberica sa spain frosst laboratories inc delaware frosst portuguesa produtos farmaceuticos lda portugal glycofi inc delaware hangzhou msd pharmaceutical company limited china hawk falcon llc delaware heptafarma companhia farmaceutica lda portugal infodoc norway international indemnity ltd bermuda istituto di richerche di biologia molecolare spa italy istituto gentili spainc italydelaware johnson johnson merck consumer pharmaceuticals company new jersey kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware kiinteisto oy viistotie finland laboratoires merck sharp dohmechibret snc france laboratorios abello sa spain laboratorios biopat sa spaincountry state name incorporation laboratorios chibret sa spain laboratorios frosst sa spain laboratorios medichip sl spain laboratorios neurogard sa spain laboratorios quimicofarmaceuticos chibret lda portugal maple leaf holdings srl barbados mcm vaccine co pennsylvania medco de mexico managed care de rl de cv mexico medco holdings de rl de cv mexico medco servicios de mexico de rl de cv mexico merck company incorporated delaware merck borinquen holdings inc delaware merck capital resources inc delaware merck capital ventures llc delaware merck cardiovascular health company nevada merck finance co inc delaware merck foreign sales corporation ltd bermuda merck frosst canada ltd canada merck frosst company canada merck frosst finco lp canada merck hamilton inc california merck hdac research llc delaware merck holdings ii corp delaware merck holdings inc delaware merck institute vaccinology delaware merck investment co inc delaware merck lmc cash management bermuda ltd bermuda merck oncology holdings inc delaware merck resource management inc delaware merck respiratory health company nevada merck sh inc delaware merck sharp dohme argentina inc delaware merck sharp dohme asia limited hong kong merck sharp dohme australia pty limited australia merck sharp dohme china limited hong kong merck sharp dohme enterprises bv netherlands merck sharp dohme europe inc delaware merck sharp dohme holdings bv netherlands merck sharp dohme holdings limited united kingdom merck sharp dohme ia corp delaware merck sharp dohme international limited bermuda merck sharp dohme investments bv netherlands merck sharp dohme ireland ltd bermuda merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy merck sharp dohme lebanon sal lebanon merck sharp dohme middle east limited cyprus merck sharp dohme new zealand limited new zealand merck sharp dohme panama sa panama country state name incorporation merck sharp dohme philippines inc philippines merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda merck sharp dohme sweden ab sweden merck sharp dohme switzerland gmbh switzerland merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme bv netherlands merck sharp dohme bulgaria eood bulgaria merck sharp dohme chibret ag switzerland merck sharp dohme comercializadora de rl de cv mexico merck sharp dohme doo croatia merck sharp dohme de espana sa spain merck sharp dohme de mexico sa de cv mexico merck sharp dohme de venezuela srl venezuela merck sharp dohme farmaceutica ltda brazil merck sharp dohme finance europe limited united kingdom merck sharp dohme gmbh austria merck sharp dohme holdings de mexico sa de cv mexico merck sharp dohme idea ag switzerland merck sharp dohme industria quimica e veterinaria limitada brazil merck sharp dohme inovativna zdravila doo slovenia merck sharp dohme international services bv netherlands merck sharp dohme ireland human health ltd ireland merck sharp dohme sland hf iceland merck sharp dohme limited united kingdom merck sharp dohme luxembourg holdings sarl luxembourg merck sharp dohme manufacturing ireland merck sharp dohme ou estonia merck sharp dohme pakistan limited pakistan merck sharp dohme peru srl peru merck sharp dohme pharmaceuticals llc russia merck sharp dohme quimica de puerto rico inc delaware merck sharp dohme research ltd bermuda merck sharp dohme romania srl romania merck sharp dohme de rl de cv mexico merck sharp dohme sa morocco merck sharp dohme sia latvia merck sharp dohme tunisie sarl tunisia merck sharp dohme limitada portugal merck sharp dohme ilaclari limited sirketi turkey merck technology us company inc nevada merck ventures inc delaware merckbanyu co ltd japan merial ia llp puerto rico merial thailand ltd thailand merial animal health co ltd china merial animal health ltd united kingdom merial argentina sa argentina merial asia pte ltd singapore country state name incorporation merial australia pty ltd australia merial bv netherlands merial belgium belgium merial colombia sa colombia merial distribution sas france merial gmbh germany merial hong kong limited hong kong merial inc delaware merial international trading shanghai co ltd china merial italia spa italy merial japan limited japan merial korea ltd korea merial laboratorios sa spain merial limitedllc united kingdomdelaware merial nanjing animal health co ltd china merial new zealand limited new zealand merial norden denmark merial philippines inc philippines merial portuguesa saude animal lda portugal merial sa uruguay merial sas france merial saude animal ltda brazil merial taiwan co ltd taiwan merial venezuela ca venezuela ml holdings canada inc canada msd nippon holdings bv netherlands msd norge norway msd proprietary limited south africa msd thailand ltd thailand msd australia pty ltd australia msd australia superannuation pty ltd australia msd brazil investments bv netherlands msd chibropharm gmbh germany msd china investments bv netherlands msd eurofinance lp bermuda msd finance bv netherlands msd finland oy finland msd international holdings inc delaware msd ireland holdings sa luxembourg msd ireland investments ltd bermuda msd ireland resources ireland msd korea ltd korea msd lakemedel scandinavia aktiebolog sweden msd latin america services ltd bermuda msd latin america services de rl de cv mexico msd limited united kingdom msd magyarorszg kft hungary msd mexico investments bv netherlands msd overseas manufacturing co bermuda country state name incorporation msd overseas manufacturing co ireland ireland msd pharmaceuticals private limited india msd polska spzoo poland msd puerto rico holdings inc puerto rico msd scandinavia norway msd sharp dohme gmbh germany msd somerset ltd bermuda msd stamford singapore pte ltd singapore msd technology singapore pte ltd singapore msd technology lp delaware msd unterstutzungskasse gmbh germany msd ventures singapore pte ltd singapore msd warwick manufacturing ltd bermuda msdessex gmbh switzerland msdj holdings canada inc canada msdsp ltd united kingdom msp distribution services c llc nevada msp distribution services r llc nevada msp singapore company llc delaware msp technology us company llc delaware neopharmed spa italy pt merck sharp dohme indonesia indonesia pasteur vaccins sa france readington investments inc new jersey rosetta biosoftware uk ltd united kingdom rosetta inpharmatics llc delaware ruskin limited bermuda sanofi pasteur msd denmark sanofi pasteur msd ab sweden sanofi pasteur msd ag switzerland sanofi pasteur msd norway sanofi pasteur msd aps denmark sanofi pasteur msd gestion sa france sanofi pasteur msd gmbh austria sanofi pasteur msd gmbh germany sanofi pasteur msd ltd united kingdom sanofi pasteur msd ltd ireland sanofi pasteur msd nvsa belgium sanofi pasteur msd oy finland sanofi pasteur msd sa portugal sanofi pasteur msd sa spain sanofi pasteur msd spa italy sanofi pasteur msd snc france seneca llc delaware sharp dohme sa spain sirna therapeutics inc delaware stellarx inc nevada telerx marketing inc pennsylvania msd foundation limited united kingdom country state name incorporation thomas morson son limited united kingdom tradewinds manufacturing srl barbados transrow manufacturing ltd bermuda uab merck sharp dohme lithuania variopharm arzneimittel gmbh germany less exhibit power attorney undersigned hereby appoint celia colbert kenneth c frazier severally hisher true lawful attorney attorneys execute behalf undersigned whether behalf company officer director thereof attesting seal company otherwise annual report merck co inc fiscal year ended december securities exchange act including amendments thereto